var title_f38_28_39360="Diverticulitis BE";
var content_f38_28_39360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55313%7EGAST%2F58560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55313%7EGAST%2F58560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulitis of sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single contrast barium enema reveals spasm, rigidity, mural thickening, and lack of distensibility of a focal segment of sigmoid colon in a patient with sigmoid diverticulitis. Note the presence of a small diverticulum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intramural diverticular abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema in a patient with numerous sigmoid colon diverticulae demonstrates an air-containing intramural abscess cavity (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39360=[""].join("\n");
var outline_f38_28_39360=null;
var title_f38_28_39361="Patient information: Alcohol use — when is drinking a problem? (The Basics)";
var content_f38_28_39361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15334\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/18/20778\">",
"         What's a standard drink?",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/alcohol-use-when-is-drinking-a-problem-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H38470284\">",
"      <span class=\"h1\">",
"       How do I know if I am drinking too much?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If alcohol is having a negative effect on your life, you are probably drinking too much. Answer these questions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have you lost control of your drinking? For example, do you sometimes find that you drink more than you meant to?",
"       </li>",
"       <li>",
"        Do you need to drink larger and larger amounts to get the effect you want? Or do you get sick or feel physically uncomfortable if you cut down on your drinking?",
"       </li>",
"       <li>",
"        Have you lost your job, gotten in trouble with the law, or had problems with your friends or family because of alcohol?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you said yes to any of these questions, or if you just think you have a problem, mention it to your doctor or nurse. He or she can help you find out if you do have a drinking problem. Do not be embarrassed to talk with him or her about it. Alcohol problems are common. They affect 18 million Americans. And there are treatments that can help.",
"     </p>",
"     <p>",
"      Another way to learn more about your risk of alcohol problems is to take an interactive questionnaire (",
"      <a class=\"calc calc_patient\" href=\"mobipreview.htm?19/20/19776?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). First, you might need to learn what a &ldquo;standard drink&rdquo; is (",
"      <a class=\"graphic graphic_figure graphicRef56818 \" href=\"mobipreview.htm?20/18/20778\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H38470291\">",
"      <span class=\"h1\">",
"       What happens if I keep drinking too much?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who drink too much can get serious liver and heart disease. They can get different types of cancer. And they can damage their brain. Plus, people who drink too much are more likely than people who do not to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have car accidents",
"       </li>",
"       <li>",
"        Kill themselves",
"       </li>",
"       <li>",
"        Drown",
"       </li>",
"       <li>",
"        Be seriously hurt",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H38470298\">",
"      <span class=\"h1\">",
"       What treatments can help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have problems with alcohol can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        See a counselor (such as a psychologist, social worker, or psychiatrist)",
"       </li>",
"       <li>",
"        Take medicines",
"       </li>",
"       <li>",
"        Take part in a social support group like AA (Alcoholics Anonymous)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these treatments can help, and they can be combined.",
"     </p>",
"     <p>",
"      There are a few different medicines doctors and nurses can use to treat alcohol problems. They work by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Changing the way your brain responds to alcohol so that it is less fun",
"       </li>",
"       <li>",
"        Reducing your craving for alcohol",
"       </li>",
"       <li>",
"        Making you feel sick if you do drink",
"       </li>",
"       <li>",
"        Helping you feel less sick when you stop drinking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H38470305\">",
"      <span class=\"h1\">",
"       Can I stop drinking on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people get over their drinking problem on their own. But people with severe alcohol problems should not try to cut down without the help of a doctor or nurse. People with severe alcohol problems can die if they stop or cut down on drinking too quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H38470368\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/28/39361?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15334 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39361=[""].join("\n");
var outline_f38_28_39361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38470284\">",
"      How do I know if I am drinking too much?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38470291\">",
"      What happens if I keep drinking too much?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38470298\">",
"      What treatments can help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38470305\">",
"      Can I stop drinking on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38470368\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/18/20778\">",
"      What's a standard drink?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_patient\" href=\"mobipreview.htm?19/20/19776?source=related_link\" title=\"calculator 1\">",
"      Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39362="Piano key test for distal radioulnar joint stability";
var content_f38_28_39362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Piano key test for distal radioulnar joint stability",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The piano key sign tests the stability of the distal radioulnar joint. With the patient&rsquo;s elbow flexed and their forearm pronated, the examiner grasps the ulnar head between their index finger and thumb, and the distal radius with their opposite index finger and thumb, and then pushes the distal ulna in a dorsal and ventral direction",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39362=[""].join("\n");
var outline_f38_28_39362=null;
var title_f38_28_39363="Pseudomembranous colitis scope";
var content_f38_28_39363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomembranous colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAbUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAK0tD0ifV7pooXiijRd8k0rbUjX1J/p1Na3hTwjda1by6jcH7JolscT3b+v91B1Zj7cetegzeBdafwzHqjWiaV4fLKtpbSOPNnJ4DEdST1ya561fk92O53YTCe1tKekb29TlRNbWNiLHSYmjhP+vnbh7k+/onov581nzM24hMlm4VQOc+ldZdeEnsRH9puAZ2wdoP3faoxpMVlJbXG8rJC6yq3U5ByD+dcXN1PoI4Wy5Vohlz8PvEGm6PBq+tww2ccrgQwvIPN3dQSnUfjXoWl/FWL+zDZeMdKGrnaqSSfLiaMdA6Hj8a5Txb4q1fxLJDLqdx5iIMjbwCemT6niufhtd2WLHBxjjOfan7RrUI4ROKjUV3/XXQ9WPxZe2s3ttA0Wz0q0EZitfLHzwZ7gfdIrzqCKEwxiEEFRznsTSW9huKgDG88D+7WummJbwq7K248DntWcquybOqlhoU1aMbEtrCSgfbyvyjPpV1I8deSeAKfbqAFAGQvb0NSs6LlmOEzwP61zybubcqAQsTnK4HUH1qvcxMvyFSR15GatGTDNl8llwKd5wCbWJZeoB/Wpu0yGjNS0V42O0En5fwqNrV40KkKSo6jtWrGCB+6yFPJHYVHqeYkUqMIe471ak72JerMdTPb5a3coXGDtOM1XufKaJi6bZR/d6H1Jq6ZEVGWSM5bpVC7PDFSAAMAe3pW6bCxlSQBQpABA7HvWdOmCeTjv61rznqpGD1H+FUpF3MVPHqfSqTMZIzJIxhm/nVaVuoIHI/KtN4xgjJzjqRVSaLPIxgj860jI5qiMeWNLiIRXRIVQfLkHJQenutY15aSWkoSUcEZVh0YeoNdFNGAO+fQVXk27PKmVpLc87c8qfUV0052PMxGHU9epzxpKt31mbfa6MJIG+7IOn0PoaqjnPOK6E76o8qcHB2kJX2r+2t/ySzSv+w1F/wCiJ6+Kq+1f21v+SWaV/wBhqL/0RPTJPiqiiigApyKzuqIpZmOAAMkmtHw/oeo+IdTjsNItXubl+y9FHqT0A+tfQ3gX4faZ4TgS4nWO/wBcGCbgjMcJ7iMH/wBCP5Vx4rGQwy11fY3o0JVXpscN4G+Fyxwx6p4uV4oxh47DGGYdjIew/wBnr619BW3w98RXNrby6TceH/7PeNTEp81dq44ACjHHpXM3jmeRkX5nkI6+tdDoV/eaLaCHT5pouSWUP8oPuK+fli1Uqc+JV12XQ73RlCKVLQvWnw98QG7mjlis4ggGLkyZST/dA+Yf8CArnNJuIL43YhYMLeZoXYHKsynBwa2NQ1DUtQV4b3U72WGVdskHmARuD2IHP60ttbJbRLHbxLHEi4CqMACuDFVcLb91e/mVSVa/v2ITFyuSFOO/NV5ofkAUfMxwM1t2g3RyReVEyNyHZcun0OajaAM/Xc4Ppya46c9bmz7FC3sTtBlbLAZyBwKvR2yjBA7ZzjrWhZw9SoIPRcVPHEsakHKsOhrshPmMZGVHGqqVdQZD92Tkfp3rn9QbZdSY6dx2zXS3KbCd3HpzXOarIkMcksvOBgGu+ktQirnM3epSrOcclP4jz+FTWuou6b2xgngH/CswFpnaVguc5Ax0FSMnVsqD6HvW9zp5FY2RfqQzO6jj8KPtceSflIHU9sVhNtckPiMAc45xUAnbcwRF2DgN0LfhVJIn2SZ1EE8T7SFG3GODUz3cKjIwFx2rlbeby3VJFLY4UDr+NWpLlA6iJVKnoD2ppEukWr26V3xGeh6gYH1FcV458CafrkL3umtHaar/ABKfljnPv6MfX866B/NkZVAyQcYAq6unlyoZm3Drx0qoVXTd4vUidGLVmfM2o2Nzpt5Ja30LwzxnDIwx/wDrHvVWvqDW/Cml69pTW+qQyXE6AiCaEYlQ9tvqPUH9K8W+Ifw213wObebUI47jTrgfury3bcmcZ2N3VhnoffBOK9fD4lVlbqeVWp+zlZM4iiiiukyCiiigBa9j+Dnwcn8UCLWfEsj2GgDDxp/y1vfZP7q+rH8PUZ3hPwXFo0kV/wCI4Y7i/Hzw6Y+cIezzY/MJ34zxkV3MOr3au8r3DlsbcRnaoH90AcAD0HFctXEpaRPWwuU1K0eeTt2Ot+IUWjQ6no0VtbQ21jp0Jja1iI8vaMFBjuc5JbvXI+JPEk2tFJr0yy3EZ+TJ2qi9gFHHFZsszyzLI+WXB5b1qEwMxxnljzurglUblc+kw+EjShGO7RXnM12XeaXLE4wB1qfSiLa/juJYFufIG4RMeC3Yn274qzDYswBOSM/e7VopZGNizqBzz2rOUro6XBbGDLbPeTzXE6oJpmMjhVwv4DsKlTTMKCDjOF6dK1/Os4GDNcRvjOQOdtI2pWUbHEhI6A4qU5bE+6ilBAQ/CgHOOfWrXlyy7Mh2kAPIXrU/260JzGH+Xtjn8KunxWkFrJ5dsrOPlU7avQTl2Mt4ykaoxIz1HSka5VflypyMMcZ4HYVm31/c3t1JO7IrPxk8BaqkSJKwkBDYxz/EPX6UMVzVScNuOOCcjnirn2jeAAACo4J7VhwkhiGBJZcL6VbsZJJJBBIq/vBgk8CpaTIbLn2lkUhfmPQk96bNeM6gSEFRgqMYxVaSQBXAU8Ntwarlvmyx7YFUorcg1vNtpISkinI+YMPWsWdMvwAyEbjntinlNyfMSoHUg81CbdyQCcgjNXewroqSQu+CRle5HcVVliOTInQcZPar0iSAgFgvp7monVSWVyR9OlK5nJlF4e2eAM/U1Vkt2HUjLDIX0rRddp5IPPJ9KqOR5rMOqj8KqLZhIzJoWU4YAH+tUJ4QVyucH271tyOGxnBAGcmqcyjDMCdhORj1raLaOaoroyPmhdwFV42GHjP3WH9D71Qv9M2QfarMmS3/AI16tEfRv8a2JlJOePmqCOWW2nMtuxVhwQRlXHow6EV0Qm0cNampKzObr7U/bW/5JZpX/Yai/wDRE9fJN9p8eoF7jTY9k+C81qP4fUp6j27V9b/tpqz/AAu0lUBLHWosADr+4nrpUkzzalNwep8U113gbwRe+KLpSziy00HEl3Ipx9FH8Rrv/hz8HmeKHVvGQaGAjfFp/R5PQyd1Ht1ORXoWrhLd4Y4IhHAg2xRxjaqj0C9q8jFZok/Z0NX36f8ABOuhg+b3qmxNoemaX4V0sWejWywwtjzpXOZJT6u2P0GBRc6gQWClck5B9aryTXF2i5XbGBgY6Gs26jmhXEiktzggfrXjcrb5pO7PSjFJWNvQAtxcvK5G8HvXTLG3UhQ316+9c/4Agaa0aaTO4sQoP9a68RfK3BBHHsK8/FzSlYLalSKIE8DJB5HTAq8Bui2BTx6UsMeQMDAB69TVzCFFXAyTyTmvNlPUq3YLGILGSV+Y9QeKIoCXDnPGeehq4IsBcnIA471IYcjcAc+3pVQl2M2MtgMhmBAI+Wn3EQOGPIbrmpkCtGH5yBg1Bfy7YozxuPIAPX616FB3MJLsY2pkpAScBFJxurgfEtwbgiOE7sH7o4/Gup1/Ulcsj5POBj1rn5NPMkomlYoByqDj9a9al7quy6atuYPkxooAY7urGop0Ms2R8qqOMHr9a2ry0XG4Z354AFZ8yGKQYwz56A8EVupXN7lWeMEJxhc8/wCFNVFWTAXdjr71OsTzSuXycdB/dpxt5GJIyNo44IyaeiBMg8tRI4GSWPA/xNNkj2bd/PsK04bfMfmP8mB3OK0rHwjrN/Cs1rZN5BGRK7bFP0J61Lmgc0tzGjgbcrEdSMZPStOLKSgbdxY8nPatC+0S+0tYl1CPyy44+bIP5VDYvB5oAZcjgYOalVEzOW10aFhbM7qIhvI5UDirl8I7/Trmz1CCK6tpxslgcfKw/wAR69feo4SEwwLCQHkjPStHUZrN/s0mnLJtK4mV+cn1FQ56mEoX3Pm34h/Cq404XGp+Gw9zpy5eS2PMkA74/vL79R05615SeDg19n6ksisot8oAc5B+avPfHfwptPENq2o6KI7HVRy642wTn/2Vvcce1enh8wS92r9/+ZyVMNfWB840Vc1XTbzSb+Wy1K3ltrqI7XjkXBBor1k01dHGe+mxRYQwAzjls5JqL7OQckBnbqMdvatm+ZIoBkA4656kVjSXLsxKEjP3QvJFeLO72PvoSsiSazWNC07xxr1yTyfpWdLqMMLFLaNpmPVmGB9KLlbjYkxR7hFJ83AO5R6gd/cVYjtrEJFJ5yNHKfkKnr34rNQktZMr2ibcepEl9eSBUjEcKHgbRnH51IkNxKmy4dnTO4lm+79Ktx2LRscxuquMgsOtadlpzSxRqkDIjHG+U9abnTirsht9WYS2IZdzRoAe3rT205BH1xtIAyOtaDac8zlY5GlkViMbcY9/pSyaHfyRKWVUVv493H5VLqwW7FojNEXlTrJESEXhiBz+FdL4e0MNZS6hcRKJix8uMZyo9T9a5OdjbOY1dnXOCRzjFEeoXUUrtb3siue6MQSPWrTiyZarQ2fGdnBYzwXQSCKF0IaMcHd6471zyzGd42u/MIQfIvdlqxbWOoavLJKZGuZANrNI3JpJ9Nmsrl7fUIzDKihhz94eg9TTstgv0EHkP5v2ZWEecIkj5YetS3EEaOIVlNygAxIuQF9qjYiTEjRqrR8BwMbh6H1obKhlQsjNyPanFIQyaPad6MSQeo5xUcUwjk2SwssoHG4YB962Lq9tbmzQjS4La9QASXEDFRIo9U6BveoZ5XurNPPkV4uCqMuGY/X0ouluTdlMbJTsOWJ9qlaM+WWjQ7RzkHqPallCxgwhFDuOCDyBUuTHb4SUmNQAQV5zWTZLKE8bOQwAAxgE+vpVJ43dyjBUdeOR3rVMgcuqqfr2JqjPDlycksq8DsP/AK9VFNkGfLGGBG35uhweorPkhAbgc9cAVsSKCcj7oOfeq0kSMpPAJ79c1qm0Q0YToQ2cbu3XvURjODz7ela0kSqxCYLHpnvVeWEZD5xn8f8AJrVSOeSMto0Y9uB+tVpY+D8ucDPB7VoTRbZFIGVxxj+tQS42r8uTyPxrRM55xRmKpSSN0Yh88MpwR+NfoT8RLe3n0i1e4gjmeC6WWEugby3CuAw9Dgnn3r8+ZQPM4wR71+iHjOPzdKjGCSJgQB/utSxjthqj8jhatVgea3NtJIpchmA+Zv8A9VcrqFnE4kuJj+5j5APY+orvpogYyExgDAPb6GuP+I4NjpMUEOVMnUn1r5KhO7sj07I5BtdWIYQcjkCmaXrZlvBDdqrq/UAdBVjwn4XXxHqX2U3UFlDEnmPPKf0UHqaXTdIhiFzJEHdo5SiSEf61R0I9BXoSUeUScb2PRNO0yOxgiW3RVhlG7d9auNDlRhgcds4zSaG7XOiAPgPHjAJqRmGwbV5/u+teDVbbaDQfbJt+Y5wOoJ4FSSgLLGcnGRgdf8io4JMAg5we69KnkH8ZwEXnNcsoXYOa6FjnAyB7c9KmXcQSN2QMc9SKoxzBow4xtBz05rM1bWxbIsVuu+U8hEOT+J7Ct6OHlJmUmatxcRQq/mOiIo5LHgH+tclrGuPeXHl2o8tCMKx6n6VQuxeX0yy3suD1CJwqj+tEMIif92u054OOpr2aVJU1ciyvcbHEuN7sGcdTjOKhZ3PzEYUDtVqSOf5mYDcOo6ZqJ4Xmz5QKOeBkZx710QmguVbh1ZPmkVFYAByQCarxWiTsBFgNnvyDV46Tai3CSRlpWzvnJO4+1M8OWcC+KbXTbq8ls7CUZZwmS3P3N38AI/i7Vspp7Cc1FXFt9Lhht7rdcXf9pHK29uYlMMpxwWcDKjPvn0pgt2E0kbR73QDf5Yyu727/AJ103iQR2niWGx0G/S7sJrZpJgG37GXgDzBkEnngkVJ4MtkfUZL24Qpa2yF2z0LdgKipKVJcr3JhJvXUr2enwaSsb3UIub4jfHbt92Mf3m9T7VBqs02pMDqMjTkH5VfJRf8AdXtUFxqM99fTlgSzuSCFIwM8ZP0q00boihyN+OCO31rinUtubqKM6W2CQbQP3WceWTwD6e1Ztpawec1wN2UPIXqPrWxeHYkSOhHc8/0qO1gaPchDc8/LyD/vVvTnpqFtC3ZeZduN8IXHbOQw9a24dPRgAUUt7YrPssReXjkjORj+ldDphWQHbgbSMf8A66mTsZO6Mu80lpopD0ZRgAED9KINLlgso0HQAk+9b13xPFHCpcsfnbb0q1dRMIwoBJJwe5ArB1W9yTgtW8O2GpTI+pabYXbou1ftUCyFB6AkcCiuyGnIhIZyAegxmitY4lxVk2HKux4OLV7yVWmYgbeR7VoW+mwJtOOUHPHUetbNnYD7OM4DY4ar4sCItqpjPr1zXrOTPejUsjJjt1gwLeNGZlOB6e9eL+IIdW07WjfT25g2TeZEYxmJTnPGOP8AGveJI/JlOADtTGOn1qO6WGJI1uIoWR1+VHGRn39qdCo6U3pe5hisP9ZilezRz+n6vDqNlbX1vDiJl3Sbjna3f9amuJWkM0dzG4Z0DoQDjaO4Arovhx4JtL67nubyJrOyWQulsp+Uk98f06V6YdLs4SP9HjG35fmXJZf8KzdFPWOwTxcaTUJay62PGdUki0ezhmtyZJbhVUtnGf8AaPsK5zVrn95LaWt811bAAm4xsDN1IUeg6ZrvPjPoQtdNTUreNbe0TCugHzNk/wAPtXlNvA858ybckUfyoM8t/wDWpQo2+Lc6aUo1IKaJd0kjMRtVR8oI6Ee9LLtJcKmEwB05NPRSpwwGCdykd6sIg2lAcHqW68VvZA0FoxjOUeRGBwfLOB/9emzwy3U4NxI8wTruP3V+tTLC9urGPae7bu4ParSR4jcZ4PUY459aqwk7FJLdvL6BsfdBP3RSNA8qARkgHoSeQa0ni8uMIowOvB5/GmNBcEsFXcNvCqO/rSYbmZ5EkaneAcDBI6mls4HkIRmCpjcYyeXHqDWyiiUZdcYG1gO9Mltf3agIFPUZ/hFTytiv0M1jE0w8jG8ghWYfdNKsZK7XycLgHpzUqQ4LbAdoPB7mr6wrjdgbQMfQ0clhSMieBktQsbbJnOQCMgD3qsA5O2QKrHrt6VuTxgJGMZyMk9hWYUR3KFgyN904wd3akrpshGbHC0kkoVMmMZPriqbJn5jtGa3LiNkG+5RopiCuQOD7ms/7Org7Tux046VtGaYMzZbcE46FRkVXMJDdBk9iev41sC3diQoIAU9D0qpLARGF2kjqAe1aaMxkjHZdrkEY96o3MfztgYY9Tnt7VtTwNncdqnGR7+9UZoyVwyjcOtUjCcTDuI8Pgdug9q/Q7xSpbTVAz/rBnH0Nfn1dxYJPyjONp9BX6E+IgDYqDz+8H8jUYx/7JU9DzqulaByEUA86KHA5PIrhPivaNcalbWhYpEJBvbPQd/xr0WNvKvYXbBAOK5L4r2bLeW9woJDMD7GvjcPU987k/et5GHLZafHdr/ZEc8dgse1vPILs3rxwBVeLb5wGVCE/KOlRy6lFFFukbLNxgDvVGKZjfh7hhHDjoRkn3Fem02Rc6/T7r7JbzCJRzwMj9aS3vVkjXzXAlB+YDpWDNrUfCW1vIy4xk9PwqoNQuSwIWGJOgOOfxrF0k9WLVnTm8w7eUxAzyMdfxqC81gKpXeN391fmLf0rn5PPuXCzyuwPVQdorQs7NUQsUBYjt0FQ4RjrYLA893dYRJTBbt95h1P0qezjWN2VFwQOXb/PNXIY0Vh5oztGQvYe5rBudQ2yyGZyFGSDnp7e9dNKDmZtu5oO/wAxYElgMkVWguFnlCxsrNjI2H+tYTapPdSBIB+7B5x3H86uxPbWNzJLAQrOAWQ/0rpdKysham9FGI2Vi3mFs5z/AAmpJVLoPKxkfeYDB/8ArVkrq8Yb7y8nrnofapW1iONA0vyDPr941zOhJMTky41yj3MYZogH+XfKSEU+rEA4+uK5rU3klvnFvKrrGxUyRnK/UZHStC8uoJ/nikTBGSB3rKjBM5MZ8piM47fjXTBKKu9xwtbY6TwszC5jiiVAr9fl6e9b7Fl0qWyBAjaXcxz8xP8AhWRoaCG3Lxf61uHkPYf0q/NMiKFByVGR71wV5SbNUlsVliWIbUySDx71KoQIWOCw7mmQ7rl1CEA/e4OKjvZUt4JHc5ccdOv/ANeuG7lKxuo6GZeuTM0wyXYYDHkCptLDvPHtG9h6NzVaUiYhUbIPpxg+lMstXtLbV1sd/wC/Uf63+EE9s+tetFPlskQ4m3PBM0mIgRNnlB1Nbmh29zMN06i3ReAerNVKzkZb5ZCAD0Zc810dpcoQFjBJzWFST2Iexo2VgkbMylySOSxzWhJbqV/ecgHIIpliSY2O3aB1Hf8AGrQUEcD3ye9ccn3OSUmmYVw2ydw3yH880Vp3Vh50xdcYPvRSVRdyuaL6nk1si7YgWA3KCDjrUksyqzJGCQPmLev41WY/IAG2hFHI5/KmNciA7TGDHsJ3Z5U+lfWSaSPZjFlK+nM052IRkYO/isnWY2uEkWBmbaoYsDgDHf3FXL6eK4gPmqw1BjuVw3yIv07k1lSzsy5JzxyPepWvkdcNDvfhv4stmlSwnDBpiEViMYb3r0O4lI1EB4t8qDAA7+lfOflfOtwu9ZlG0Op2hSepPqa6Cy8R61qkVjoOk372bRZFzqG7fIyegz0I9qSly+69jjxGDU588fmb/wAWfEFvd6ZJ4fiYXOqXEg3rHz9lUckH3PpXnmq6Vf6Zplpf3doFtnPljYSSo7Fq9L0fRvC/hq2muDqEE0j533M0u55HPUtnkH61R8S+I9HvNAmWO5SawgO/aEOXf0x/WiSe7KozUEoQWh5PNcp56gBhGh+UY2/WrkLiSMtGOc9O+Kp3Lz32xp9i5Yt1yVB6AfhWzp9o0tq01sGaGE4LAc/l3obUVqdU3oNjVJjHCWYI33C3Un3NXWKxuYApRk4wehNQGMytGEILtzz0AqZkkjUrIoIUZU4ySfSkrsy6gziBCXQs6jMiDsaetykryqpK4GcNxn3qu8HltGY5jJIwy8eMFPqe9X4bZAQQFDZ+ZhzxVcvcp2SEtAySybVDGRc7iepoeRyJHaMnBw2euKtM6bDGzqSpGzA5P1PaoS4MoQAmPoG7/wD16uxBz+q2ckDPqFmWJAzLGxwHUdxnowH59DVfSfE9pqeoG0iEijbkOxx5nqMV0Op6aLq3nsZGdxMMHacHHpmuBuPCl9pF5De6ZILkRPuMZ+Vh6j0ORW1NwmrSevQ4q8qtOSdNXj1O6umJDKRzwAR0x6VlSp/pkEgztVtzADk+tXFuhJEoQ7Y8iQowwyemR2psu0Y8tu+Sw9a5lKz1Ou+h1Lmz1K2aeFI3iK8jGenY+9cldDTLyGdoVmtbiI8Iejin293dWckxgZoxKfn287j6iqK7pLkyPy56H19zV6dCIxt1KZOGQNkjsfanvE0gfknseOtWBC/MwADR5Yqew9RTlJZyxbCNyT60ubsRNmTcRLsJkBGAPrj+tZN5GoYuFcnbwD6V0U+GiYYy2eOOKzZhuVzvBHbP9K1izFs5W5QbiQMt1INfoNrwzZrnpvHb2NfAN4m1icgDrmv0B1rH2MbsfeHU/WljP90qeh5td/vYHKajhQGJwy8gnNZvijUbHUPDjxXLgSAYyO1aOtMAASf4cV5F4x1eO2ikgXGHOck/yr5DC0PaS0Ovon2MMtBb3kiW8jyjrvc8fSmyarDEcbmaYcHHQf4VzUr3N0dxmZYz9xFA5+vtWnY2iYUP8zjGCcde/Fey4qKsxN6m/atcz7FB2bsYC8jmti2tFjBDH94TznkE+1Z+lEowDBcE4INbkLbRgsQC38P+FcNWTeiE9CdbPewTbyRyf4qux4ZEjKEFBhuOoqO3nQysHIDYyMnOaknlUFnkbkdR3xWdODejJlIq3EwRJS7nylHUHB/GuBv7j7XOXBA2NwM5wK3vE2p74WijyARjOBx+FZmkW6SkbwWKjnHf/CvVpx5I6kruFggRNxbDEZB74rJvtRt4pQJX3E/jj2rW16SJ7gIpYy424HYVmtpEYRdqqzkYO7nI961UlbUBBLE+DgH0wc5qpqeoFVA3NGucE7cnNXLmyWOIALtdTyU4/Kqtu7u0glIlQgjA4IH+1SjNdASJdHuGnmLBmGOowfzrbhm8uQiTqATkjj/9dc74dcKkqAAhX+UL0x71su/mcK3JODxWdSaLjC7OltNWVbXcPnUjp1xUtq800hkc4J4VSegrGtoVVQqnb2Oa39OhMzIihsf3gOQK8fE10tEdUadjW06PY29RufbgnoKw9QQ3F2kcTGSNCWLdGFbd4rl1W3A3EfMx6D/CrlrYrHbtsAIIz5jd646VTllzMp3SOM+zvNlI3KITgkdT/n1qeHwzbtPbuu9XibcwzkufetX+z5JJBJDGwRBt3A5JrZ0Sya53EKRGo+Z8jj616P1hJbk3aRlyFxM8o429QeeK3dGuHkdJQwMY6kc8VDJYMJpFI+QjhuxpPDC+VLLbzEHL5U9KzdVSRD2O0s+HMin5X5xzWmoz6EDpjrWRAHglZFA/AfyNa0JzGDjmuaczgrLqPxRTwOKKaoX1Oe54MWYW2Ao6dazLx3kQFvugY9K6JbyxvIpI7SRX+yt5c6hcFG9xWbeW6zEGIDA5Jz+hFfTc9RdD6mn5nNTShjtl3ZI2jHf0xVWVJLcNuzvXkjORg1cuoZoJGuViLJHkv/s5rNMizQOoPJ6bj1+lWqvc3SaK95LIFYSqo3D5Rmq0GoXtuZfs7RRzONnnL94A+/atOSyuAYnlQGLaFGOTu9KZ/ZjR6m9nJD5JmHmFT/Dx2odSIcytqY8dq17NIkMD3Eygbxuwnu3PWnpb2cQdbhpHkjOYI4z8jnuGpxiMs1ul0ZLWJSVAjONwz3NbKWKJKEtoo44oxlXkYZI+vrTclHclzsVdGsFS8F9eIkwYfNbgYCei1tkvNGIYlWKENuBXjr2qrDuYqGBUHnC9cVp28AKPtBVuoyeorBx53dmUpEf2ZIwGQbpXyHP9z3qJo36Z3elWZXnM68LGpG4qe1QTXQ80noSOARjPrW69zclXKt1D5LPJgKzAAAelWLWQsW3BSwXgdBVG6mVfKyrbX79cD0qvFIyMyM7PgYVwOnoDTU7lWbRvafHA5kE3Ab5hz971Oe1K3lIxk+6CQMD26VlWskMVhcpNDIboEGKRDw3qDVmFy6qz8NgduntWia3CUbamj95biRVbOAzcVkamCbd/JB2suUNbcdwChYDluCB7Vk6hJ/pIESje4yh6jFBnHR6GpbWmly+H7K6kWFIJE2O7n7r98nviuU1D7HDeFdNlkezxjMh5Lf4VFfRnYIcsLct5nlZ4DdyKgV8P8q7mJGVIoViuS2ty0p8yLqEkHK47n0pImUk7s7h1GOajmUfKGyUJyc9jUCXRSQefnrjjrj1qXG2xm0XygL7416nGSeKrTRkljGfnU8qen4U7zQoZlK7Rx74qG4n5CtnZj73/ANektzJ3ZHdOPKPTbgbu/wCVY8g2uyJllPPPXbVqe4wrKqYHTis6Zx5mY26DPuK2RlK9rFK/CbSScgdM/wBa+8fEDFbJCDj5x/I18EXcn7v94AWY84FfeXik405OM/vB/I0YlXwtReR59bWrA878VXkgVYojhSPmfPb2rwbWtRF9rssK5Kw/KAOdxr0/x/qP2e3lY/eVCMivHtNt9t2kxBMjAkleTXj4Klyx5mdU30NC0IVXadDhuPl5rZsJIDgqSQo57YNQ2kSlfkHzHqvpV2KFAvzKCCACR1rWok2Y3NC3lj8sMGBJPHtVz7SxyqtgjnjmsoW6MdyZAHGParMSNAQEY5PJHWsXTgtRczNCK6Ij3lgGHG7n/CqWq3bJE5aUs/UIOKikeRnZfMKqeeKqzyW9pbma8lAx13Hk/jVwUb2QORUZ3mO+5kWONeWLNgYp1tq5ui9tozeXGo+a5YZx9B3rj/EmsHVSYGDQWf8AAh4Mnuai8N6qkW60lIQpwB0/M12Oi3G5Laeh6NY2CRKJIjudh8zOcsx9/SrPlhUCEKrN9054/wDr1i2F/InrtI5I5zWvK6SxIwY9OA3auGas9SvUqzkRsVfDHnlu1Zc0AAMsYU47A4/GrF1cAyFVIYgdc9Kr3bD7NnnJ6Y6GhOxpFGVo03l38wkKhJDwF4AI9a6O1UsVOBtzmuWij8l2bcvLbtxGcV2WkI0trC+Rkt+YrPEvS5tBamrZwdA3ORknuBXSWKYKL8yAcsVrLsotznIJ4ycjr9TW5pqs74VWO0fMOwr5/ESOpFyG1EpwTuibksO/tWpPCTCBj5R8q+1MhUCQMgDDGOKvykRsF2AZH51xe0ZEnrYprDthRFZVjPynNWNMhW2c5BznkdjU8FtuO+RcqOQoHWrChXZ2UZZuuO1DrNIylJbEpRJ7gOwxx2HX61garavY6nHdwqDCxwy/1rdQ4t2wvfAGenvST2qzwiKQklu4q6Vdp6mUZcr12JLKUOBkbwfunNa6cACsPRFkhMlvMuHjb5fcVtDue5rb2yvocuIVpWJ80VH2orq+sN9DmseT+ILe1jsPDF1blDePaeXdhFAMg2dXI6kEd6xZbR47xQobDDexP8I9KSylkmt0Z8ZVRz0rRhdvMkZzzKRnvj6V9o5Rkz6SlF0Y8t77mRcxu9sYsMq7iSwHX2rjNW0uRH8y2TCRnkDrk9vrXolyULOuRgA8+tZFssMdpKsUQefcHDPwqe5rKaV7o66VSyucXby3VjdAzhkUpuC54U+uKdeXMk0TT3krPLIAUYdx657Vv6lpNzqN2y2cfmu4G5ugPvV9PBSSWEgZpJZiArFPur9KytF62FUlFbnnz6lJLDulXLBtpx09q0bfbL5aEh1jGTF1yazb22aC5mg3YCEqDjGMUWlwiPEYgd4HbqxrVcttDCemx1VpJEkLGXLP02jqoq1JcqzKyxFsLgjufesTT7hBh9wB5BJ7GtyAWwhQxhmbn5h1p7GaZn3V8MmIEeYnzHJ9aoySO/yvnpjIGa0JzpQu3F2jvAqkoYjhhL2J9V9qht7trS2mPy+bKMYUZJ+lRzX2N1ZLRGe6TRkxtGWx6nk/SpoVc/N2c7sD+HHrU0qmIsjxOrsAy855PaopL2K3lkRCPLC48pTjLUbuw9ycoSCyjgnjB+UnvS28jiNnYMAOAF5H407TrK8vtON5aJ5sKk4CffA7nHcCoYboYDxuCpPb/CqUWuhLsWortZChO7gjocFvaptQuo3lEsSeUoGMDqh9KzZJCXleJgMeo4qu92+GDgKHPAP8Hqa0stzIsyBXwjZA659qZo1vZXa3Ed7Mbe7Vv3ZB4K9s1X8/JRCu4rg46bvrVCRiju6EOhc71I/Qe1HLYak2rGrqlnNaYjlKyScFSvRl9asSW+n3NvO5Mf2eFAADw27HP15qjbSmaUkljFGPkU84+lOntd8hXON3X/69JtX1IkzPtQGjKgnaD8pYdqqXLhYpFO4gnqa0JLbY5bzDlTjjoapX4YRq7j5ueOmBRtIzuU/Ja4RpXcRiNcLjv9ax5JcFgATjnPrVh5j0B+XoQD1rOvHG4lGOSccjpW6RlJjLhtwUqTuPOAK+9/FnGmoT0EgP6GvgBmBTAbAB7dR9K+/PGLbdJUZwWkCj/vlqVdf7NUXkedV/jQPnb4iSmS4aEfemOSR6elcjaQGKcqr7eyqvNdT4uBbV448/6o/hmuauyDd5DYCHHJ615dBtRsjpmWEuTaQEXIZZt/yNjgj04/nV+O62gMyEEjIyRWW4yu5xhCMrg5J+orn9fumhsm3TTRuT8o3kAn6U+T2jsZPQ7X7fGwDI+AD3PFVbjxJY2oxNcxIN3ZgWY+gryea5uJY5JL25m+Ucxq+B+IFZ4BhMdzHGIXzkgjAI9zXVHLl9pmLrJbHrkuvyTrm0iVVznLnDflWPcia6kMt3KZHP3Qw4H0HSsHSNWguTuzsfoRjgfj3rXeQsrFmUjpheB9aydJ03ZIalzDsoV3t5Tso6uvBqldWKSTM6DDuM7+uPb6Us1/EN5B2kDHzVbSbMabsEDkYORWqbiCF03VHtlaGcsFHb/PSt5dS86FVTcDjHB6iufuCtwUdMKV460lmWtpVwc27DAGefzrOpBS1saRfc6eDBSQRIA44Lt2+lSqrCDcWLKnB/+uKpRTZUFSQD0CjIP19qv23MRU4z+o/GuGd07G0VpcoTxjb5eDtPI6HJrovCrF7UIcK8TYyefwrnpg+75M8+o/kKveHboQTtGqgBuueMe9TUjzRNItnpFqELHcgAx0/rWhbTlRkk8cKfSsqGRjbjacFgBu65rVs1CIq5yF6A8/kK+fxEbPU6Iy0N6xZsxxtgA8E//Xq4xG7Y4ygP385IrPtjiZASpAGfXBq2AwuCx5ifnbXnTVkKW5o24Ywouc5PGO1LDHsRwF+YkjjrTrLBlXAB49KvbbRd8fzsTyQCTj8amMHN7perscU58rtYqJ5YiVScFjgDGDmp2gWBQZG+mcc1C4dYdsgj+9lQvI29s+9MFx58gD4dV+6Dzg+1KyV7k2ctVsXNmGicDkcdetWAearZLcLjzEAPPSp4W3oGBzmqjdvQxl3JaKOlFdikZHhmncwjBxhRVlZdsbYX5l447Vi297thTaMuo478VZN2hdiWBHbnvX3ux9MtSyxEknBxkcD+lU7q3WWUNv2oo+YA8Gk+0KrkllORuHoT6Uw3gVWkdhuDYC1lNvoaJtbHT+HZQjspQMyDGfSpfEF/LbwGNIzFwcuTgsazvCGowI8qvglmxhu1WPGVwlxJsnKRyLHuVc8AVhPnVLc5Jr97qjx7xAA0jbwTNywH9459axo5ZWljKklsA59DW9rqKtmXjBleRvmYnlB7Csnyliwq/KkiZ4OSa1pSVjVmpApx8zbpGGTjooNaU1xJDa7WlwVIBJOM1Q051Muxf3gVcjHGQKZflHzK7BXJwFY9RW3Mr7BFE93uuAZGIKQjhgcZPp71JYh7kRRuyr8pYkHDA1lyXCvZlGICpyqjj6k1HDPtZGhB3RfOD3NElc11sbuo+XFBBFbtLJOBuaRj1J/wrI1O5uLt47e5feka7Y/lwV+p7n3qW5vcorsVfzR8ozjPt7GqzqLiJJth3q3Ck4DCohdasIu25taL4pEOgNpphSRrcEJLu+Un3x3rAtpWJDKwG8liueFq/qV1/aFtbxizitChO/YPv/X3qK2gRcsgGQp78VXOkJ2SLaSgxBSxDLxuz1HpSXZCnn5lAw2e1RwIEjUqRgc46g0kxCJ5hG8kZYE9faq1MXuRsxyJFyzMOCehA9PWriR5JMeDleD7+tZgPyRqCRGnI/2c+lW4HaQrjhR0GcH61MpNaCZrhQqo0SbWVcNn1pdwBJ2ByVwmT909zVNrosNgAJ+6TmhZm2BN2VwayV2Zy7jbmJlwE5LHj396ytWODsK5AB5zWmZmLbNvB6MT0+lY9+z72XIz0/CtoJt6mVzG2YO1sAfdOff0qtqVmIRuikz1UqeeKvTL8px26NWXcyOEYkgEk4UnvXWkQ3czVU9AflOf/wBdfoB4zbZpcR7+cMf98tX5/SkJhhnA6+xr9A/GSCTRyD2fI/I1GKdsNUfkcNT+NA+bfExUeI3PBGCSD/KuZu5czowICOccckf0re8bSG21JHY5flQa5eaZTe29up+VBvJHrXlUF7l0dFR6l5s7kMb/AHFweOtcp4mmVr6GNmCiMfKOua6Se8SCB3mYFFXnHrXERK2o373tz8oJ/dr7f0rpwsLy5mYVJpKxDJH9ltJMDazknp2qiXWdhGh+8oVMjge5rV1NzJFGpPc5wMkisiwijWeQ+Zlv4scYHp7V6ke7OVltLB0DnDEKuGbGATSLJL9jY7mhDH5cNzx/Kr/9px5FvBEzuFyQ3OB7mq8tvhjIvzu3UA5Aoe+pGyKOwyxqxkLenuf8aktry5sWLwuSpHzRNn9PekkBgcgf6onkkY20shjI2rxjoetNxT0sNN7mzZajHKfMDHDDhW/hNa0bia2XBOf51wSSMsucleep5P8An8K3tNvynLOcHjIPeuapRtsbRqXep11hIGASXg5wABkj6+la0MpJKps3DgjNYdnMsyhjlc8kjg/lWhbyCO4jeI7l6EAdq8uvGzOqElYuzLkZ6lQevaq3zLIJ1J3j8j+NaM6qMOvKH06iq5RSCOeeaxUbl81jr9B1aKe2O5v3oAG0noa6qynO6Jz+IHavHoXNrfDJKI/3X9DXe6VqW6IA4z79q8/FYVvVG0X2O+tnAYd/7vPStS3YyFlCksvfsRXKWF9woJycY9q37W8CsAWBBHSvFrUXEu/RG5bydGyPl464NW1GHLJgEjBrJiuELDdwOvPerEdwSSI/1HArhcdTCdN3JLh3dRGg6nmnCNkYKSAvUtmmHgJIpBJ655FMu3KxKi/6xiKkSV7JGjanBlkcYBIA9xWVpd5Ja63d2F2QEf54D29xWkzEKkeRvAye2KxtZcxXsc4VHaLgqR3PpXbhvedjOK5rp9Tp1JPpkdaKq6RcRPZITJ8/8W7rmiu76tc5JJp2seD2EUGwPu6rirElnFLvaPONv4fhWPbOyojKcHHQ9TT/ALXJG+xSQCeF9K+ue570ZvoNvY/IYDcQRwCR0rPnuDlmPQjByOvvWnqrefBuHynphuc1zlxIW3H0/SpbOiMtBGvZbV4pYZWRwc5Hp61ONWfUUM0ok3dCScl/qay5JYFjzJJkA8e1Ty3MOxDHkQDGVX+KiaurJCcky2Y/JVJpM+ZKCoQ4wVPesSSKKCURxMAPrk5qa5meW5MylzGcBYm6oPes1iTMilQJCxLMeh9qdOl3Ykr6mnbzeVCkaJhxJvDgfOBjkZ9Kp30y4DMd25u560t3d29yDlpbZwuHYEHzW7Y/uj61lTs0xBZR5anaH6f5NbJW0COmpMC7SNvyE7n19quQA/IULADkFev0qtZ8FhGcRZyxbliK1EXZuaPG1+FB7UXK5ixpCxwT3DynDuhG5l3cH0Hr71LPbyhQXYudoIwoBK9uneq0KyYLIcMBtAPb3+lWrkSKGTeMKuS4NFribVyqUdMISdz8kd6TyDKUKOwXoygc5omyztESGiADqxyHNSwsGV952lRzjr7YqeVCewhULGQmHB+UYHQ1XvbZ4YlYNjAIZR/EKsW0/lxyKAuRxwORUchaWJguOByCe1O7TM+Yz4/uIrMeD8vqfapTMvqeoAA/WorhSCqA9V4fvikurrc8I2InkIEyB973PvV2UhOxZV2N1uRsxgcY4I+vrV2E79wb0yBWPFMoErKN+xcsD71Ygnfy1yPqSecUOCsZyLbSrGApLOP1FZl44knOGATHIPar93KjLgEYUZJPWucubkzMwX7inhs1VOL6mL1HTyR7DyfmPHrmsu5kUjJ9cewqW4l2kqTyBnr2rMnfPPO317muiKMZaEc4DOct06iv0K8XnbpOc4w4/ka/O0yjeobpjjiv0R8Ygf2Pkk4Dg8fQ1hmCtg6nocjd68PU+Yfi/vtb+y8gb2bLBQOfrXn/ANpFnCWuHUSMN7+ufQV6R8Yjv13TAcfdyRXjvitGku5DGx3RkYHYVwZclOkkzoxLs9Ca5vJtSUERnys8LuIGPU1LFK8BVREScfe7VQs78CAK4EZT5WI6Gr1uxnAIlKr2PrXocvJokcTfNuIw320krjhQTxXL2koAd2AZmY49/rXRa5OlrYSKpVZG+Uetc3bFViAl25PTOMfhXRRi7XZlNl0XY5y2G7kDr9KspdmZBGOAOQ1Y0jCRMKAFB6Hjn/PrTI5jGxPykjgAc/rVunclS7GzK7bSpwX6kYzmqYkDy7AzRnoeMnH+FJDcfLknLKP4u3tT7NAJyvBwM5PXH9aL8q1H6EyoCCxTBPTB6/jSWTbX8p8DByA3pV54S1uFQqQeBjt+HastiEndXADHgZFTfmRSTR0dhfNbSgOzFSOCe/0rqLS4EkY2MAx5Ujkn61xtth0XIAcLjPtWpaFoPLVT+768noa461JM1jNnX2931EhBycZHAq40g2nBBx37fnXMLcjaNx5z827/AAq7FdKN4fMiYAAY8j6dq8+VKSex0qSaNe4SJ0YOTjHKjnNM0q/mtJPLnWR7cDhx95fYiooJUVtrjaTjacVddNrq8Z+cdcdDWU9rNG0Gjp9N1Peq4dSVGc9c11NlqKS7V59sdT9K8wx5YMluPKlHVe35Vq6Zq2CPMwj9ivSuGthVNXRqmj1K3u1Izltp6n0P+NaKX4DdTvxgDPQVw2napG6CN3KsP4u341u2siMQyOrDPOGz+lePWwkkXzJ7nSQztIQhbC+npV1drlZHYDYRt5+9WHauFkQFkO7+IHr+FWBdK8j7CMxnBGcn8q5Hh3cmVmbSuZHZ3JweAMc1UvVWWYh+q9h3qdXAhEjuqqBk55z/AIVmyzyLIZ4mBB+8CO3rmvQwuGcdWYJpO5RvI7lpQI5JYlA/h5zRWrbmO4TzIJFYHrx0NFd/urcOZHj8dqdhKfIUAAWThmX+8B6VSdNvMfzHOWBrTu50dRdmUoFTBd+Ag96x2uYC2DKCBk4BG7B749PevebOqD0JLi4zB8qgr39a5fUW2hyBuXrn39617lgyqV6LkcHr6VlG6srSUtqe4xqOEUZ3fWktZWRsnYZpccL4eeIMh4LMODTL6Kydi8KsGUfLHngfWku9dsJIikJbaq5CbcYrIkuTKWOBtONwH8q1jGTeugcy7mt9tVSGUqGP3SR36VT1E3VlAbmdVRXOxXPOT7VQkGI/kfbk/dPTFZuoXMtxIglleREGIw3QfQVagug/aWJIbxhc7sYKg9Rwfai0Sba0RLN82ShPypn39aijjRVYYZrhRuZW4H4VPDL5TxfLiMncVb+M9gabXYSqX2NXTojFeIhTLh8K7D5U9zWlcwxfNJBOZJixWYKMKg/vL6/SsVpJZpXnut6iXllXsB2FbUsKrZwzSyJaxlRs55kHofesno0yr23ZGYjI9v5BaFVUiZQM+evqfT6U+QeVbvGyYjfgJ/dX3qJmZY7klgDERIsinsO1Q6hdtOfNdnLyKGfJ5z2q1K4nNXshzPKgcKCOhBPQiiCebafMO4j+VMjuWZFWXB+b5R/jUM11l3KLtIOPxqrPYOe+hYkdnbcUKsBwe596i+1P5RUhS79arSXR64I/Gq6zgzkqwIxxkdD9KfLfoTzI0bqfYhjfaScAHHJHpVKTe8gIVURuMHtTZJBsjLA7QSvXkGo/MYMQwDenPH4UlGxLlYfcySRQoozkHOO/0PtTopnYhcZGPmFV7ucmUuuT0IzUQlzuMWct95j/ACrSOxDkT3lw8rBE/wBWF5wetU2JjGNq7icVI2AoI4x1AqncuSuPm243Z9BVpXMpMrXDkl8DA757VnzkjgAZA496szuSflIwRx9KoSyAdAQ3pW0UYzkRE9jjB9DX6MeM5ki0lBJ0klCD64J/pX5wSuPTkn8a/Q/4lSiLSbHJI3XqKD77H/wrLGRvhpryONO9aB86/FiUP4mslc8IhOQx5xXlt3HvuZrlgwR25JJ4r0j4myFfFBaU7wsRPPGa4kWwOnqSTw2cdeK8/BJQppHVXd2cddoY7tl+d1IDKAeBWpbXUdvasWJLkZZQcY+tLq8H2WRVIIGMxk9x6Vl3t2iWhGAztxivTi+dHBLRleZ2vZTcOQADhUHp603ZHFEzM65z1ApscoFuivGu0HqByfbNJJhmkznOM5HOK1V3oYtiBVePKsMfnn61GockgKF5ypA7U9JD8oCL04bPBqGVnZsNggA4IFaInQl+Z5yEbg8g/wD6qntnMdyGKrtxtJB/XFQ2h3SOoY5A657UqnaWjIIBPAz1qJK+hSslobtvJ83DnA98qaztQJS7WQoSR2Bx+PtTbGYJiKQgjGPal1DEhjYZ3H1rFR5Wap3Ne0yF+Uq24Z3egrRsptrKo2nPAJPWsXTJVD7QdxT8z610VnHCygncpJJUla5qjsawWhpw24l2tnhTyParZtCZAsZOMZBA6VUsZCyt83zxnBxWkjrLkAkoenGCDXDUk0bxiVMPCjIflRzgEd61bC4cRLknZtxk8H8ahZiA7fK8XQrikRMuqhCqLyQO9Z891qVa2xrnbKishGSOg7Vl21q9vf8AmzO52nKnPB+oq4kLhwcEgjKkD7o+lWDCs0YUE7t3pUXSLUnbUvW90Y5EO7archs9TW3Z3Wdsisc7uD3rkmXdGELDehyM9DV+xusXMRYnexwQOprOdNMu7Z31nNKSD5r4Ge/Na2nStHKqkloyQdh5GfWsawACDGSxI3e1akIXzkL569R/WvPnGN7WE721OmvJvLVZhudF6qDxii6KmNW2o6P82OgFVY28xWxyB1PYin3D5thtUBRwF9TWkElsZNsrXE5kYZiZccDyyVGPwoqhmRXYOWHPHeitWkTqeb6S/na5pblQ9rFJuu0I3Kynj5h2FaMttpc0fiBb3T4obuxm/wBAlThoI2OWXOcMD2rz2HWpLF5x88fnQ+WwweU7g1HqHi9ZrYAyDBjEe3pwK9yEGtTpunuWNXuooyzoSik4BHTisGW8jd234YHv2rm9Q1jzDtViF6jngVmNqv3snjPQdDWlOi07ilWWx1k62zDMeVJPI7GqyPiQYbJDZJA4+lc02pZJUtjPWi21Ro2DCTkD8K3dNhGuupt3E8sjFclR0J9aihJeKcSdMAqfQiqEV/FcxXElwTvA+TBwAabZTGSRrZmbyn5Yg8Z9c1PI7WNHVTNG5myQZMhgMg+9FrdmO5Lq4dkX5VPesaa5VZWRZd6IcBj3qGS6VWdE6dc9x9DV+zujNVVFnTHWpJLZYemwlgR94k0s924jDSyb88DnIQ1y8U+SSCB35/pVuO9RNKNscFvM3Iw7/Wp9klsaKua5vn353kJgAjPWpYr9CxkYtkDG3r+NYC3BLAZAJHfpThcGCTKEb8ghgafs0TKsdGbvY7bmLBerDvVVr5nf92H2DqG61ivebmOORk5zTGuScjOSBkbTxQqYKqdAt4hBV2JHQkDpVQXTKrqpOTkZ9RWWJ2wOf+A+tJG8krbYVMj56DsfejksP2vY1fPYShy+PY1L9oaWQoiMSOc1f0Xwre3Sq82VjyM7h/Kt+PQltUYgZbHzHFYTqwi7GiTe5zSW7sMksFOAM/0qwVVAF7dsd/WtSa3MLuCBtAxj+tZN3lBjv2PoKhTcmVypLQqzuSxXdk9jjFULh8EjnA4+pqWaU4BJGQce+apTMwzn19etdUDCZDM3LcHOMYqlcPlge3cVPKx3HHcVQlbv2963ijmnIjdgeVyCDX6E/FtymiabjnOoRj/xySvzwfJfHXJyOa/Q74wDHhu0fONl6jf+OPUYtfuJehyUpXrxZ82/GC7RvF4Zf+eIQ/3awnVUtVhJyuMggcZq58RGWTxVG+UI2AjPIrFkkKtuZyB0C5zivOoQ9xHVWfvFPxCY2SBDngfKMdK5jV7U4DDhhyw9ffNdFdb5bjLLkL0zzUd1ZpdxukqgM3Cnpn3rrpvlOeWqOS8wLhAuFPIYUh8zYGOMA5OOhprLLFdtDKoMiHaT7DpircVpKdNm1Pcn2OGQRsGk+dmPovpXZvscskQKm4sgQnPzZ/8ArVE+wkhVbeB68GlnkYcg7c8g9cVGSzuQmDxkkcnNMOghYiVXGAR97H9KurEzymRlO4DAVeabawfvVds7gck4zitN3iQMyqxOPXnNZzn0RUY33KswQRYUr5o5JxxUAl8zbvBfAzk8Yp7ZecNt2junOaI492CcA5OD3NJOxeqLtkAtzGM5YDoBjFdHbSv5C+obAOcYrDsLNgMsOWGSM8D3rftoGZQArE/w/wCOK4q8os3pppFyHbMSxGDnG5eOfp3rVtwwi271JH8Q/wAKoWtu527ySV79MVoC3lSNfLyXzkba86c0zojHuXI4XELSPgI3Cgnk/wCFPW2W5+Uyuo75P8qhsLKZBI12sskr9APmAHr7VvaPpv7tWJDKfujNQpKINlWKC4VNiSP6Ank/jVi8D2aMWwzY5A6k10cVslvGzY3gDOQep+tV4bATTGadAZOoU9h71nOrEa1MOKKWa2jlaMq2MYIwDUTRjcobKSDnb05+tde8KbQNnydMVnXeniXPGQDkA9R9KxWJi9DRI1vDt5JNaZucJsAARecj3rfikVhtPGeQc15zBeSaRIn2vKxs+FkxwfY+hrqoLrZjgZJzyc8VzVk90WzsrCYtbYJzt96WedFbbICR6jtWHY3mHaRWbAPU8flT7zUB83UgngdaKTZhJGheyIrJvYcjjvRWMt40mSo3gcfT8qK2u1oQtC/r/wAOtNnhcOZUkA5yoB+pryjxJ8GmuC7WF+D3HRay/gz8dW02OLQvHkstzpgUJb6hjfLbez92T8yMV9BX9tG0cVzavHPazKJIZYmDJIp6Mp7ivpqmFUNYaGVPH1JLlm7+qufI+v8Aww8Qacd0avNHgnOPu/WuGvbLULMnz4WXnrivuCSNZB8wB5wc8isXVfC2l6oGF1Ywlick7eSfrWar1Ydpfgy3KhU+KPK+6f6M+LGlcZDZBpVmwcnmvp3WvhFpN4GeBDGcfLgAgfWuO1L4LyRkta4kPdchfx5q/wC0Ka+OLQ/qilrCovnoeLG6JOT6Y4qQXZVSisQCOcGvTJvhNexTMoidsDORgg1FP8MZ4/voyjHBx/On9fw/c0WXV+kl955r9oOOMdMYpnmk5BPBrt7j4f3KkbFLH0HWsm48IXsYPytge3atYYqjLZkSy/FR1tcwRK5U/wB09aclw4YkNjAxV5/D98hAVWOeOlVJNLvIyQYjxxmtlOD2ZjKjXhvFiw3LoWOSVI5GaZFKccFiR0z2pRZXbMFEJzU8ekXvXyzjqfahuK6kqFV/ZZEkzZ9z71Ik5XOCSx/hqzb6FezSLuBCnvXTaP4RwytNzg8nrmolVgupvTw9aXSxhaRpd3qMw2qVXpnvXrPhTwva6eoaUBpiuDuFLounwWn+riGT1z1FdJZpjOMYK55/hNebiKzlod0KSprzLyRJHAUXIHQBu1Z+pKpDYHAxxVmaQLEAw4C/rWPeXalslsE+nevPjFtl7HO6r+7kZgDn+L2rnNRcZY4+XHfkmtvVLhG3HJAJ+bHNczeyDkMBnqK76Ue42zLmk+Y457evNVZHHBGc/wBakupMMdv3sVQlkJJA4Hv613wRx1JCzNg9wO9U5n64HXpRJLycE8frVYkscKCSfSumMTgqVOgNgcDknpX6LfFqWCPw3Ak88MTTXSxxCRgPMco5CrnqcA8exr86GYRcI26Tuw6D6V9n/tpsV+F2kspII1qLBB6fuJ6Van7WDhfcwhU5JqXY8U8fN5WtRb1C7BhgwHHtWL5yvFuwpB5OeM1z1l4skvxHbeIHM4ACLctyyjtu9fr1rbNv9nGVYPA3zJKDkMPr0rz403StGR2uaqaxFiuYwQjkbR1Y8/jV1GSQ7emOQfb19qzGsBdIJEO0k8Fc1HGtzaOPNKnbwMj/AAp3T6kWaexneKrUAreRkHnBxyPwrFFw62xtw8nkMd3lFiAT2O2uvuZFNs3nDNq+QSOqmuYuLMxMFbDKDlZO5HvXTSndamNSL6FQKzYJRueDt5rRt4I4bctIFJUcE5BP1qPeilklUe2PWkmn3RhHBUY4xzWr1M0tRRK0RdyV3HgcZp6oZZOSBgZLL61Xg3OuB0Xg+gFanKw4VdoC9cVEnbYpFY4MgRjwFyc8Vp2Fkzqh27QBk5HIP0qnpUPn3CoSoXOQemPeu2tIILeMM5JwOQx4Y1yVqrjobQjcg0/TNoUztlyOBj71bNtZeYcFSMe3H51DpzSXJPlAhD95n5/Kt6zs1BXqQv8AePGa8qrJvdnXGy2HWWnRqFLEfNySeprSS3jixgDaDww9adFAEUv2449TV+KIFgpIDDmvPlLXU0KTxku0ZIQdckcZ9KtaefKIjPXuq5wB61ZntlRDIW3Of4cZquzlJbZgShzznpn0PtUKr0LcbmtK8ZTZG4YEZIHWn2keSFYg56Y7fWs6eaBrjzHzFMB0zhSPWrlgUIdYZS2/kndnH09BQ4ymtCbKKL6qhZFAJxwferFppx1C+S2LojuCVMh2rge9EaBgDuYH7oOTyfrVm4RZYYFYquzksTyawlTcdQUuxyuo2ySx3sDYzG5i3YwCR3U9x9KzNN1EHNpIfLuICF+fpIO3PrXW6xEbWObzo9vy7ssNvHqK4rXdEudM+y3F9G0cN3+8gDDhx16/jXXQXOrMHJHQW906PKSWHqO4pk9zIqqOAHPy4H3j9azbWd2gcRgtKeAvXFcD8Q/HtpZRGx09ku9RB+eRTmKP/E/pXVQwcpTtEznNRV5HqDavpekokeq6jaWLyDegmlVC49RnrRXyZqF9dajdyXN9cSXFw5y0kjZJor2I5Wray1OJ4t9EVa9V+EHxf1DwQy6ZqSHUfDcsgaS3Y5kg7Foieh9uhx2ryqivV30OM+/LV7LWtLg1fQrtLzT7gZjljP8A46w/hYehp8YDZVifQV8bfDD4i6v8PtUefTilxZT4W5spsmOUeuAeGx0P86+xPCmv6N438PprHh2fdF92aByPOt37q6+noR1BrkqYe2sDeFXpIt+UMHA7YzUMlqrN/wABq6sZBwQR7iiSLLfKcetcFWNkbRdmZP2IMvGORniq1zZg7g6gjHII6VuiMhcnGAOKhmj3AkgH2zivLrRVjrpzaZxOpaFGQpjU/h/Oudu9KRQVckqQB0616U8YMeSKwL22AyRjnIwelccKrT5T16FZ2szgH0dVmU7QSvIyKoXGhQtvcoAzHJA/wruXtht5UAE4B75qpJblQ3KnHA967YVWdympbnDL4ehVl2pz2JpzaVFuyU59AOK6h4QSdw+UcH2/+tVaePYMnK4GPXFdEarZMkuiOc/s9In3LyR3x3qeNRk9VwOg/nVq4HzY4wOnPeqjuc5OPl61spXOaaLsMiImOTkDkdq0LWcEON3GMj39q59rjaSeigZ5NRi+Ck7c4HTmk48xzSR0F/dFY8lvmAwR/erk7+5IJy3Q/wCcVPcXodAN4JIyDnisHUZw4L9yODnvRTp2IuRXVwCeCATn2rAu5t3GSNvT2qS8uGYvuA9vY1k3MuV29SO9d9OBhUnYilmO5QOOpqhNNknk80XDlmAznHeoANx3McJ3auyEbHnVql3ZANzkgdB1PpQ8gUbYs+7dzTZJMrsThB+v1qKtTklLsLX2p+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET0EHxVWvomuT6afLYCe0Y/NCx4+o9DWRRUyipKzHGTi7o9W0uSC9sjJp0okhXqpGGjPoRmrQt1kADkZPHFeVabqF1pt0txZStFKvcdD7Ed69L8O6/Y66qwSiO2vj96I8LIfVT/SvKxOHlT96OqO+jWjPSW42fR5UkYpjBPTPH5VlXuh3kIaSLIQHJ/8A1V20kTRRbjyAcZ9KcFLqdyZTt3zXJHFygbypKe55XdxGNh5iPFnn5hTPsizDdFPnHIBGK9Pu9Niu0KTRh4x8xBHIH9K43U9FksHea0jMkGc7G5YD2ruoYyNTR6M5qlBx2MG2VUcliC27rt6n0q7NICr/ADAEjGBVJnDSbx8meo9qk3F2UKGAIx0611tX1ZilZl/SCqtvb5ccDHc10sHmXRij/gByfeuWso2UJEqhix6Dgj3zXU28JZosOQw6hDz+Ncld21OmCudhpcSiPAIA9uhrcgiUID68DArJ0mAhFwpyw4J54+lbsMTKMZxj+9/SvAr1Ls6oQSJoVDOAo56cVMiBZMlc4yMikjRVUMECj19TUjiUDciggckVwOVzZIndQ8f7vLHjHPaq8kCmDaoBGM4qaMbULfwsOcf/AFqkyCAmeAOO+Ki7KWhh6vb+ZYxvHjzE4JPIxW/oESvawSRnkDLE8Z9qiKLsbAHlkY2mpNPjezjMcS74CdwUnBH0Pp7V1U6mnKYVEdBD+6HO3jpn+lT6deR2mr292FDrGSCj/MpB65rHlu/3YBxtPX3qq12It2CSmOmauzbTjuZFjxlNHqPie51lSU82BLb7Op3Lhc4Y/XPQDtWFq9ykfguWK6lEcVvIHNxM/wAsK9wpOevoKo+LPEemeHbGO91eQ+dJkxWqn95Jj0HYdOT+VeC+O/HGpeLroeeEtdPjP7mygJEae5yfmb1J98Y6V62Gw1TEy55/eY1K6hZLobXjb4iSXsT6b4f329jjbJOeJJ/X/dH+eOledE5OT1pKK96nSjSXLE4Jzc3dhRRRWhIUUUUAFb3gvxXq3g3XYdW0K5MFzHwwxlZF7qw6EGiigD7E+HPxF0Tx/o6y2ssdlrEKbrvT3bGw92jJ+8nf1GcGur85AcM6cjP3utFFeTioqM+VbHVQfMtSItG2SJU/76psm1uDLGehzmiivMrRR2R0ZDKYlXAkTJyOtZrQR3chUFE2g5bt+NFFckaMeY7KbaVzGkiTzmXcuVzkg8VUljQoeBjHrRRWvKkejBsoNbCRizEAgY+tU723KJg9QueD1oorWKuzRydjm7vYCcAE9iDwfrWTO4LdCO2fWiiuyEUYybKFxLlDk4GOMniqjTlc4zkjHB6CiiuhRRzzZWe46LxjtVC4uAwAPPPGKKK0jFXMJSZj3ON2Dkk9cd6zZnyjED247UUV1U4o4qsnYqPGqjfMSqdQp6v/APW96rTSGRs4CqOijoKKK3R59V62IqKKKZkKOtfan7a3/JLNK/7DUX/oieiigD4qooooAKcrFWDKSCDkEUUUAeheFfHQCRWWvEsq/LHdL95fZ/Ue/Wu8jSMFZrc+ZGV3AJyCOxFFFeBmVGNKSlDS56OGqSmmpdBbcfKxAbfnkvnv2NVr6Ay7mQDnu1FFefB21OpvQ5PVdHiE7MFI3DPy9FrKjtxauQNm316DFFFexSqScdTnnFJmnbPBGqKGyccZAGa3tDtXldSFBD/dycZFFFZ4jRAtDt7CEhgAh2gHOPStGPb8pH3T04zRRXi11qb02XET7pI3L36mpSFwVGRg8UUV50nqbCSsFD+hGC44I+tVZi0ZyORjvxgetFFCHew9GLBFGST0UCtbTLtdMvLiHUdPGpxyLhJFl2NbHHdScH8OaKK6KKSd7GdWPMtzn1N1pWi2q6ncfb7nJElwi7d/p8prifG/xGtdGjNpprJdaiB0HMUJ/wBr+8w9OnrRRXu4HDwq1LzRyYirKMdDxLVdSvNWvpLzUbiS4uZD8zucn6D0HtVOiivoEklZHm7hRRRTAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of Clostridium difficile-induced pseudomembranous colitis. Left panel: Scattered pseudomembranes are visible on top of the mucosa, being separated by areas of relatively normal mucosa. Some of the lesions have a red halo (arrows). Right panel: Yellow pseudomembrane circumferentially covering the entire colonic mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYANgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UopSCKACTgUBuFXbCxkvWOPkjUZyeh9h71c0/R3JSW8TEXXYDywrdRNmRFGEUDAReKwqVktj08Ll7naVXRdjY+H3g2DxFEbmTUdOsktJgGgupXgeRSez42/rmtbxhaaFpOprF4be9t5WI80pdrNEf91wct+Nc9pst5ZRyi0maEXCbZCn8Q980kcKgZdBI4PWuWVRs9inTjTjZLUNf1CS+1BpjFGjAAERoB07kjqfes4RkOGJBzzg8GtP7Kgm45LclW7UxoFef5VGzIBU8VKlY2tzashSPeNqHC579atCIMDk81KlsyOE24B5yBn+VSCKI8bcc9fSobe41B7GcmUJDjocZqO4OXygJI744rYe3jZCWjRm6ggc1V+ykThljDAnB7YojLUvltoU4gX+6QCBkmnkbWck5BAHynGauoiISEQLjtinNGhOXQGhvsJR7lBQhHG7HcHGD71Glv8AvDk4QnoCafdI6szKQF7DPapLedHUqMAjoRmh3sPl1D7IQpG8D3zQbUKAS429ySatqyMDjBx14qNkd8FeFJx1oUm92NK5QEZj3fMNo5yOppQQRv2EgdVxV8226QZi3HP51KkEbSFHiAPpQ5FKDRnecBjKsM808AsADxV2WwVYyFhAfPpx/Oq6rglQOVPYUb7B7NjrQbVbknJzzVZyrYAXZz6VftlbaQ4JPao3hRlUqmCT1obVwlDUzJAQXAAcHhl28Ee9Y17oZZXlsSX2jLQ4+YD29RXWLAOhiTAP5mle1dWEiRbCP4ulbU6jgzzsTgVVR5qQQcHgjtRXdaj4ci1WItpsax6mv/LFSNsw9R6NRXbGpFq9z5+rhqlKXK0cQivIdqKWPoBW/o9hHAySzL5kvULjIX61a0yyWzAVSC7DcZP6VeiixNwww1ctWvf3Ynq4PAqFpz3IzvUvnr16YFTbHK5zkt0wKuKjDGWBIp9uDIW6qV55rkc2eqk2yC1+ZkjkypANXooVG7B4AzyetK8KtCGZuD29KjOYn2OMjj5h0qXO+xXLoSQRhmJXJx1BPFNjAF4p2j/ZVhx+dKGAYH5cDvnmobWUSzuMsQv60nKSY1YuSbip3D5hnheAaiiRX3FsgjrTpJiCS/AxwcjNV/tyhlzHk4xknPHvReW5S0LiZX58DBGMHqKiKgtg4K5zkGoZpmeMKEO714PFQlGWLGQoA575oVwbeyJbjG/crnOO/wDSozOTxwPbrUQmXaq7WU/hThHsk37geckAYzTu0R7zBtrtuZOR6jmqssQjlwu8A4NXmHmkcspPQjkGpBbMSMN0pOTRfLLqQQg5ZQCAO9WY4Ac8EYHIDZzUkSMqsAcEn0q9DbqXAbBdxgnsKiUnui4RbK0MW6MhAxKH7vrTjblp492MEdFPStCzgbaCwKoDyxOAOaGidTudQBn72OtZynK+h0Ri2hlxEggwSQBWLLHsuRgbfY9K6pGj2Yfa44AC8Gs6aA+e5fIjHbn5RRGUl1L5Ha6KSW8alGVW/wBoZ6f/AFqbLaqsuCGAbkc8V0Fla+Xbu2AVHI+blhjrVOQiSXkHOM4PGKrnldBKk+xRS2iBXKvn36VZaBMAHOAeABxV6CTOxMEMOO351cmBRdh+bvnoPxqZVZXIlTcUYH2WFTv5B6ZHFFaCIwlCkO45xgDA/MUVopTfU53Ru9UcRBtBQ7VIIz06+1TgKHBAIBbpjOKVIowSH44/Cp3bf5ar823gVvKVpWMaaTj5ApyewPTB4NSWXmBnEq8jp6VLFGgG8j5+pyeaeoUsxVizN1/wrOVRLQvRIcD5bbj8y+nXFCOj5cHcG4GR0oQDdhhj0OaiyV3DB65oUrg2iGRNkUqMNrNyuO5qlBcpFwchun3TVm8J2AgjcAetZNrG1xIRkZJPA4xVppq5DexpTTho3If5j90YIx+NVVWRJG3DMZHY1dtrUMihw2emVPX6VoiwVyiPG6nqoOce1L2iTsaRh2M7llVSQDjvQscjfKOD7nrXQW2hSBtxhmdgOFRWz19MVsQ+H3jQyTWl3Fjr5iOAP0rJ1kdMKN3qchDbAnIVA1T2tvv34jTIBPJ6V3FpoCiQq7HcBnDM3H04pJNFiW4iKCUOwwSCct7dOlR7ZM2WHtqcfHatJj93Ht+tTNp7NGMKitnjBBrtI9PiiEjESKF45NWBpymP545UBHG4lRUOsX7CJwcenuFOMAk+oq9a2rDJaMeZ23MMCupTT1eFTLFMg3cNyP6VPcWCRNHvDEEZHzH9eKbqp6FxpxSscykWd4lA5GGXP5VXkBZMFVXb3BzmuobTt0Xm/N83VCT+lNt7S35UtGjZyRI+KlVEVyK5hxCLaquo5HIz/kVBcQMbg4CmLI6cVuwWXn3Rj2svUjcSOPbvUD2yo0iFXBU89c01USK0sQafHlGE43BTkHGSPpVC8tijllVOT94YGfyrUsRsMnBB6DPelvYBtU/M7ZwcEmm5oa1RmwRhI0YLh/7wHSr7KpCk5JPGRnFNSNBECcgDqD1FT28Y8ppMAr0GTip510DlViDyAZA2xQoODjFFblrErP5aZ5X2ODRVqaMlBHk0CeT5cmAQUA+vFPhYGbA6ewqN5CuImVfKUDPrVuN43AWLGccZ4romrnlRtyjS23O7pjOaSHc3zKMEenep4YHflyvl+maleLBLQjAI59qlJILXKnmOJj5incOxHWmvcqgZZAc46CpUQ5OWGAerGq8lrPeXEZgUBTwcnH6U/Un2Tb2KFzcAiKOBVZ27etWLDTLmJ12xnLnIb3NdLZaMFnENxGq8cNgdfriuvtNKVmCJGCQoAPHFZTqu1kjrp4W7uzkbHQ7x9pIAOM8Hr7VuaToMl9czQy+bCI13qxOcjoOBzXU2EccCPbyqA+04yK0vB2oxeFEumQLJcTNxcyrvdF9FOcCufmfU3nBwi1CN2dB4U+GVmunWl7qz6oblAfljkwB+eOPrUvi19Nsw0EIuftGBtSQ/KV7knPWuefxhJNLI093dSq3ITcdo57881BceLVnSVBbwupG0MyEsB+dapQS8zhpYevGrz1JX8tjKjljkLlHcbOMHr+FWBGAwO4g4wAaxH1G0M5dCyMONpHH4U631LdLkAkAYYc1lJXPW511NJVdGZBu3MpBJ5BH0rSgtZJoENsJ5WiHzDcDtrn574JbLuLbm5XjmrNlrktrllGdy7W4NSlqRNq3um1d24hsosysZm5KseMVWnYSImd2V6kc4rJi1Ty4mzlssW+YE4/Wq1zqThN8ZBIyQFyM1XK3oEZq3vM1dUd7G28+FXuJDgBQMA/j2rcs/BhvNFgvNMv7W9u7jn7DM2znuobByRXADU5in7xi64zgnt9Km0/V1kdGgnljeMkKRldp9uf5UbfEZ1vaSS5J2+SNmW1vNG1WVbuKSOMfK5I3GM+naqusWb29xuEnm21x8wkU8MfT2roW8YWr6BLba5bJOrDb5oUl/Y5zzXP6tp15Y6ZYXEzM1jMpkikY8AensaE03eI41G3apo/zMq3IWeSMneRyCauBS7bUwMDJqBCrIWiweOvrV6KEq2/gMw+7noKL9zsgjNlcCQg9Cep71LHGIsB1KqxyCeaXVYQ6eYp2lOox1ohdJbdTztGOvUUk+X4Q9mjobOHYjsiDjsODRWtp0Sx2w3As4wdzD8sUVSasc0qtmfPqIroj8E7QOtaK2qs6bRzis60WQxIxUbGAAXuPc1txxZQFnYHoMd/xrum0up41HmdytFI6RujcqDy5HFL50hIET7mbjC0tykssnkRtlOh9a1NK0NXby9wZ/7wHT61lKcbHXCF9ijY6e13MIjG7ZHIXt9a6uz0XfAgXgLw3Xmk0KzjgYhmIB/i28j2+laN3fpaSPCpVo2Oc9+aynUuzrppR3G3MKNB5VyuUHGc4K+lPbUJLW2WCGTeQPlbj+dZ73U8p2ksFB5PrSW2WnYyMCDnJxUc19B+2S2J2u7i4nBkQ7yPmIHHtiob553jS3DFpGOdqr296nuJlht9yA7zwMjmmW6TRukrkMx6Z7UKydyZVb6MrhI4YzFIhR+uM4FOik4UE5HTNSyIZZH89huPAOKZ5CIuPTr6Gk5LqRz3Kl1CokRIlBY8nnOKZbyPbPOScoAeKsXUR82OVSFYenPFQ3YDjCqAWPJx1quaLQuZdRILoXEhMvGD8ozzirYnwNoG7HXHasi83QRCSMZcfeAFWo5TIsTQ8A/e/wpbBzJmgSzxnknvz1qOKE7GRgcH16VJE2fmwAAegp1yxEDODt44I9aOa2gNp6nPpDIt5MoDf3c44qtqdgiOqxKc4yGNbot5DukY/MwHUcGqt4BHIgBG5xwCOlUpakO70Zi6fqc0kv2O/YGINgEALtr0Sz1t5vC1xobSvNZufkwwITHo3UD2FeaahppdTKjbSOW46nmr3hHVyjGwkQHcOCSc+tKUbe9EUKkXJRqa9jpom8lhEgxhcBcE7sfrWnDGiopyyjPzbTx+NYyXbx3JkjJTIKnjOa0182WFwT5eVx0ySKwbfU9KD7D7+JjbSyGM+S3+rmAJV/XmsXSJyySRuR9/gAdP612jNHd/Dye1b91JZkuQq9R7/WvNtKvBETuRQxPBB4FOVuXQmNa7tLQ9a0cvJYqWJbrwBRU/hktJYROpwRknH8PNFZqcVuziqTfM7HhiJ5KCIBkKKMgnPFTJI0jRwwnEuODVCaZrh1jtg0krKM+1beiabhYp7lXWVOCuOfrXrVX3OPDrTQsWGnuUVukhPO7+ddbZRx2KNIQGyOWPtVAGNVDHAxzk1zuv6zLMRawykqG5Kn71Yq8ju51T1NTVNXt7y48qzDBwc7gO/pUEEYciSfcXB6EVW0+eC2CO8LLNydvuabNe3THzGIUkfKDxTtbYydS+rOgVljiPzAMehbGKzoryPDI7YODhlOSaoQvcX1sRP/AHuBiq1ysNvqMSW/UABgemaEr6DVS2xrJO8s8bSIdqsNnt71auZZAFy2MHr60yJGKHBUKW+Wi5V1TcVDYPIzziokkaXTRHdNMVzkZ6YFTWlxGsWCS7DjNRXN1EuxtwwBjBqotwkav5bDDHIxU2Fz6lp1L7uwI4GelV7hQqbnO1gPXiot13M2y3PLHhj2q41tGblQ5MixgBh2zjk09F1J1M2C+MMZadd0I6tVaJ86iZ4Ina2kxtA7Vt3i2axCPCKsvGDUscCQ6e8FlKsBAJRzyAavnsiGrFFbmOabAljyGxhXGQfQirr3CpEAx3e2afqun6HLp2mPp9kbfxE7gXl2rfuiO7Edqsa94RtNM0ZNQTW0umlOFiiOChPOW9qfutbmUKrt7xSh1CNmG1WYY4z0z6VC/mySFyqDJyAayEu7iECIFXC/dbHB7ZqGfVJ2k+VthA9KSh2Nva6GjeBnjfdjywPun1rk7h2t71LhCV2EEEdq6b7clxCjGUFujccGsC9KGaVUZdn54q4rTUynOzujq7C+i1Gy8+MhiuA3GMNj0rplbEIYgnjp3NeV+G7vyrqW380qjfN7ZH9K9HjllZUbeOBxmsZx5XY9LC1eeN3uXF1T+ylluIV3yyJtKScjFefB2GpREMA0kpJHQcnPStjWbsyOyxMfl+VhXOyqz6vYwW4LyGRcovJPNC1WpVRpO/U+gvD8TQ6cvmH73ICkHNFX9KgdFji2EsAu3IGKKzilY8urVSm7nz5o9s7+VPGdrFAfcDvmuphxChfcOmST2rFstoRGUkgj5hnvVXVL0m4ECDA61vNtuxMKnLAm1fV/tLukbbUAx/ve9N0mzDRgsn75f4m6nvWcQhdXKE44NW4btjKkZJC/qaG7KyIU9bs0Nwmu1JIWKM8ue5qrIg1K6WQ7vLjOAV4zzVWe8CQPApBRmyWHUfWnaXcjZywVQeAeM+9K/UftFfU2owVYpCAT6DsKg1y0hayd1HzKRhh94H/Cq0N6ftBMW4sDxjoaXUp2ljEpQiNeqjrU82ppGel2X7RJpLCGJWPyDl26nNTefFDbMJnBk5wB+lVLfUkESkK6gL0I4qvJOodZkVT2O4YH4VLmXzdUZsDPd3EgZkTJ5LcZrXmt44VVfM3sOo9KZJaPdZmKoqsOMDmobnTwsSshOPzzRz33GpNFz7SEJ8rAP+yahuLuVDK0S53ck5xTpQIoI3kAUdCR2rOXUIRnjOeM460t9kROpbRi+a9zMGcBSgwBUV7fXEkLRSOoT0HtVTzJry4do8xJ2AFQNBFgvOxMmeRnitoq5zOo3ogbU7l+ZLohsbeOMgetJb65dNKscpO0DaSDziq1wYAgMa5Ib9Kiu4opFLgkECtYqL6HO6kk9zUGrq5ZBtUZ4BHJFEjpcfOpClB3HWuZkTyJEbh0PP0qeK6YNvQsQOozVOn2KWJfU2LSV05kyU7A9BSbwGuG28Eccdar+cZVITGzrnvUc0wWAxZ+eouXzq2hBIPslxFNGflz6/54r0e1uxJpytgA43EDua88vYlFptAXecHjpW7pN2ZIFQZAC7VB7AfzqauqTOvC1nB27lqa4LvJIQFBOcCrfw7sH1vxpHcKh+yWxyXHGDWJczCGGd1JBXPzDjBr1P4QW507wms8quj3bkgEY3DsawqSUYt/I3dRylY9R0wKspMQbAOAM5NFJpYHlhUA3kZJ6UVnGWh59VJyuz5ueaSC3jeWQ/dAUHisqOQz3Ek2dxJ60/Wp2lTZkBBggD6VDafJCq7SD1zXdJdRw0iWUmVQQ7YPpTPOMm/bj2qKdxGNwwc8cVmi5cDajHH6UKHNsQ5amgJVR/Liy7PwTip4Y3gtkZ/m8xuMdhWZpJC35nY+ZjI2nt9K6mxAk/fMF5+Xa3YUppLQuFnuS2UsECNuIO3o22mwXEEk5Z5A/U+WPT6Utw8KRShvLjnByme9dj4EvvBIljuL7TprfW5InRr0nMKHGMhfWs4wUipT5PM5+00ufXoIbmO5tdL8NzS+TJqU7fOHHUKnUn6Voqun6VcSxW1v/aumIgiS5ueBI/cgdeKrWOpQWXgu0to/KfWtJ1N57a6lwy+UWzkp0JrHv9c86+uLqRkkechsINoBA9OgrR04bF05O7czXE0SW3lgh264PAT2rKvdTSIltwZQe3TNYWq+IYRGU81dnfZ1J9K5+88R7lWOCEbF6M3UVUKF+gquLhHS52NzI9zDulc4GSqr3qjNcW8MaqflTBYr6e9c9ql1rVraWs19EY7a6XfC4AIcZ7Vlxs87yfaHY/Kctmto0Ulc46mLT2RvvrcEEBhEgZwMYXPJrLk1lieE7evSs8QDzMHp2NNQqA4bHBrRU4HL7WTLX9qz8AZKdwaBqUjcOWweOtViQBjBx296R8bTwc1oqcOiIU5p6s05HE0W1m5AGMdqjtn8tCkhO/PH0qpBLhAvGQec1IWAkLgrgdu5qHDoaRknqy/C8kcoO4hT1oeZjI2G3Z6EiqrXTAjC8d+KnDBwHBAPWoaS6HQpIuTtutFCgltmPpVrRmLKN7ttGe9ULVmeJw3TPWtDw+PMMgOAF6VnNKx1UWuYXVVbzI4vmbzWCgZxn2r6F0Ozki03ToNgAhjRdp6Djp9a8K06zXUfGFhCSWVWG7AOARX034dslB3Ss+VwACMZrirpaRR1Op7KLkzUsrMQQDcAH9Qc4orat7dVUJ94uOhPSiuqFKPKro8d4hX1Z8TSSqWCqm4bRSLMBG2ASVPOTVWR9jArkKRg+1NkbKlUJ2nliT1ocDaD90knu1OVEZYnvnpUIO8BQCEH3hTS6xgAg06QqAeQM8U+VIlamhaeXGhKZ5AO70NWrO6VYSXyxBPGaoRsqiNSSCF6etV7i6UMsaHbg/NgdTWTi3oXe2xu2kq3N6jugG3+E9/pV29u7S33l5EVguWUHtXHX+r+VMq2pGQOfrWGzSSyOZHLMxyc+tawoOWr0RjLFKOi1ZuT69GhlW1hZged7Hpx6Vj3t9dThfOlYjtjjFNhWMxMznDhunqPSlOxvvc10xpxg9Eck6tSejehEqZXpg+tOdGC4GCCKQ7mAAGAvQ1NHIhADHLe4q22ZpCO1xNHFE8rPHHwiFyQv09KsY+fnkUwDOdgHFMO/wA4K3GByPWp1Y0rksv3SMDBqIRBkAblgOPepCpklXbgoPQ1IMBirDDClqOzT12KsKkk7uMGrM6/uhjsarS7t+BlSP1qUtiJhk88Aim77jW/KQEZlO4DIODUiqH3MvG3rUYIUnPWliYIr7t3PSm79ClK2hcikEijAPSnJjzkXHfmqcEgXg5XirikHaR/+qs3HU0g7suxEIjdqvaR+7WU9iuRjisyBwFYSZO4ccdBV61V5MQxAmQ8YFc9RWTO2jdM9I+DummfUH1EtkK205Hb0/Gvo3RLZmWM8cD7vXArzb4T+H3tNKhJjVWIBdGIOBzz9a9Zt7do0DKChUdhgV5yUpTckLG1LRUFuJLtigldztGMbqKq6nK7+VEzZzyfTNFdq5pIwpRXLeR8PKWcfvD1HYUMVII3DP1qNpD8iY5HXHSo5CuCxUcntXS4K+prFe6LL8zll7CkL+bHgEDJ5qF7ra5ATA9c01p0ABHfuKpx8iZSUdS087qu53AAHXvWVNcySSEqdo7HvSTOXdlB+XNRbsPsAHStYQsjlq129ESRLsckkEn1piLucjcV5pwO04PQ05mB4IHHSqMVysbtAyAePX1oDEtkLn6CnKNytjt1FKJQOi4Gc4p27FrbQQYPNII0wGLAH0pY1LEg8Z5qQoCu3AyO9LRD5dRCQiDa3fp1ouQXlAH3iOajcKg+YHd/OpoVL7nYgMe3pRotR2S0HxRbWCMSF9RT7jAcsWyuMCkklEYHGaguJPMdExx3xULVlSjdCBRLIWx8qjtTclxhsbQegFPlkAJSMY7VGCAMKKvYzbSEcAEk/hTo/mByenWo3GWBPQ9qfH3I60rCUeo4JzuH61Pb/wABK5J9qbjjP6UQHy5w/GO/NJrQ2grbFmR3wDIMBR6V3/w98PyajqKzMMkj5V2nGMjnIrjNFsm1y+8reVRDuIAzxX0/8MvDSw6cZ5IipAHlpxxXDiJbQuenh0oRdWey29TsfDNkYFjkAIwqqR24rppZGaN2dwox04rP09BGoWMhj3A7Uy8uy7lItxK/xZwKVKmoq55ta9apczvNLPLIxDYz97sPrRVXU5zCtqoBRLiYRySKf9WPX6UVs3FaHQqkEk5HxWjsGO85x1GMYpXYumBjJ6A9KjALIWcnPeot5UhgQccYrZRuzODvESdSinIGSeuainwVHljAPWp5jmLc3JI/KoXIIXvVrYxqEQBXr+dMkQkkjHpUjDAzz+NAxwSefSq21RzeQ1E2g5Ofc04qAitkb88inDbv+bkUgwSe/pSuacqsNIJPyA4PvUqquD6AZPYgU3gKxLDPpTVzyVZiSMGi4rWHI3mPlPuipd4VQR97NQqHQfuxg9KPm2AM3TmnuNbDlA89vMySOo7VKxWThCAw55GKrFnV2cHr1p00qlwIfQcj+tTygpJasPNy+6Q4K8Yx1NOiJYmR8A9qhZN2SzD+tIOvU07ImUiRpA7ZXOPpSYpcADjihcAgnr2FAnq9RFUnntT84BxSjKhgVwe4NMZsKdgJHrSLUbEhcDHJG0ck963PCmgPrF/F55aO1YhmIODgGnaB4auL6ZftULRxEAgvkY75969W8M+H4/t1tDbWp+zlgsjNnL9uP/rVzV6/KuWO57GEwfO/aVPhRqeAfCdlc3k3kQiKyjYF0X+JgOAT2Fey6RZyX0kccQkXSkU/vlIUkjtxWboWipZqLaBJEtpcGaRVH3gMd+mR611Uj22j28MFruW3GemWyT1ripU+aXNLoc+PxPtJ+zo/Ly/4JX1fVIbeL7PAqBgAATwfqa5ya9zINmVx1A7mi8m+130rytjccDsQKpyIySNtYbR3rsm30OnC4aNKKT3Fu7kGElmLAdc/w+9FY2qTiOzZlKgsdoGM5orCcnfQ9SjQglZo+Uz90k/yquvIznqais7+OYbbg7JAuN5Od3+BqaVGVexBPGK9Jw5WfLU6inC8XcVncgqQCCMZzUXHAHQUoz1yCKRSCOKdtCZSuxjHORSdD2NSgc8jimtj05ppIyae41epBFLkZ460yQEYz6daVcY5HPrT5UF7IcSPbNO3AcYxTQC0ZcbTj3pGXB6g96SQ3zLUfvGP0pjuScUZAxkdaaSCenNOyJbk1oKWOOlNAyP1pxXPpTSpGB1zRZCs5bjuqjmgLn+LijOAM44oLhT2zU8o0rjQ+6Vo9pGB1p6MqSBnP3en1q7p2l6hqzqlnbuwP/LQqdv513nh34clbvzNYZXjUBgIywB/Ej17VMpRjuduGwNau04L59DgLGyutUmUW6MxYgZxx+PpXo3hj4fm1kWfVGO7G4KF4U/WvQtN0620uzFva4WLOcdT+fWrCadJqTIC2xR04IP/AOquapNyVkz6HD5XSornq+8/wK8Gji88m2gQbc8gAc+5713XhjRUsI44lIL5x8pwOvGP/r0/SbGK2CkKWO0A5PBx6CtL7UkcgQBtw6is1RS1Zjiq0qj5IbGrHcLbIyBt2PU4JrnrzUJb6VjgxrjAXOMCmXl+N4G7cRkEjkjms+MKj7i3ydqu0ehnh8KoXm1qaAkCpgjGKz7i+CF8KCuOSCDn8qgvL9YsoS2W+6COtc5qM7OdoJLv1AxkUNJbnfSoX1ZfeVrq7ztxEOM0VXFwkMSBBzj5vc+tFTyx6o6uU+SQM8scCr+nXwWRI7o7rcevas4nNFes433Py+lVlTlzROhuli83dbsPKIzkVAwZOmcGsy3uHhIxyPQ1sI8dwMxvlSMle61hKLierCrDEbaMiJO3OabnI+Y81Y2Ljk9qikjUNkEn+lSpFTpSSuMIHelBHUEcCmuMMA3focVDvw2PfrTSbMm2nYmUkKQr4B64pQSeh6VEHAznP5U8MB3odwUnsxzZOOSaAPbmk3ikL5XjOfpRqO48nFJhmbAXJ7c4qazspbuQRpw3XbyDXd+H/B4hHmXJzOR7Mqj1HqaidRU9ztw2Bq4h+6tDktL0G81B1VYWwTjdxt/nXdaB4FswTJdR/aApIw64BP5/Wup0+xijACIFQYB4A9ucda1reGOEZ3YBPBxxn2riniZvRH0WGyqnTV5K78yDTLCHT08qzhSIbdpwece1WpJEt4QFYKAQRubvSktISjApJ/e6cVPY24eVXmO+SM7gDjBA9eKyUpSZ6aioo0dLtZZhG8is0pOQu3hh7CujtoVj+RlMZ64brWXBclJEkikKyKcq1Sahqckjm4uZDI+MbgBmrbdjhqRqVJW6GtcXcdvFu3bQOm2sm91B5SdrkEjnjrWLdXvnz+XkFmGcYOB+tM+1siCNl2Nn5SW5pOUmVTw6h7zNSGRQ5MjjPYHrSXt1iNT5qoc9ulc0dYt98zliwi/5anj/AICvqa5e58SmbbGjIVY5+6ePY89aa5tkXKys2dXqGpkTOqHJB5bv+FUzffOFdw4xkEcEe1crJqoiCyu5Bf7p6gfhVO51MzBpCY4oEOJblsgKPzpqM2ZTxMYK7djo7nWZrpzbW5HmZOd5KhfckjgfjRXkfirxZNqER06wzDYxkqzByWn56k+ntRXXHCSkrt2Pm8Rn7jO1NXXzOSFLxg0UV6B8wLx1HHtTopmicNGxBFFFKw4ycXdG9p9zFe4X7kwHC/3vpV+K3jcbt21geAp/nRRXJV9x6H0eCqOtTUplmOyimYh13FTznP6Utvpdu1zynyknC8j9aKKwjJ9zsjTjfYlfSbVzKVQA49ztPvTE0iFuEgMhAySueKKKlzkjSNKDeqFg8OmSZSrR4b+BkPT61u2PhqJXDuikoQduW+b6UUVlVrTTsmddGhTjqkdNZ20Me1oECMRtwhJ2jHp3/GtqOBmiUYHOTwvBI9T0FFFclWpKx6lF7isWZR8jAYzjGMYqVgAqmQHy27Hg5+nU0UVCm3KxrdluKLytzT4VccZ5I+tTeesMAeeQJGOAxI5FFFTGrK1xSk29TMuPECrmGJWJB5csMMPaqE2tHe3IXI5GBx9P/r0UVvGTaRzzm0royL3XpBGrI+MdDhf1z/Sse/1+4uGkJlypX7uwGiiuhM4ataempkz3wlYM3yAfL0GBnsO9VZdRWFzt3YHG0Yz9aKK3ic1atNWM+5v4ldrm5yE7Rjq5965vU9SuNQkzK22IfdiU4VfoP60UV3UYq1z5nMa85T5WyjRRRWx5p//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39363=[""].join("\n");
var outline_f38_28_39363=null;
var title_f38_28_39364="Oxandrolone: Drug information";
var content_f38_28_39364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxandrolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/53/9045?source=see_link\">",
"    see \"Oxandrolone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxandrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Androgen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Weight gain (adjunct):",
"     </b>",
"     Oral: 2.5-20 mg in divided doses 2-4 times daily based on individual response; a course of therapy of 2-4 weeks is usually adequate. This may be repeated intermittently as needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Weight gain (adjunct):",
"     </b>",
"     Oral: Children: Total daily dose: &le;0.1 mg/kg; may be repeated intermittently as needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Weight gain (adjunct):",
"     </b>",
"     Oral: 5 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F204325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution due to propensity to cause edema.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F204326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxandrin&reg;: 2.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxandrin&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F204339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who, without definite pathophysiologic reasons, fail to gain or to maintain normal weight; to offset protein catabolism with prolonged corticosteroid administration; relief of bone pain associated with osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, excitation, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne (females and prepubertal males)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Also reported in females: Hirsutism, male-pattern baldness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Also reported in females: Clitoral enlargement, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prepubertal males: Increased or persistent erections, penile enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Prothrombin time increased, suppression of clotting factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, premature closure of epiphyses (in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine excretion increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bromsulfophthalein retention, habituation, voice alteration (deepening, in females)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nephrosis; carcinoma of breast or prostate; hypercalcemia; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood lipid changes:",
"     <b>",
"      [U.S. Boxed Warning]: May cause blood lipid changes with increased risk of arteriosclerosis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Anabolic steroids may cause peliosis hepatis or liver cell tumors which may not be apparent until liver failure or intra-abdominal hemorrhage develops.",
"     </b>",
"     Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests. Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis. Discontinue use if hypercalcemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; COPD: Use with caution in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Use caution with concomitant warfarin therapy; warfarin dose may need to be significantly decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients, they may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May accelerate bone maturation without producing compensatory gain in linear growth in children; in prepubertal children perform radiographic examination of the left hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: Discontinue with evidence of mild virilization in women; early discontinuation may prevent irreversible virilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Anabolic steroids have not been shown to improve athletic ability.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16122504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if oxandrolone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F204317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxandrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $785.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $1597.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxandrolone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $552.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $1125.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kicker (KP);",
"     </li>",
"     <li>",
"      Oxandrin (AU);",
"     </li>",
"     <li>",
"      Oxandrolone SPA (IT);",
"     </li>",
"     <li>",
"      Vasorome (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic testosterone derivative with similar androgenic and anabolic actions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F854656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Half-life elimination: 10-13 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10181 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39364=[""].join("\n");
var outline_f38_28_39364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709184\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204321\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204337\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204323\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204334\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204324\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204325\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204326\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204313\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204339\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204314\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204335\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204316\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204303\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299799\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204307\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204308\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204318\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204327\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16122504\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204317\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204310\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539909\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204302\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854656\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/53/9045?source=related_link\">",
"      Oxandrolone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39365="Tamsulosin: Drug information";
var content_f38_28_39365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tamsulosin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/39/30324?source=see_link\">",
"    see \"Tamsulosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flomax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ava-Tamsulosin CR;",
"     </li>",
"     <li>",
"      Flomax&reg; CR;",
"     </li>",
"     <li>",
"      JAMP-Tamsulosin;",
"     </li>",
"     <li>",
"      Mylan-Tamsulosin;",
"     </li>",
"     <li>",
"      RAN&trade;-Tamsulosin;",
"     </li>",
"     <li>",
"      ratio-Tamsulosin;",
"     </li>",
"     <li>",
"      Sandoz-Tamsulosin;",
"     </li>",
"     <li>",
"      Sandoz-Tamsulosin CR;",
"     </li>",
"     <li>",
"      Teva-Tamsulosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Benign prostatic hyperplasia (BPH):",
"     </b>",
"     Oral: 0.4 mg once daily ~30 minutes after the same meal each day; dose may be increased after 2-4 weeks to 0.8 mg once daily in patients who fail to respond. If therapy is interrupted for several days, restart with 0.4 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bladder outlet obstruction symptoms (unlabeled use):",
"     </b>",
"     Oral: 0.4 mg once daily (Rossi, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ureteral stones, expulsion (unlabeled use):",
"     </b>",
"     Oral: 0.4 mg once daily, discontinue after successful expulsion  (average time to expulsion was 1-2 weeks) (Agrawal, 2009; Ahmed, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Patients with stones &gt;10 mm were excluded from studies.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F224760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Not studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6144844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Not studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 0.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flomax&reg;: 0.4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 30 minutes after the same meal each day. Capsules should be swallowed whole; do not crush, chew, or open.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of signs and symptoms of benign prostatic hyperplasia (BPH)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4369799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of bladder outlet obstruction or dysfunction; facilitation of expulsion of ureteral stones",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F224801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flomax&reg; may be confused with Flonase&reg;, Flovent&reg;, Foltx&reg;, Fosamax&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tamsulosin may be confused with tacrolimus, tamoxifen, terazosin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flomax [U.S., Canada, and multiple international markets] may be confused with Flomox brand name for cefcapene [Japan]; Volmax brand name for salbutamol [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flomax: Brand name for tamsulosin [U.S., Canada, and multiple international markets], but also the brand name for morniflumate [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (6% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (19% to 21%), dizziness (15% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal ejaculation (8% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (13% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (3% to 4%), insomnia (1% to 2%), vertigo (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4% to 6%), nausea (3% to 4%), gum pain, toothache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8% to 9%), back pain (7% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (5% to 6%), cough (3% to 5%), sinusitis (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions (angioedema, pruritus, rash, urticaria, respiratory symptoms); constipation, hypotension, intraoperative floppy iris syndrome, lightheadedness, orthostasis (symptomatic), palpitation, priapism, skin desquamation, syncope, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tamsulosin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Discontinue if symptoms of angina occur or worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of tamsulosin use when considering eye surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. &ldquo;First-dose&rdquo; orthostatic hypotension may occur 4-8 hours after dosing; may be dose related. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Rarely, patients with a sulfa allergy have also developed an allergic reaction to tamsulosin; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer:  It is recommended to rule out prostatic carcinoma before beginning therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensive use: Not intended for use as an antihypertensive drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F224788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F224751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Fasting increases bioavailability by 30% and peak concentration 40% to 70%. Management: Administer 30 minutes after the same meal each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease the levels/effects of tamsulosin. Some herbal medications have hypotensive properties or may increase the hypotensive effect of tamsulosin. Limited information is available regarding combination with saw palmetto. Management: Avoid St John's wort, black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse. Avoid saw palmetto.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F224741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take once daily, 30 minutes after the same meal each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Flomax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg (100): $623.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tamsulosin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg (100): $421.36",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alna (AT, DE);",
"     </li>",
"     <li>",
"      Comadex (EC);",
"     </li>",
"     <li>",
"      Flomax (NZ, TR);",
"     </li>",
"     <li>",
"      Flomaxtra (AU, NZ);",
"     </li>",
"     <li>",
"      Flomaxtra XL (GB);",
"     </li>",
"     <li>",
"      Harnal (CL, HK, JP, PH);",
"     </li>",
"     <li>",
"      Harnal D (ID);",
"     </li>",
"     <li>",
"      Harnal OCAS (ID, MY, PH, SG, TH);",
"     </li>",
"     <li>",
"      Harnalidge D (TW);",
"     </li>",
"     <li>",
"      Harusin SR (KP);",
"     </li>",
"     <li>",
"      Josir (FR);",
"     </li>",
"     <li>",
"      Lutsnal (KP);",
"     </li>",
"     <li>",
"      Mecir LP (FR);",
"     </li>",
"     <li>",
"      Omexel LP (FR);",
"     </li>",
"     <li>",
"      Omic (BE, LU);",
"     </li>",
"     <li>",
"      Omix Ocas (CH);",
"     </li>",
"     <li>",
"      Omnexel (IE);",
"     </li>",
"     <li>",
"      Omnic (AR, CN, CO, CZ, DE, DK, EE, ES, FI, GR, HU, IL, IT, NL, NO, PE, PL, PT, PY, RU);",
"     </li>",
"     <li>",
"      Omnic OCAS (IL);",
"     </li>",
"     <li>",
"      Omnic Tocas (BG);",
"     </li>",
"     <li>",
"      Pimax (PH);",
"     </li>",
"     <li>",
"      Pradif (PT);",
"     </li>",
"     <li>",
"      Promnix (IL);",
"     </li>",
"     <li>",
"      Prozelax (PH);",
"     </li>",
"     <li>",
"      Secotex (AR, CN, CO, CR, DO, GT, HN, MX, NI, PA, PE, PY, SV, UY, VE);",
"     </li>",
"     <li>",
"      Secotex OCAS (CR, DO, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Sulopros (PH);",
"     </li>",
"     <li>",
"      Sulosin (KP);",
"     </li>",
"     <li>",
"      Sulosin D (KP);",
"     </li>",
"     <li>",
"      Tabphyn MR (GB);",
"     </li>",
"     <li>",
"      Tamlosin (TW);",
"     </li>",
"     <li>",
"      Tamlosin SR (KP);",
"     </li>",
"     <li>",
"      Tamsnal SR (KP);",
"     </li>",
"     <li>",
"      Tamsulin (IL);",
"     </li>",
"     <li>",
"      Tamsulo (KP);",
"     </li>",
"     <li>",
"      Tamsulon (CR, DO, EC, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Tamunal (KP);",
"     </li>",
"     <li>",
"      Tarunal (KP);",
"     </li>",
"     <li>",
"      Urimax (IN);",
"     </li>",
"     <li>",
"      Urnal (TW);",
"     </li>",
"     <li>",
"      Urotams SR (KP);",
"     </li>",
"     <li>",
"      Zotan (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tamsulosin is an antagonist of alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors in the prostate. Smooth muscle tone in the prostate is mediated by alpha",
"     <sub>",
"      1A",
"     </sub>",
"     -adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptors in the prostate are of the alpha",
"     <sub>",
"      1A",
"     </sub>",
"     subtype.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 16 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94% to 99%, primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein (AAG)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensive) via CYP3A4 and 2D6; metabolites undergo extensive conjugation to glucuronide or sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Fasting: 30% increase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Steady-state: By the fifth day of once-daily dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Healthy volunteers: 9-13 hours; Target population: 14-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Fasting: 4-5 hours; With food: 6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (76%, &lt;10% as unchanged drug); feces (21%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agrawal M, Gupta M, Gupta A, et al, &ldquo;Prospective Randomized Trial Comparing Efficacy of Alfuzosin and Tamsulosin in Management of Lower Ureteral Stones,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2009, 73(4):706-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/19193417/pubmed\" id=\"19193417\" target=\"_blank\">",
"        19193417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahmed AF and Al-Sayed AY, &ldquo;Tamsulosin versus Alfuzosin in the Treatment of Patients with Distal Ureteral Stones: Prospective, Randomized, Comparative Study,&rdquo;",
"      <i>",
"       Korean J Urol",
"      </i>",
"      , 2010, 51(3):193-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/20414396/pubmed\" id=\"20414396\" target=\"_blank\">",
"        20414396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang DF and Campbell JR, &ldquo;Intraoperative Floppy Iris Syndrome Associated With Tamsulosin,&rdquo;",
"      <i>",
"       J Cataract Refract Surg",
"      </i>",
"      , 2005, 31(4):664-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/15899440/pubmed\" id=\"15899440\" target=\"_blank\">",
"        15899440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldman HB and Zimmern PE, &ldquo;The Treatment of Female Bladder Outlet Obstruction,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2006, 98(Suppl 1):17-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/16911596/pubmed\" id=\"16911596\" target=\"_blank\">",
"        16911596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pischedda A, Pirozzi Farina F, Madonia M, et al, &ldquo;Use of Alpha",
"      <sub>",
"       1",
"      </sub>",
"      -Blockers in Female Functional Bladder Neck Obstruction,&rdquo;",
"      <i>",
"       Urol Int",
"      </i>",
"      , 2005, 74(3):256-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/15812214/pubmed\" id=\"15812214\" target=\"_blank\">",
"        15812214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossi C, Kortmann BB, Sonke GS, et al, &ldquo;Alpha-Blockade Improves Symptoms Suggestive of Bladder Outlet Obstruction But Fails to Relieve It,&rdquo;",
"      <i>",
"       J  Urol",
"      </i>",
"      , 2001, 165(1):38-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/28/39365/abstract-text/11125359/pubmed\" id=\"11125359\" target=\"_blank\">",
"        11125359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9654 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39365=[""].join("\n");
var outline_f38_28_39365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224755\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224794\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224759\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224760\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224761\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6144844\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224732\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224719\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224735\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224734\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369799\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224801\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224792\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224723\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224788\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224751\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224729\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224740\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224741\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224739\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224742\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224722\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224737\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9654|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/39/30324?source=related_link\">",
"      Tamsulosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39366="Sodium chloride preparations (saline and oral salt tablets): Patient drug information";
var content_f38_28_39366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium chloride preparations (saline and oral salt tablets): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15097?source=see_link\">",
"     see \"Sodium chloride preparations (saline and oral salt tablets): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/41/36503?source=see_link\">",
"     see \"Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      4-Way&reg; Saline Moisturizing Mist [OTC];",
"     </li>",
"     <li>",
"      Altachlore [OTC];",
"     </li>",
"     <li>",
"      Altamist [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Baby Saline [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline Nasal Gel [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline No-Drip [OTC];",
"     </li>",
"     <li>",
"      Ayr&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Deep Sea [OTC];",
"     </li>",
"     <li>",
"      Entsol&reg; [OTC];",
"     </li>",
"     <li>",
"      HuMist&reg; [OTC];",
"     </li>",
"     <li>",
"      HyperSal&reg;;",
"     </li>",
"     <li>",
"      Little Noses&reg; Saline [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Sterile Saline Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Stuffy Nose Kit [OTC];",
"     </li>",
"     <li>",
"      Muro 128&reg; [OTC];",
"     </li>",
"     <li>",
"      Na-Zone&reg; [OTC];",
"     </li>",
"     <li>",
"      NebuSal&trade;;",
"     </li>",
"     <li>",
"      Ocean&reg; for Kids [OTC];",
"     </li>",
"     <li>",
"      Ocean&reg; [OTC];",
"     </li>",
"     <li>",
"      Pretz&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris&reg; [OTC];",
"     </li>",
"     <li>",
"      Safe Wash&trade; [OTC];",
"     </li>",
"     <li>",
"      Saline Mist [OTC];",
"     </li>",
"     <li>",
"      Saljet&reg; [OTC];",
"     </li>",
"     <li>",
"      Sea Soft Nasal Mist [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      Simply Saline&reg; [OTC];",
"     </li>",
"     <li>",
"      Sochlor&trade; [OTC];",
"     </li>",
"     <li>",
"      Syrex;",
"     </li>",
"     <li>",
"      Wound Wash Saline&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral and shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low sodium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used in the diet to meet sodium needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to mix with a drug that is given as a shot into the vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It adds water into the breathing tubes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the fluid in the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add water to the nose passages.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691651",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin fluid in the nose passages.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean wounds.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium chloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral and shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703769",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high sodium levels or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablets with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only by a puffer (inhaler) or as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All eye products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694920",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gently press the skin under the lower eyelid and pull the lower eyelid away from the eye slightly until you can see a small pouch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put in 1 drop. Wait 1 minute before the next drop.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gently pull down the lower lid and squeeze in how much the doctor told you to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Release the lower eyelid and keep eyes closed for 1 to 2 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12120 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39366=[""].join("\n");
var outline_f38_28_39366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221678\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022976\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022978\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022977\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022982\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022983\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022985\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022980\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022981\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022986\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022987\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15097?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/41/36503?source=related_link\">",
"      Sodium chloride preparations (saline and oral salt tablets): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39367="IgA nephropathy: Recurrence after transplantation";
var content_f38_28_39367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   IgA nephropathy: Recurrence after transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39367/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/28/39367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation is the treatment of choice for individuals with progressive renal failure due to IgA nephropathy (IgAN). Despite the observation that IgAN is one of the most common causes of glomerulonephritis, there have been no large, prospective studies defining the risk of recurrence and resultant graft dysfunction in patients with IgAN who receive either a living donor or deceased donor renal allograft.",
"   </p>",
"   <p>",
"    Recurrent IgA deposition, as determined on biopsy, may result in a wide spectrum of manifestations, ranging from an incidentally noted histologic finding to mesangioproliferative glomerulonephritis associated with hematuria, proteinuria, and progressive renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/1\">",
"     1",
"    </a>",
"    ]. IgA deposition may occur alone or be concurrent with other significant pathology, including chronic rejection.",
"   </p>",
"   <p>",
"    Issues related to recurrence after transplantation in patients with IgA nephropathy or Henoch-Sch&ouml;nlein purpura (IgA vasculitis) will be reviewed here. The treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECURRENCE AFTER TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk of recurrence and allograft dysfunction or loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of histologic or clinically significant recurrence of IgAN varies in the reported literature, with the incidence probably increasing as a function of time from transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Given the lack of a prospective study involving protocol biopsies, the true risk of significant graft dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graft loss from recurrent disease is unclear. However, despite an increased risk of recurrent disease, overall graft survival in patients with a history of IgAN is",
"    <strong>",
"     similar",
"    </strong>",
"    to that of patients with a history of non-IgA glomerular or non-glomerular disease.",
"   </p>",
"   <p>",
"    Histologic recurrence, with or without evidence of clinical disease, is observed in most cases. As an example, in a combined retrospective and prospective study that reviewed biopsies from 29 allografts, histologic recurrence of IgA deposition was found in 17 patients (58 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/5\">",
"     5",
"    </a>",
"    ]. Three of these patients had a normal urinalysis and normal glomeruli on light microscopy, while five had hematuria, heavy proteinuria, hypertension, and progressive renal failure due to IgAN alone. The only predictor for recurrence was a longer time after transplantation (46 versus 15 months in those without recurrence).",
"   </p>",
"   <p>",
"    Given the lack of a prospective study involving protocol biopsies, the true risk of significant graft dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graft loss from recurrent disease is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. In retrospective analyses of allograft biopsies obtained due to clinical concern for graft dysfunction, the recurrence of IgAN has ranged from 21 to 58 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Among those with graft dysfunction attributed to recurrent IgAN, eventual graft loss has been reported in 46 to 71 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest reported retrospective analysis (532 allograft recipients with primary IgAN) is from Australia, where the estimated 10-year incidence of graft loss due to recurrent disease was",
"    <strong>",
"     9.7 percent",
"    </strong>",
"    (95% CI 4.7-19.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/11\">",
"     11",
"    </a>",
"    ]. Allografts in IgAN recipients exhibited a similar 10-year survival as allografts in recipients with either non-IgA glomerular or non-glomerular disease. In this series, recurrent IgAN was a less frequent cause of graft loss than either chronic rejection or death with a functioning graft. The risk of graft loss in relation to donor source was not evaluated. The presence of additional pathologic conditions, such as chronic allograft nephropathy, may also influence the risk of graft loss or potentially underestimate the contribution due to recurrent IgAN. A Korean study of 221 patients with IgA nephropathy found that although the presence of chronic allograft nephropathy was a more important predictor of longterm allograft function, 10 year graft survival was still lower among those with recurrent IgAN without allograft nephropathy compared with those without recurrent IgAN and without allograft nephropathy (70 versus 91 percent, respectively). The hazard ratio for graft loss with recurrent IgAN was 2.5 (95% CI, 0.9-7.3), but this was not statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were reported in a review of 10 retrospective analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/13\">",
"     13",
"    </a>",
"    ]. At a mean follow-up period of 67 months, there was a 15 percent incidence of significant graft dysfunction and a 7 percent incidence of graft loss due to recurrent IgAN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Donor effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting data exist concerning a possible increased risk for recurrent IgAN in recipients of living-related allografts compared to that with unrelated (living or deceased donor) allografts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several retrospective analyses have found no increased risk of recurrence based upon living versus deceased donor status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8,9,14\">",
"       8,9,14",
"      </a>",
"      ]. Another report found no difference in risk among recipients of living-related versus living-unrelated donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By comparison, other studies have reported an increased risk of recurrence in recipients of living-related allografts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/10,15-17\">",
"       10,15-17",
"      </a>",
"      ]. There was no significant difference in graft survival based upon donor status in some reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/10,15\">",
"       10,15",
"      </a>",
"      ], while others reported a survival advantage for living related donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is therefore possible that, in renal transplant recipients with primary IgAN, the donor source may have an effect upon the likelihood of recurrence in the allograft.",
"   </p>",
"   <p>",
"    However, there is",
"    <strong>",
"     no",
"    </strong>",
"    basis for avoiding a living-related donor source, largely due to the reported equivalence of graft survival independent of IgAN recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     HLA effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA specificity may affect the likelihood of recurrent IgAN, with the presence of either HLA-B35 or HLA-DR4 increasing the risk in some series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Other studies noted a higher representation of HLA-B35 and HLA-DR4 in the IgAN population, but their presence had no effect on the incidence of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/6,9,10,17,20,21\">",
"     6,9,10,17,20,21",
"    </a>",
"    ]. An analysis of the Eurotransplant registry revealed that the 10 year graft survival was significantly lower among patients with IgAN and HLA-B8,D3 than those with IgAN without HLA-B8,D3 (52.5 percent versus 69.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/22\">",
"     22",
"    </a>",
"    ]. Graft survival was worse even among those with zero mismatched kidneys suggesting that graft loss may be due to factors other than rejection although no definite association with IgAN recurrence was demonstrated. Conversely, the presence of HLA-B8,D3 did not influence graft outcomes among control patients with",
"    <span class=\"nowrap\">",
"     pyelonephritis/interstitial",
"    </span>",
"    nephritis and polycystic kidney disease.",
"   </p>",
"   <p>",
"    A separate issue is the importance of HLA matching:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 54 patients with 61 renal transplants for end-stage renal disease due to IgAN, there was a statistically significant decrease in graft survival with",
"      <strong>",
"       better",
"      </strong>",
"      HLA-DR matching [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8\">",
"       8",
"      </a>",
"      ]. There were insufficient numbers to separately calculate the effect in living-related versus deceased donor recipients.",
"     </li>",
"     <li>",
"      A registry study of 1354 patients with end-stage disease due to IgAN from Australia and New Zealand showed that zero HLA mismatched living donor recipients were more likely to develop recurrence (17 percent) than the whole cohort of living and deceased donors (7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, although graft survival did not differ among those with recurrence and zero compared to one or more HLA mismatches, the survival advantage of a zero antigen HLA mismatch was lost.",
"     </li>",
"     <li>",
"      Conversely, a Korean study found no association with full HLA match and the risk of recurrent IgAN among patients with IgAN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other risk factors have been proposed. These include an increased risk of recurrent disease in patients with increased serum IgA concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/16,23\">",
"     16,23",
"    </a>",
"    ] and markedly decreased graft survival with chronic rejection in combination with recurrent IgAN compared to recurrent IgAN alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Timing of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;If IgAN recurs, the time to onset of clinical manifestations due to renal IgA deposition appears to vary. In one study of 61 transplant recipients with initial kidney loss due to IgAN (of whom 18 had recurrent disease), the mean time to clinical recurrence and allograft failure was 31 and 63 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8\">",
"     8",
"    </a>",
"    ]. Occasionally, patients may develop early graft failure associated with crescentic IgAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/18,25,26\">",
"     18,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A correlation appears to exist between the time to onset of renal failure after initial disease presentation and the time to the development of clinically significant recurrence in the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8-10,27\">",
"     8-10,27",
"    </a>",
"    ]. Thus, patients with a rapidly progressive course of IgAN in their native kidneys should be informed that recurrent disease in the transplanted kidney may manifest early.",
"   </p>",
"   <p>",
"    In the patient with early graft loss from recurrent IgAN, a rapid return of clinical signs related to IgA deposition may be observed with repeat transplantation; however, this is not certain. Data on the expected outcome in a second transplant after the first was lost to recurrent IgAN are limited, but good long-term function has been described, despite evidence of IgA deposition in the second allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8,27\">",
"     8,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Markers for risk of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all glomerulopathies, increased urinary protein excretion and increased sclerosis and fibrosis on renal biopsy with IgAN are associated with an enhanced risk of progressive disease. In one study of recurrent IgAN, for example, urine protein excretion greater than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and biopsy findings of prominent glomerulosclerosis (involving more than 30 percent of glomeruli) were associated with universal graft loss by six years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/28\">",
"     28",
"    </a>",
"    ]. By comparison, urinary excretion less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and a renal biopsy in which less than 10 percent of glomeruli show glomerulosclerosis forecast stable allograft function at nine years post-transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although persistent microscopic hematuria may be an early marker of recurrent IgAN, its onset does not necessarily predict a poor outcome. A review of 41 renal transplant recipients with primary IgAN found a higher prevalence of persistent microscopic hematuria compared to recipients with other native renal disease (32 versus 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/29\">",
"     29",
"    </a>",
"    ]. Hematuria in the IgAN patients was not associated with donor status, renal function, or time since transplantation.",
"   </p>",
"   <p>",
"    While persistent microscopic hematuria in a patient with IgAN is likely secondary to recurrent disease, this should not be assumed, and other potential etiologies should be investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether the likelihood of IgAN recurrence is affected by the type of maintenance immunosuppressive agents used. No significant difference, for example, has been observed in the incidence or severity of IgAN in studies comparing the pre- and post-cyclosporine eras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There is some evidence that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil may decrease the risk of IgAN recurrence in the short term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/6,30,31\">",
"     6,30,31",
"    </a>",
"    ]. However, other studies have found no association with mycophenolate and recurrent IgAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Furthermore, in an analysis of the United States Renal Data System, the use of mycophenolate was associated with a non-significant trend towards an increased risk of graft loss due to recurrent IgAN (HR 1.79, 95% CI, 0.49-6.49) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/35\">",
"     35",
"    </a>",
"    ]. In this same study, a non-significant trend for a decreased risk of graft loss due to recurrent IgAN was associated with the use of steroids (HR 0.57, 95% CI, 0.12-2.71). However, neither association reached statistical significance. In an analysis of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) of 1521 first time kidney transplant recipients with ESRD from IgA, maintenance steroid use was strongly associated with a reduced risk of recurrence (subhazard ratio 0.50, 95% CI 0.30&ndash;0.84) after adjusting for age, sex, HLA mismatch, dialysis duration, and transplant era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the choice of induction agent has any beneficial clinical effect on the incidence of recurrent IgAN is unclear. A retrospective analysis reported that the prevalence of recurrent IgA following transplantation was significantly reduced in patients receiving antithymocyte globulin, compared to either IL-2 induction or no induction treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/37\">",
"     37",
"    </a>",
"    ]. In this report, the 10-year cumulative recurrence rate, as defined by clinically directed biopsy, was 36 percent overall, 9 percent with antithymocyte induction, 41 percent with no induction, and 41 percent at a shorter five-year follow-up with IL-2 induction. Maintenance immunosuppression varied with the era. Graft loss from recurrent IgAN was 6 percent overall, and there was no difference in overall graft or patient survival based on choice of induction agent. Another study found a reduced risk of recurrent glomerulonephritis with thymoglobulin induction compared with either IL-2 or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    induction (HR 0.13, 95% CI, 0.02-0.98) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/38\">",
"     38",
"    </a>",
"    ]. Among persons with IgAN, the recurrent disease occurred in 0 percent, 7.3 percent, and 3.7 percent with thymoglobulin, IL-2, and alemtuzumab induction, respectively.",
"   </p>",
"   <p>",
"    Adapted from its use in treating IgAN in native kidneys, angiotensin converting enzyme inhibitor therapy may delay progression of recurrent disease in allografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, it is not clear that graft survival is actually improved by initiating either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker following the detection of recurrent IgAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have also been case reports of fish oil having a favorable effect in recurrent IgAN, but no studies have been performed to support its routine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HENOCH-SCH&Ouml;NLEIN PURPURA (IGA VASCULITIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (IgA vasculitis), or HSP (IgAV), which has renal manifestations indistinguishable from IgAN, usually occurs in children, but has also been reported in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5993?source=see_link\">",
"     \"Renal manifestations of Henoch-Sch&ouml;nlein purpura\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding recurrence rates after transplantation in HSP are limited. One analysis found overall a recurrent rate of 15 percent and graft survival rates of nearly 90 percent at 10 years, while another pooled analysis demonstrated clinically significant disease in 35 percent and graft loss in 11 percent at five years post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These latter values are similar to those described above in IgAN. Also similar to IgAN, patients with a rapid pretransplant course culminating in renal failure tended to develop prompt recurrence in the allograft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF GLOMERULAR IGA DEPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal allograft recipients without native IgAN but with cirrhosis or celiac disease (gluten enteropathy) may develop mesangial IgA deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Impaired removal of IgA complexes in liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and the formation of IgA anti-gluten antibodies in celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/48\">",
"     48",
"    </a>",
"    ] are thought to underlie this process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the increased incidence of celiac disease in the diabetic population and the occasional patient with preexistent liver disease that progresses to cirrhosis after renal transplantation, IgA deposition that is unrelated to recurrent disease in a renal allograft is not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/49\">",
"     49",
"    </a>",
"    ]. Despite the IgA deposition, it is unusual for clinical evidence of renal disease related to IgAN to be apparent in a native (or transplant) kidney in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The absence of clinically significant disease is postulated to result from a lack of complement activation and resultant inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/45\">",
"     45",
"    </a>",
"    ]. The degree of concurrent IgG and complement deposition on immunofluorescence may help clarify whether the mesangial IgA deposition is solely a histologic finding or relevant to graft dysfunction.",
"   </p>",
"   <p>",
"    In those with liver disease and progressive IgAN, the nephropathy may resolve after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/50\">",
"     50",
"    </a>",
"    ]. Similarly, in a native kidney with celiac disease-induced IgAN, the nephropathy may resolve with a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no published data looking at the potential recurrence of IgAN in renal transplant recipients in association with celiac disease. Although it would be rare for a patient to have graft dysfunction as a result of IgA deposition in this setting, given the incidence of celiac disease in the general population, particularly in diabetics, consideration to screen patients with recurrent IgAN for celiac disease is not unreasonable. This is particularly true in patients with otherwise unexplained diarrhea, malabsorption, or iron deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION OF A KIDNEY WITH IGA DEPOSITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both deceased and living donor kidneys with IgA deposition have been transplanted into non-IgAN recipients. In one study of 70 living donor kidney biopsies obtained just prior to transplantation, 13 percent had glomerular IgA deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/53\">",
"     53",
"    </a>",
"    ]. Another report described the presence of latent mesangial IgA deposits in approximately 16 percent of biopsies obtained at the time of transplantation from both living and deceased donors otherwise considered healthy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/54\">",
"     54",
"    </a>",
"    ]. Graft outcomes were not reported in either of these analyses.",
"   </p>",
"   <p>",
"    A prospective analysis of 83 recipients of deceased donor allografts with IgA deposition reported an increased incidence of early acute rejection (31 versus 19 percent), delayed graft function, proteinuria, and hematuria compared to 259 recipients of a deceased donor allograft without evidence of IgA deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/55\">",
"     55",
"    </a>",
"    ]. Serial protocol biopsies tended to demonstrate gradual resolution of IgA deposition within 45 days following transplantation as well as resolution of the proteinuria and hematuria. Despite the increased incidence of acute rejection and clinical signs of allograft dysfunction, graft survival at one and three years was similar in both groups.",
"   </p>",
"   <p>",
"    Two other series with a total of 12 patients noted rapid resolution of IgA deposits after transplantation in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. At present, our practice is",
"    <strong>",
"     not",
"    </strong>",
"    to use kidneys with known IgA deposits for donation. However, we have unknowingly transplanted deceased donor allografts with evidence of IgA deposition evident on an early post-transplant biopsy that has resolved on follow-up biopsy with no evidence for adverse outcome on graft function or survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible that, in some renal transplant recipients with primary IgAN, the donor source may have an effect upon the timing and likelihood of recurrence in the allograft. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Donor effect'",
"    </a>",
"    above.) Therefore, the expected advantage in allograft survival with a living-related compared to deceased donor source may be negated. Overall, however, there does",
"    <strong>",
"     not",
"    </strong>",
"    seem to be any basis to avoiding a living-related donor source, given the reported equivalence of graft survival independent of IgAN recurrence, the expected deceased donor waiting list time, and a reported decrease in patient mortality and increase in graft survival with earlier transplantation in relation to time on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39367/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with a rapidly progressive course of native IgAN should be informed that recurrent disease in the transplanted kidney may present early. Recurrence of IgAN that results in graft loss should not preclude consideration for subsequent retransplantation.",
"   </p>",
"   <p>",
"    Despite the lack of proven efficacy in improving long-term outcomes, angiotensin converting enzyme inhibitors or angiotensin receptor blockers should be initiated with evidence of recurrent IgAN. Whether routine, early post-transplant initiation of these agents to all recipients with native IgAN, independent of disease recurrence, is beneficial is unknown. At a minimum, they should be included as first line agents for blood pressure control in this population. Other modalities, such as fish oil, remain to be adequately tested. There is no evidence that any immunosuppressive agent, alone or in combination, is of benefit in either preventing the recurrence or altering the course of recurrent IgAN.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/1\">",
"      Kowalewska J, Yuan S, Sustento-Reodica N, et al. IgA nephropathy with crescents in kidney transplant recipients. Am J Kidney Dis 2005; 45:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/2\">",
"      Andresdottir MB, Haasnoot GW, Doxiadis II, et al. Exclusive characteristics of graft survival and risk factors in recipients with immunoglobulin A nephropathy: a retrospective analysis of registry data. Transplantation 2005; 80:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/3\">",
"      Koch MJ. Considerations in retransplantation of the failed renal allograft recipient. Adv Chronic Kidney Dis 2006; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/4\">",
"      Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/5\">",
"      Odum J, Peh CA, Clarkson AR, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 1994; 9:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/6\">",
"      Kim YS, Moon JI, Jeong HJ, et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001; 71:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/7\">",
"      Kessler M, Hiesse C, Hestin D, et al. Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis 1996; 28:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/8\">",
"      Bumgardner GL, Amend WC, Ascher NL, Vincenti FG. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 1998; 65:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/9\">",
"      Frohnert PP, Donadio JV Jr, Velosa JA, et al. The fate of renal transplants in patients with IgA nephropathy. Clin Transplant 1997; 11:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/10\">",
"      Freese P, Svalander C, Nord&eacute;n G, Nyberg G. Clinical risk factors for recurrence of IgA nephropathy. Clin Transplant 1999; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/11\">",
"      Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/12\">",
"      Han SS, Huh W, Park SK, et al. Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int 2010; 23:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/13\">",
"      Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/14\">",
"      Ponticelli C, Traversi L, Feliciani A, et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/15\">",
"      Andresdottir MB, Hoitsma AJ, Assmann KJ, Wetzels JF. Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol 2001; 56:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/16\">",
"      Wang AY, Lai FM, Yu AW, et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001; 38:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/17\">",
"      McDonald SP, Russ GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 2006; 82:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/18\">",
"      Brensilver JM, Mallat S, Scholes J, McCabe R. Recurrent IgA nephropathy in living-related donor transplantation: recurrence or transmission of familial disease? Am J Kidney Dis 1988; 12:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/19\">",
"      Matsugami K, Naito T, Nitta K, et al. [A clinicopathological study of recurrent IgA nephropathy following renal transplantation]. Nihon Jinzo Gakkai Shi 1998; 40:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/20\">",
"      Hiki Y, Kobayashi Y, Ookubo M, et al. Association of HLA-DQw4 with IgA nephropathy in the Japanese population. Nephron 1991; 58:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/21\">",
"      Hiki Y, Kobayashi Y, Ookubo M, Kashiwagi N. The role of HLA-DR4 in the long-term prognosis of IgA nephropathy. Nephron 1990; 54:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/22\">",
"      Andresdottir MB, Haasnoot GW, Persijn GG, Claas FH. HLA-B8, DR3: a new risk factor for graft failure after renal transplantation in patients with underlying immunoglobulin A nephropathy. Clin Transplant 2009; 23:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/23\">",
"      Berger J. Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis 1988; 12:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/24\">",
"      Sumethkul V, Jirasiritham S, Chalermsanyakorn P, Buranachokpaisan W. Chronic rejection: a significant predictor of poor outcome for recurrence IgA nephropathy. Transplant Proc 2001; 33:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/25\">",
"      D&iacute;az-Tejeiro R, Maduell F, Diez J, et al. Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: an unusual clinical evolution. Nephron 1990; 54:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/26\">",
"      Streather CP, Scoble JE. Recurrent IgA nephropathy in a renal allograft presenting as crescentic glomerulonephritis. Nephron 1994; 66:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/27\">",
"      Ohmacht C, Kliem V, Burg M, et al. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation 1997; 64:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/28\">",
"      Kimata N, Tanabe K, Ishikawa N, et al. Correlation between proteinuria and prognosis of transplant IgA nephropathy. Transplant Proc 1996; 28:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/29\">",
"      McDonald KJ, McMillan MA, Rodger RS, et al. Persistent dipstick haematuria following renal transplantation. Clin Transplant 2004; 18:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/30\">",
"      Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/31\">",
"      Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/32\">",
"      Vongwiwatana A, Gourishankar S, Campbell PM, et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/33\">",
"      Chandrakantan A, Ratanapanichkich P, Said M, et al. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant 2005; 20:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/34\">",
"      Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012; 27:2965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/35\">",
"      Mulay AV, van Walraven C, Knoll GA. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 2009; 9:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/36\">",
"      Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011; 11:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/37\">",
"      Berthoux F, El Deeb S, Mariat C, et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008; 85:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/38\">",
"      Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007; 83:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/39\">",
"      Oka K, Imai E, Moriyama T, et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000; 15:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/40\">",
"      Courtney AE, McNamee PT, Nelson WE, Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 2006; 21:3550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/41\">",
"      Ng R. Fish oil therapy in recurrent IgA nephropathy. Ann Intern Med 2003; 138:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/42\">",
"      Meulders Q, Pirson Y, Cosyns JP, et al. Course of Henoch-Sch&ouml;nlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994; 58:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/43\">",
"      Han SS, Sun HK, Lee JP, et al. Outcome of renal allograft in patients with Henoch-Sch&ouml;nlein nephritis: single-center experience and systematic review. Transplantation 2010; 89:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/44\">",
"      Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/45\">",
"      Pasternack A, Collin P, Mustonen J, et al. Glomerular IgA deposits in patients with celiac disease. Clin Nephrol 1990; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/46\">",
"      Amore A, Roccatello D, Picciotto G, et al. Processing of IgA aggregates in a rat model of chronic liver disease. Clin Immunol Immunopathol 1997; 84:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/47\">",
"      Amore A, Coppo R, Roccatello D, et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994; 70:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/48\">",
"      Coppo R, Mazzucco G, Martina G, et al. Gluten-induced experimental IgA glomerulopathy. Lab Invest 1989; 60:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/49\">",
"      Cronin CC, Feighery A, Ferriss JB, et al. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am J Gastroenterol 1997; 92:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/50\">",
"      Ghabra N, Piraino B, Greenberg A, Banner B. Resolution of cirrhotic glomerulonephritis following successful liver transplantation. Clin Nephrol 1991; 35:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/51\">",
"      Woodrow G, Innes A, Boyd SM, Burden RP. A case of IgA nephropathy with coeliac disease responding to a gluten-free diet. Nephrol Dial Transplant 1993; 8:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/52\">",
"      Coppo R, Amore A, Roccatello D. Dietary antigens and primary immunoglobulin A nephropathy. J Am Soc Nephrol 1992; 2:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/53\">",
"      Rosenberg HG, Mart&iacute;nez PS, Vaccarezza AS, Mart&iacute;nez LV. Morphological findings in 70 kidneys of living donors for renal transplant. Pathol Res Pract 1990; 186:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/54\">",
"      Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/55\">",
"      Ji S, Liu M, Chen J, et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant 2004; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/56\">",
"      Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/57\">",
"      Koselj M, Rott T, Vizjak A, Kveder R. IgA nephropathy as a donor-transmitted disease in renal transplant recipients. Transplant Proc 1991; 23:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/58\">",
"      Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/59\">",
"      Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39367/abstract/60\">",
"      Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7344 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39367=[""].join("\n");
var outline_f38_28_39367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECURRENCE AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk of recurrence and allograft dysfunction or loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Donor effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - HLA effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Markers for risk of progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HENOCH-SCH&Ouml;NLEIN PURPURA (IGA VASCULITIS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER CAUSES OF GLOMERULAR IGA DEPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRANSPLANTATION OF A KIDNEY WITH IGA DEPOSITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5993?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39368="Early cardiac complications of coronary artery bypass graft surgery";
var content_f38_28_39368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early cardiac complications of coronary artery bypass graft surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Sary Aranki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39368/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/28/39368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of coronary heart disease (CHD) has evolved significantly over the past several years due in part to improvement in both surgical and percutaneous revascularization techniques. The majority of patients with chronic stable angina are still treated with medical therapy; however, revascularization with either coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) should be considered in several subgroups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The early cardiac complications after CABG will be reviewed here. Noncardiac complications and perioperative mortality after CABG are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=see_link\">",
"     \"Operative mortality after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIAC COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Perioperative MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of perioperative MI may be difficult to make after CABG, since cardiac enzyme elevations occur as a result of the surgical procedure and since electrocardiographic changes may reflect postoperative pericardial inflammation.",
"   </p>",
"   <p>",
"    We suggest using the Joint",
"    <span class=\"nowrap\">",
"     ESC/ACCF/AHA/WHF",
"    </span>",
"    Task Force definition for MI (type 5) after CABG, which requires increases of biomarkers greater than five times the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile of the upper reference limit plus either new pathologic Q waves or new left bundle branch block, or angiographically documented new graft or native coronary artery occlusion, or imaging evidence of new loss of viable myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend obtaining preprocedural and postprocedural ECGs as well as measurements of troponin at baseline and 8 to 16 hours after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Q wave MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative MI, as defined by new Q waves on the postoperative electrocardiogram (ECG), occurs in 4 to 5 percent of patients, with a range among hospitals of 0 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although usually reflecting a new MI, new Q waves after CABG can in occasional patients represent unmasking of a previous MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new Q wave MI is usually attributed to poor distal perfusion after grafting of the more proximal arteries has been performed. The incidence of MI is less in low-risk patients and higher in those with one or more of the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiomegaly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Long time on cardiopulmonary bypass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Repeat CABG (6.1 percent in one report) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CABG combined with other cardiac surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A new Q wave on the ECG is strongly suggestive of a worse outcome. In a report from the Coronary Artery Surgery Study (CASS), the 62 patients who had a Q wave MI had a higher mortality in-hospital (9.7 versus 1.0 percent in the 1278 patients without a Q wave MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/2\">",
"     2",
"    </a>",
"    ]. Among patients who survived to discharge, there was no significant difference in mortality at three years (6 versus 4 percent).",
"   </p>",
"   <p>",
"    Worse outcomes were also noted in a report from the BARI trial of patients with stable angina who had multivessel coronary disease and were treated with either CABG or percutaneous transluminal coronary angioplasty (PTCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/3\">",
"     3",
"    </a>",
"    ]. Among 1427 patients who underwent CABG, the five year mortality rate was higher when a new Q wave developed (8.2 versus 3.7 percent for no new ECG changes, adjusted relative risk 2.6). There was no increase in mortality associated with other new ECG changes (ST segment elevation or depression or T wave abnormalities). In contrast to the above report from CASS, the mortality risk increased with time after discharge from the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Elevated biochemical markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Perioperative MI'",
"    </a>",
"    above), elevations in serum biomarkers of myocardial necrosis (CK-MB and troponin) are necessary for the diagnosis of perioperative MI. However, the significance of elevations in these biomarkers is made difficult due to their release as a routine sequela of CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. An increase in serum CK-MB above the upper limit of normal has been noted in 62 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link&amp;anchor=H32#H32\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'After CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with elevations in serum biomarkers after CABG have a worse prognosis than those without [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/7-10,12\">",
"     7-10,12",
"    </a>",
"    ]. The relationship between myocardial enzyme elevation and survival following CABG was best evaluated in a study of nearly 19,000 patients enrolled in seven randomized trials or registries with follow-up between three months and five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/12\">",
"     12",
"    </a>",
"    ]. For both troponin and CK-MB, 30-day mortality increased significantly as the ratio of the value of the biomarker compared to the upper limit of normal for that biomarker increased. For example, the relative risk of death was 1.00, 1.89, 2.22, 3.61, and 10.91 for troponin ratios of 6 to &lt;10, 10 to &lt;20, 20 to &lt;40, 40 to &lt;100, and &ge;100, respectively. Similar findings were noted at one year.",
"   </p>",
"   <p>",
"    These marked elevations in serum biomarkers of myocardial necrosis are thought to result from early graft failure, inadequate myocardial protection during bypass,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distal embolization of plaque material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated serum troponins may be more specific and sensitive markers than CK-MB of a new MI after CABG, and may be more predictive of early complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. This issue was addressed in a report of 224 patients in whom serum troponin T and CK-MB were measured every eight hours after cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/11\">",
"     11",
"    </a>",
"    ]. In a multivariable analysis, serum troponin T concentrations &ge;1.58",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (which represented the upper quintile) were the strongest predictor of postoperative death or shock immediately postoperatively or at 18 to 24 hours. Serum CK-MB did not have independent prognostic importance when troponin T was measured. Long-term data were not provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early graft occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early (within the first 30 days after surgery) occlusion occurs in approximately 5 to 10 percent of saphenous vein grafts. These occlusions are usually thrombotic and are generally related to technical problems at the anastomosis; injury related to manipulation during harvesting may also be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of early graft occlusion appears to be reduced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy, which is typically restarted within six hours after surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 3 to 6 percent of patients develop clinically apparent postoperative ischemia as manifested by ischemic symptoms, significant ischemic ECG abnormalities, hemodynamic instability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two series of patients undergoing urgent postoperative angiography for recurrent ischemia, SVG occlusion or stenosis occurred in 37 to 56 percent and internal mammary graft occlusion or stenosis in 12 to 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one of these studies,131 of 2052 patients (6.4 percent) undergoing CABG met one or more of the criteria for ischemia at a median of 12 hours (range 0.5 to 96 hours) after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15\">",
"     15",
"    </a>",
"    ]. Angiography was performed in 108, while 23 went immediately to surgery because of severe hemodynamic compromise. Angiography revealed normal grafts in 45, saphenous vein or internal mammary artery graft occlusion in 41, incorrect anastomosis in 29, graft stenosis in 14, graft spasm or a displaced graft in six each, poor distal runoff in five, and incomplete revascularization in two.",
"   </p>",
"   <p>",
"    Revascularization is generally attempted if the anatomy is appropriate. In a study in which repeat CABG was evaluated, 16 of 43 patients who underwent acute angiography were not revascularized because it was not necessary or not feasible due to poor vessel quality or nonavailability of graft material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal revascularization strategy for early graft occlusion is not known. Repeat CABG is one approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], while balloon angioplasty with and without stenting has been performed immediately after surgery and for treatment of fresh anastomoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Both procedures are associated with risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat CABG has been associated with 30-day mortality rates of 7 to 9 percent in clinically stable patients and as high as 39 to 50 percent in patients with severe hemodynamic compromise or severe sustained ventricular tachyarrhythmias who underwent immediate surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PCI may be associated with high rates of angiographic and bleeding complications, particularly in patients treated very soon after cardiac surgery. In a series of 10 patients undergoing urgent percutaneous coronary intervention (mostly SVG lesions, six fixed with a drug-eluting stent), significant periprocedural complications occurred in four [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/17\">",
"       17",
"      </a>",
"      ]. There were three perforations (one during stenting of a distal vein graft anastomosis, one during high-pressure balloon angioplasty of an internal mammary graft distal anastomosis, and one during PCI of a native artery total occlusion). Acute thrombosis of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent occurred in a fourth patient, who was not loaded with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . Major bleeding complications occurred in four patients, including two with cardiac tamponade, one with gastrointestinal bleeding, and one with excessive chest tube drainage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the safety of drug-eluting stents was uncertain in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/17\">",
"     17",
"    </a>",
"    ]. This is a particular concern in patients at high risk for perioperative bleeding, since the need to discontinue antiplatelet therapy increases the risk of stent thrombosis. The balance between stent thrombosis and major bleeding is especially critical in the early postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Recommendations for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update for percutaneous coronary intervention concluded that there was general agreement that, if feasible, PCI should be performed in patients with early ischemia (usually within 30 days) after CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/20\">",
"     20",
"    </a>",
"    ]. When the lesion is in an SVG, use of a distal embolic protection device was recommended, if feasible. This approach was not changed in the 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA/SCAI",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is our practice to recommend emergent cardiac catheterization for patients developing acute ischemia soon after CABG. Percutaneous revascularization is performed when feasible and if at least a moderate amount of myocardium is jeopardized. We believe this offers advantages over early reoperation in many patients. Caution is required during treatment of fresh anastomoses and the operator should be prepared to treat possible perforations, including the placement of covered stents if needed.",
"   </p>",
"   <p>",
"    We generally attempt low pressure balloon angioplasty for early treatment of distal anastomoses with stenting used only if the result is suboptimal. In comparison, for severely thrombotic grafts, we frequently attempt revascularization of the native vessel with drug-eluting stents. If stents are to be employed, we proceed with usual measures for the prevention of thrombosis, including GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading, and are prepared to treat bleeding complications if needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H8#H8\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the management of late recurrent angina after CABG are discussed separately. In this setting, angina may be due to graft problems or progression of native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=see_link\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Low cardiac output",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequent complication of CABG is a low cardiac output, primarily due to left ventricular dysfunction. In a prospective observational study of over 8600 patients undergoing CABG between 1992 and 1997, the incidence of low output syndrome varied from 6 percent with an LVEF &gt;40 percent to 12 percent with an LVEF between 20 and 40 percent to 23 percent with an LVEF &lt;20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impairment in left ventricular function can result from a variety of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardioplegic arrest and ischemic injury, which can lead to myocardial stunning and diastolic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced preload which, in the immediate postoperative period, can be induced by loss of vasomotor tone, intraoperative and postoperative blood loss, increased capillary permeability, and a high urine output due to hypothermia",
"     </li>",
"     <li>",
"      Excessive afterload due to hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arrhythmias",
"     </li>",
"     <li>",
"      Perioperative MI",
"     </li>",
"     <li>",
"      Mechanical complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low cardiac output is often transient and responds to fluid replacement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a brief period of inotropic support or, in patients with marked hypertension,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    . However, cardiogenic shock can occur and, not surprisingly, is an adverse predictor of outcome (",
"    <a class=\"graphic graphic_figure graphicRef77573 \" href=\"mobipreview.htm?23/37/24159\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pharmacologic therapy is ineffective, mechanical support with an intraaortic balloon pump or left ventricular assist device is necessary. Occasional patients need to return to the operating room for treatment of a mechanical problem such as acute graft failure or tamponade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vasodilatory shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary bypass, not limited to bypass surgery, can be complicated by vasodilatory (or distributive) hypotension or shock, which is characterized by a primary and marked reduction in systemic vascular resistance with a well preserved or increased cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual treatment for vasodilatory shock in the setting of cardiac surgery is low dose intravenous norepinephrine. At least some patients have inappropriately low serum arginine vasopressin (AVP) concentrations and, in those who do not respond to norepinephrine, intravenous vasopressin may be effective. Increased production of nitric oxide has also been implicated, and treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , which inhibits the production of nitric oxide, has been reported to be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38537?source=see_link&amp;anchor=H17#H17\">",
"     \"Postoperative complications among patients undergoing cardiac surgery\", section on 'Vasodilatory shock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias, most often tachyarrhythmias, are common after CABG. Although it is difficult to predict patients at risk for perioperative arrhythmia, preoperative hypokalemia may be important. In a review of 2402 patients undergoing elective CABG, preoperative serum potassium concentrations below 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    increased the risk for serious perioperative arrhythmias (odds ratio 2.2), the need for resuscitation, and the incidence of atrial fibrillation and flutter (odds ratio 1.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) occurring after CABG is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, AF occurs in 15 to 40 percent of patients undergoing CABG and up to 60 percent of those who undergo combined CABG with valve replacement. Beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    reduce the frequency of postoperative AF by 52 to 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/29\">",
"     29",
"    </a>",
"    ]. The beta blocker should be given before or as soon as possible after cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of therapy for prevention of postoperative atrial arrhythmias is uncertain, but the beta blocker is often continued until the first postoperative visit. However, many patients who undergo CABG have a clear indication for the continued use of beta blocker therapy (eg, previous MI, heart failure, or hypertension).",
"   </p>",
"   <p>",
"    Atrial fibrillation that develops after CABG is usually self-limited in patients without a prior history of AF. The arrhythmia reverts spontaneously to sinus rhythm within 24 hours in 80 percent and by six to eight weeks in over 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachyarrhythmias associated with CABG have a variable effect on prognosis. Nonsustained ventricular tachycardia (VT) occurs in 17 to 97 percent of patients and is thought to be reperfusion-induced; it is typically benign, although some patients may be at increased risk of future life-threatening arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained monomorphic or polymorphic VT or ventricular fibrillation (VF) occur in approximately 1 to 3 percent of patients, usually within the first week after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/32,34-38\">",
"     32,34-38",
"    </a>",
"    ]. In two reports including a total of 9,159 patients, 114 (1.2 percent) with VT or VF, predictors of perioperative ventricular arrhythmias included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/35,38\">",
"     35,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;65 years",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Body mass index &lt;25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"     </li>",
"     <li>",
"      Unstable angina",
"     </li>",
"     <li>",
"      Ejection fraction &le;50 percent",
"     </li>",
"     <li>",
"      Pulmonary or systemic hypertension",
"     </li>",
"     <li>",
"      Prolonged cardiopulmonary bypass time",
"     </li>",
"     <li>",
"      Requirement for inotropes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an intraaortic balloon pump",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with perioperative VT or VF, compared to those without these arrhythmias, had a significant increase in postoperative mortality (24.6 versus 1.5 percent). In one of the reports, intraoperative VT or VF had a greater impact on mortality than postoperative arrhythmia (42 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphic VT is typically associated with perioperative MI, combined with multiple risk factors that are present in the perioperative period such as hemodynamic instability, increased sympathetic activity, and metabolic abnormalities. In comparison, sustained monomorphic VT is most likely in patients with a history of a prior MI, heart failure, and depressed left ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. When all three of these factors are present the risk of VT in one report was 30 percent, a 14-fold increase compared to the absence of all three risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/36\">",
"     36",
"    </a>",
"    ]. An additional factor may be the placement of grafts across a noncollateralized occlusion in a vessel supplying an infarct zone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/36\">",
"     36",
"    </a>",
"    ], suggesting that reperfusion may restore electrical function, creating reentrant circuits, in a previously quiescent region of myocardium.",
"   </p>",
"   <p>",
"    Magnesium supplementation may reduce the incidence of postoperative ventricular arrhythmias. In a meta-analysis, 10 trials including 1195 patients were identified that evaluated the use of magnesium for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/39\">",
"     39",
"    </a>",
"    ]. Ventricular arrhythmias occurred significantly less often in patients treated with magnesium compared to controls (6 versus 13 percent; relative risk 0.52). There was no effect on length of hospital stay, frequency of perioperative myocardial infarction, or mortality.",
"   </p>",
"   <p>",
"    Ischemic preconditioning reduces ischemia-reperfusion injury and appears to reduce sustained",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    after CABG. This was illustrated in a trial of 86 patients who were randomly assigned to two periods of two minutes of ischemia followed by three minutes of reperfusion or to no ischemic preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/34\">",
"     34",
"    </a>",
"    ]. On continuous ECG monitoring, ischemic preconditioning was associated with significant reductions in VF after declamping (49 versus 79 percent) and VT during early reperfusion (0.7 versus 3.7 percent) and 24 hours after reperfusion (0.1 versus 2.1 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bradyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative bradyarrhythmias requiring permanent pacemaker implantation occur in 0.8 to 4 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. The most common abnormalities are complete atrioventricular block with a narrow or wide complex escape rhythm, sinus node dysfunction, and a nodal rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38537?source=see_link&amp;anchor=H7#H7\">",
"     \"Postoperative complications among patients undergoing cardiac surgery\", section on 'Dysrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pericarditis, pericardial effusion, and tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation and clinical course of pericarditis after CABG, which is due to pericardial injury and known as a postpericardiotomy syndrome, is comparable to that of the postmyocardial infarction syndrome. The most frequent complaint is chest pain, occurring a few days to several weeks after surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=see_link\">",
"     \"Post-cardiac injury syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=see_link&amp;anchor=H12#H12\">",
"     \"Pericardial complications of myocardial infarction\", section on 'Postcardiac injury syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial echocardiography shows that postoperative pericardial effusion is considerably more common than clinically apparent disease, occurring in as many as 85 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/43\">",
"     43",
"    </a>",
"    ]. The effusion is usually present by the second postoperative day, but may not occur until day 10. In one report, effusion was present in 22 percent of patients at 20 days and 8 percent at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the effusion is small and clinically insignificant; however, the effusion may be large, resulting in tamponade and hemodynamic instability and requiring urgent therapy with pericardiocentesis or reoperation. Postoperative anticoagulation may increase the risk of tamponade in patients who develop an effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39368/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In some patients, continuing pericardial inflammation over months leads to a thickened, fibrous pericardium and the signs and symptoms of constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EARLY NONCARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related question is how soon after cardiac surgery can a patient proceed with elective noncardiac surgery. There are three major concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incomplete sternal healing. We suggest waiting at least six weeks prior to any procedure in which",
"      <span class=\"nowrap\">",
"       intubation/mechanical",
"      </span>",
"      ventilation may be necessary.",
"     </li>",
"     <li>",
"      Bacteremia in patients who have received prosthetic valves and are undergoing bowel or urological procedures. We suggest waiting two to three months for surgery on the bowel or genitourinary tract in these patients.",
"     </li>",
"     <li>",
"      Thromboembolic risk early after valve surgery. Despite routine anticoagulation, thromboembolic risk is elevated early after mechanical or bioprosthetic valve replacement or mitral valve annuloplasty. Interruption of anticoagulation for surgery or complications of surgery may exacerbate this risk. We suggest waiting at least three months following valve surgery prior to elective noncardiac surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H285870321\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major early cardiac complications of coronary artery bypass graft surgery (CABG) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial infarction (MI) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Perioperative MI'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Graft occlusion (with or without MI) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Early graft occlusion'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Low cardiac output due to ventricular dysfunction (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Low cardiac output'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Vasodilatory shock (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Vasodilatory shock'",
"      </a>",
"      above) &nbsp;",
"     </li>",
"     <li>",
"      Atrial and ventricular arrhythmias (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Arrhythmias'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pericarditis (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Pericarditis, pericardial effusion, and tamponade'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/1\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/2\">",
"      Chaitman BR, Alderman EL, Sheffield LT, et al. Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation 1983; 67:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/3\">",
"      Yokoyama Y, Chaitman BR, Hardison RM, et al. Association between new electrocardiographic abnormalities after coronary revascularization and five-year cardiac mortality in BARI randomized and registry patients. Am J Cardiol 2000; 86:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/4\">",
"      Bassan MM, Oatfield R, Hoffman I, et al. New Q waves after aortocoronary bypass surgery. Unmasking of an old infarction. N Engl J Med 1974; 290:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/5\">",
"      Stephan WJ, O'Keefe JH Jr, Piehler JM, et al. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol 1996; 28:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/6\">",
"      Warren SG, Wagner GS, Bethea CF, et al. Diagnostic and prognostic significance of electrocardiographic and CPK isoenzyme changes following coronary bypass surgery: correlation with findings at one year. Am Heart J 1977; 93:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/7\">",
"      Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/8\">",
"      Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001; 104:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/9\">",
"      Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/10\">",
"      Steuer J, H&ouml;rte LG, Lindahl B, St&aring;hle E. Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J 2002; 23:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/11\">",
"      Januzzi JL, Lewandrowski K, MacGillivray TE, et al. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol 2002; 39:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/12\">",
"      Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011; 305:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/13\">",
"      Carrier M, Pellerin M, Perrault LP, et al. Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/14\">",
"      Dauerman HL, Cutlip DE, Sellke FW. Intracoronary thrombolysis in the treatment of graft closure immediately after CABG. Ann Thorac Surg 1996; 62:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/15\">",
"      Fabricius AM, Gerber W, Hanke M, et al. Early angiographic control of perioperative ischemia after coronary artery bypass grafting. Eur J Cardiothorac Surg 2001; 19:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/16\">",
"      Rasmussen C, Thiis JJ, Clemmensen P, et al. Significance and management of early graft failure after coronary artery bypass grafting: feasibility and results of acute angiography and re-re-vascularization. Eur J Cardiothorac Surg 1997; 12:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/17\">",
"      Price MJ, Housman L, Teirstein PS. Rescue percutaneous coronary intervention early after coronary artery bypass grafting in the drug-eluting stent era. Am J Cardiol 2006; 97:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/18\">",
"      Kahn JK, Rutherford BD, McConahay DR, et al. Early postoperative balloon coronary angioplasty for failed coronary artery bypass grafting. Am J Cardiol 1990; 66:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/19\">",
"      Hanratty CG, Koyama Y, Ward MR. Angioplasty and stenting of the distal coronary anastomosis for graft failure immediately after coronary artery bypass grafting. Am J Cardiol 2002; 90:1009.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/21\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/22\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/23\">",
"      Yau TM, Fedak PW, Weisel RD, et al. Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg 1999; 118:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/24\">",
"      McKenney PA, Apstein CS, Mendes LA, et al. Increased left ventricular diastolic chamber stiffness immediately after coronary artery bypass surgery. J Am Coll Cardiol 1994; 24:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/25\">",
"      Roberts AJ, Niarchos AP, Subramanian VA, et al. Systemic hypertension associated with coronary artery bypass surgery. Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. J Thorac Cardiovasc Surg 1977; 74:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/26\">",
"      Fremes SE, Weisel RD, Baird RJ, et al. Effects of postoperative hypertension and its treatment. J Thorac Cardiovasc Surg 1983; 86:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/27\">",
"      Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction rule for major adverse outcomes in coronary bypass grafting. Am J Cardiol 2001; 88:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/28\">",
"      Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999; 281:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/29\">",
"      Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/30\">",
"      Fuster V, Ryd&eacute;n LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/31\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/32\">",
"      Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/33\">",
"      Pinto RP, Romerill DB, Nasser WK, et al. Prognosis of patients with frequent premature ventricular complexes and nonsustained ventricular tachycardia after coronary artery bypass graft surgery. Clin Cardiol 1996; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/34\">",
"      Wu ZK, Iivainen T, Pehkonen E, et al. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation 2002; 106:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/35\">",
"      Ascione R, Reeves BC, Santo K, et al. Predictors of new malignant ventricular arrhythmias after coronary surgery: a case-control study. J Am Coll Cardiol 2004; 43:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/36\">",
"      Steinberg JS, Gaur A, Sciacca R, Tan E. New-onset sustained ventricular tachycardia after cardiac surgery. Circulation 1999; 99:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/37\">",
"      Azar RR, Berns E, Seecharran B, et al. De novo monomorphic and polymorphic ventricular tachycardia following coronary artery bypass grafting. Am J Cardiol 1997; 80:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/38\">",
"      Yeung-Lai-Wah JA, Qi A, McNeill E, et al. New-onset sustained ventricular tachycardia and fibrillation early after cardiac operations. Ann Thorac Surg 2004; 77:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/39\">",
"      Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 2004; 117:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/40\">",
"      Emlein G, Huang SK, Pires LA, et al. Prolonged bradyarrhythmias after isolated coronary artery bypass graft surgery. Am Heart J 1993; 126:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/41\">",
"      Glikson M, Dearani JA, Hyberger LK, et al. Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery. Am J Cardiol 1997; 80:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/42\">",
"      Baerman JM, Kirsh MM, de Buitleir M, et al. Natural history and determinants of conduction defects following coronary artery bypass surgery. Ann Thorac Surg 1987; 44:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/43\">",
"      Weitzman LB, Tinker WP, Kronzon I, et al. The incidence and natural history of pericardial effusion after cardiac surgery--an echocardiographic study. Circulation 1984; 69:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/44\">",
"      Meurin P, Weber H, Renaud N, et al. Evolution of the postoperative pericardial effusion after day 15: the problem of the late tamponade. Chest 2004; 125:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39368/abstract/45\">",
"      Kuvin JT, Harati NA, Pandian NG, et al. Postoperative cardiac tamponade in the modern surgical era. Ann Thorac Surg 2002; 74:1148.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1584 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39368=[""].join("\n");
var outline_f38_28_39368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H285870321\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIAC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Perioperative MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Q wave MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Elevated biochemical markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early graft occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Recommendations for therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Low cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vasodilatory shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pericarditis, pericardial effusion, and tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EARLY NONCARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285870321\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1584|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/37/24159\" title=\"figure 1\">",
"      Predictive model for outcome after CABG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=related_link\">",
"      Operative mortality after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38537?source=related_link\">",
"      Postoperative complications among patients undergoing cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39369="Evaluation of the patient with heart failure or cardiomyopathy";
var content_f38_28_39369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with heart failure or cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39369/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/28/39369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common clinical syndrome caused by a variety of cardiac diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/1\">",
"     1",
"    </a>",
"    ]. Evaluation of the etiology and severity of heart failure is discussed here. Initial evaluation of suspected heart failure and the management and prognosis of HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is characterized by specific symptoms, such as dyspnea and fatigue, and signs, such as fluid retention. There are many ways to assess cardiac function. However, there is no diagnostic test for HF, since it is largely a clinical diagnosis that is based upon a careful history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"mobipreview.htm?21/9/21661\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification of HF severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, including assessment of NYHA functional class, and physical examination in conjunction with the diagnostic tests reviewed below should both establish the primary cause of the heart failure and provide a reasonable estimate of its severity.",
"   </p>",
"   <p>",
"    The classification system that is most commonly used to quantify the degree of functional limitation imposed by HF is one first developed by the New York Heart Association (NYHA). This system assigns patients to one of four functional classes, depending on the degree of effort needed to elicit symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I &mdash; symptoms of HF only at activity levels that would limit normal individuals",
"     </li>",
"     <li>",
"      Class II &mdash; symptoms of HF with ordinary exertion",
"     </li>",
"     <li>",
"      Class III &mdash; symptoms of HF with less than ordinary exertion",
"     </li>",
"     <li>",
"      Class IV &mdash; symptoms of HF at rest",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stages in the development of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several stages in the evolution of HF, as outlined by the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A &mdash; High risk for HF, without structural heart disease or symptoms",
"     </li>",
"     <li>",
"      Stage B &mdash; Heart disease with asymptomatic left ventricular dysfunction",
"     </li>",
"     <li>",
"      Stage C &mdash; Prior or current symptoms of HF",
"     </li>",
"     <li>",
"      Stage D &mdash; Refractory end stage HF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This staged system, in contrast to the NYHA classification, emphasizes the progressive nature of HF and defines the appropriate therapeutic approach for each stage.",
"   </p>",
"   <p>",
"    The long-term prognosis can also be estimated. The peak VO2 is the most accurate predictor of prognosis, but functional class and exercise capacity, the magnitude of the reduction in ejection fraction with systolic dysfunction, serum BNP concentrations, and a variety of other factors are also important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis of heart failure\", section on 'Predictive models'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two basic pathophysiologic mechanisms that cause reduced cardiac output and HF: systolic dysfunction and diastolic dysfunction. Systolic and diastolic dysfunction each may be due to a variety of etiologies. Effective management is often dependent upon establishing the correct etiologic diagnosis. As an example, coronary revascularization may be beneficial in patients with ischemic cardiomyopathy who have evidence of hibernating myocardium (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Detection of coronary artery disease'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of systolic dysfunction are coronary (ischemic) heart disease, idiopathic dilated cardiomyopathy (DCM), hypertension, and valvular disease. Effective therapy of hypertension has led to a changing pattern in which coronary disease has become more prevalent as a cause of HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one review, coronary disease and hypertension accounted for 62 and 10 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As compared to all patients presenting with HF, patients who present with initially unexplained DCM have a different distribution of etiologies. After a complete evaluation of 1230 such patients, the relative frequency of the different causes was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic &mdash; 50 percent",
"     </li>",
"     <li>",
"      Myocarditis &mdash; 9 percent",
"     </li>",
"     <li>",
"      Ischemic heart disease &mdash; 7 percent",
"     </li>",
"     <li>",
"      Infiltrative disease &mdash; 5 percent",
"     </li>",
"     <li>",
"      Peripartum cardiomyopathy &mdash; 4 percent",
"     </li>",
"     <li>",
"      Hypertension &mdash; 4 percent",
"     </li>",
"     <li>",
"      HIV infection &mdash; 4 percent",
"     </li>",
"     <li>",
"      Connective tissue disease &mdash; 3 percent",
"     </li>",
"     <li>",
"      Substance abuse &mdash; 3 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      &mdash; 1 percent",
"     </li>",
"     <li>",
"      Other &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diastolic dysfunction can be induced by many of the same conditions that lead to systolic dysfunction. The most common causes are hypertension, ischemic heart disease, hypertrophic obstructive cardiomyopathy, and restrictive cardiomyopathy. However, many patients with symptoms suggestive of HF (shortness of breath, ankle edema, or paroxysmal nocturnal dyspnea) who have intact left ventricular systolic function may not have diastolic dysfunction, but have other etiologies that can account for their symptoms, including obesity, lung disease, or occult coronary ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathies are diseases of heart muscle. This term is best suited to reflect predominantly genetically determined diseases with recognizable phenotypes (hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and left ventricular noncompaction (LVNC)) (",
"    <a class=\"graphic graphic_table graphicRef64479 graphicRef74268 \" href=\"mobipreview.htm?6/62/7150\">",
"     table 3A-B",
"    </a>",
"    ). Although in clinical practice the term \"cardiomyopathy\" has also been applied to heart disease secondary to other known causes (eg, ischemic, valvular, or hypertensive cardiomyopathy), this use is not recommended by the 2006 American Heart Association or 2007 European Society of Cardiology classification schemes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Classification of cardiomyopathies is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with HF or cardiomyopathy includes the history and physical examination, and diagnostic tests to establish the diagnosis, assess acuity, severity and etiology. Recommendations for the evaluation of patients with HF were included in the 2005 American College of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines with 2009 focused update (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"mobipreview.htm?21/9/21661\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ], the 2010 Heart Failure Society of America (HFSA) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/9\">",
"     9",
"    </a>",
"    ], the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/10\">",
"     10",
"    </a>",
"    ], and the 2006 Canadian Cardiovascular Society (CCS) consensus conference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of HF include those due to excess fluid accumulation (dyspnea, edema, hepatic congestion, and ascites) and those due to a reduction in cardiac output (fatigue, weakness) that is most pronounced with exertion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history and other findings may be helpful in identifying the etiology of HF. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic exertional angina usually indicates ischemic heart disease.",
"     </li>",
"     <li>",
"      Acute HF after an antecedent flu-like illness suggests viral myocarditis.",
"     </li>",
"     <li>",
"      Long-standing hypertension or alcohol use suggests hypertensive or alcoholic cardiomyopathy.",
"     </li>",
"     <li>",
"      Primary valvular dysfunction should be considered in a patient with a history of murmurs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diagnosis of amyloidosis should be strongly considered in patients who have a family history of unexplained cardiomyopathy or amyloidosis, low voltage on EKG, left ventricular hypertrophy (especially without hypertension),and a history of heavy proteinuria. It should be appreciated, however, that mild proteinuria can be seen with heart failure alone (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H41#H41\">",
"       \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Albuminuria'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      HF may be provoked or worsened by drugs, including antiarrhythmic agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ; calcium channel blockers, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ; beta blockers; and nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute pulmonary edema occurring during, or shortly after, infusion of blood products suggests transfusional volume overload. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination can provide evidence of the presence and extent of cardiac filling pressure elevation, volume overload, ventricular enlargement, pulmonary hypertension, and reduction in cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram may show findings that favor the presence of a specific cause of HF and can also detect arrhythmias such as asymptomatic ventricular premature beats, runs of nonsustained ventricular tachycardia, or atrial fibrillation, which may be the cause of or exacerbate HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with dilated cardiomyopathy frequently have first degree AV block, left bundle branch block, left anterior fascicular block, or a nonspecific intraventricular conduction abnormality.",
"   </p>",
"   <p>",
"    Potentially diagnostic findings on ECG include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of ischemic heart disease including evidence of prior or acute myocardial infarction or ischemia.",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy due to hypertension; a pseudoinfarct pattern may also be present representing significant posterior forces of the increased left ventricular mass.",
"     </li>",
"     <li>",
"      Low limb lead voltage on the surface ECG with a pseudo-infarction pattern (loss of precordial R wave progression in leads V1-V6) can suggest an infiltrative process such as amyloidosis.",
"     </li>",
"     <li>",
"      Low limb lead voltage with precordial criteria for left ventricular hypertrophy is most suggestive of idiopathic dilated cardiomyopathy. A widened QRS complex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a left bundle branch block pattern is also consistent with this diagnosis.",
"     </li>",
"     <li>",
"      Heart block, that may be complete, and various types of intraventricular conduction defects are observed in patients with cardiac sarcoidosis.",
"     </li>",
"     <li>",
"      The presence of a persistent tachycardia such as atrial fibrillation with a rapid ventricular response may result from or lead to HF, since this arrhythmia can cause cardiomyopathy (tachycardia-mediated cardiomyopathy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray is generally indicated to evaluate pulmonary edema, cardiopulmonary structural abnormalities and other potential causes of dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Chest x-ray'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended initial blood tests for patients with symptoms and signs of HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count which may suggest concurrent or alternate conditions. Anemia or infection can exacerbate preexisting HF. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=see_link\">",
"       \"Impact of anemia in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum electrolytes, blood urea nitrogen and creatinine may indicate associated conditions. Hyponatremia generally indicates severe HF, though it may occasionally result from excessive diuresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/13\">",
"       13",
"      </a>",
"      ]. Renal impairment may be caused by",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contribute to HF exacerbation. Baseline evaluation of electrolytes and creatine is also necessary when initiating therapy with diuretics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin converting enzyme inhibitors.",
"     </li>",
"     <li>",
"      Liver function tests, which may be affected by hepatic congestion.",
"     </li>",
"     <li>",
"      Fasting blood glucose to detect underlying diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=see_link\">",
"       \"Heart failure in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;If it is determined that dilated cardiomyopathy is responsible for HF and the cause is not apparent, several other blood tests may be warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid function tests, particularly in patients over the age of 65 or in patients with atrial fibrillation. Thyrotoxicosis is associated with atrial fibrillation and hypothyroidism may present as HF. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=see_link\">",
"       \"Cardiovascular effects of hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3046?source=see_link\">",
"       \"Cardiovascular effects of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iron studies (ferritin and TIBC) to screen for hereditary hemochromatosis (HH). In the past, prior to increased screening, cardiac disease was the presenting manifestation in up to 15 percent of patients with HH. Thus, the absence of other characteristic findings of HH does not preclude the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies that may be undertaken depending upon the potential findings identified in the history and physical examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ANA and other serologic tests for lupus",
"     </li>",
"     <li>",
"      Viral serologies and antimyosin antibody if myocarditis is suspected",
"     </li>",
"     <li>",
"      Evaluation for pheochromocytoma",
"     </li>",
"     <li>",
"      Thiamine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      levels",
"     </li>",
"     <li>",
"      Genetic testing and counseling (eg, in patients suspected of familial cardiomyopathy after obtaining a detailed family history)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) in diagnosis of HF is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography should be performed in all patients with new onset HF and can provide important information about ventricular size and function. For example, patients with idiopathic dilated cardiomyopathy typically have both left and right ventricular enlargement (four chamber dilatation) with decreased left systolic ventricular function. (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73155 \" href=\"mobipreview.htm?1/36/1605\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70128 \" href=\"mobipreview.htm?31/37/32339\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78668 \" href=\"mobipreview.htm?40/35/41521\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef75021 \" href=\"mobipreview.htm?43/0/44035\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68493 \" href=\"mobipreview.htm?38/61/39902\">",
"     movie 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of two dimensional echocardiography for the diagnosis of systolic dysfunction are as high as 80 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/13\">",
"     13",
"    </a>",
"    ]. A number of other important findings also can be detected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although regional wall motion abnormalities are compatible with coronary heart disease, they are not specific for ischemia since they also occur in 50 to 60 percent of patients with idiopathic dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, regional wall motion assessment using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography may increase the ability to distinguish among ischemic and nonischemic cardiomyopathies. The presence of six or more akinetic segments, for example, was 80 percent sensitive and 96 percent specific for ischemic dilated cardiomyopathy in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial thickening suggestive of constrictive pericarditis.",
"     </li>",
"     <li>",
"      Valvular disease valve disease",
"     </li>",
"     <li>",
"      Interatrial and interventricular shunts.",
"     </li>",
"     <li>",
"      Abnormal myocardial texture in infiltrative cardiomyopathies, with a \"sparkling\" pattern being suggestive of cardiac amyloidosis (",
"      <a class=\"graphic graphic_movie graphicRef61904 \" href=\"mobipreview.htm?36/40/37507\">",
"       movie 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef64330 \" href=\"mobipreview.htm?43/47/44787\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef78037 \" href=\"mobipreview.htm?41/31/42481\">",
"       movie 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15562?source=see_link\">",
"       \"Echocardiographic recognition of cardiomyopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right ventricular size and function in right HF.",
"     </li>",
"     <li>",
"      Estimation of pulmonary capillary wedge pressure (PCWP) via the ratio",
"      <span class=\"nowrap\">",
"       (E/Ea",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       E/E')",
"      </span>",
"      of tissue Doppler of early mitral inflow velocity (E) to early diastolic velocity of the mitral annulus (Ea or e'). An",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio &gt;15 suggests a PCWP &gt;15 mm Hg when e' is the mean of medial and lateral mitral annulus early diastolic velocities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/16\">",
"       16",
"      </a>",
"      ]. Use and limitations of this method are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=see_link&amp;anchor=H5#H5\">",
"       \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Tissue Doppler imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      However, the",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio may not be a reliable indicator of PCWP in patients with ADHF. In a series of 106 patients with ADHF and LVEF &le;30 percent, the",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio did not correlate with PCWP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/17\">",
"       17",
"      </a>",
"      ]. One limitation of this study is that patients with significant mitral valve disease were not excluded.",
"     </li>",
"     <li>",
"      One limitation of use the",
"      <span class=\"nowrap\">",
"       E/e'",
"      </span>",
"      ratio is that it does not predict PCWP in patients with significant mitral valve disease (either mitral stenosis or mitral regurgitation). In patients with mitral valve disease, a preliminary report indicates that the ratio of isovolumetric relaxation time (IVRT) to the time interval between the onset of E and Ea (TE-Ea) correlates with PCWP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short deceleration time (&le;125 ms) is an independent predictor of poor prognosis in patients with left ventricular dysfunction, regardless of the presence or absence of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Right atrial and pulmonary artery pressures, determined by the peak velocity of tricuspid regurgitation on Doppler echocardiography. These findings correlate with the pulmonary artery wedge pressure, regardless of the etiology of HF or severity of tricuspid regurgitation; they can be used to assess changes in left ventricular filling pressures resulting from therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited data suggest that the cardiac output can be measured accurately by pulsed-wave Doppler from the left ventricular outflow tract, even in the presence of a low output state or tricuspid regurgitation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81391 \" href=\"mobipreview.htm?13/18/13601\">",
"       image 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiography in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    is also useful in predicting recovery of cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EXERCISE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing should be part of the initial evaluation of any patient with HF. In addition to detection of ischemic heart disease, assessment of exercise capacity can be used for risk stratification and determining prognosis; serial measurements also can assess the efficacy of therapy and clinical stability of patients over time.",
"   </p>",
"   <p>",
"    With severe heart failure, measurement of the maximal oxygen uptake (VO2max) provides an objective estimate of the functional severity of the myocardial dysfunction. VO2max is one of the best indices of prognosis in patients with symptomatic HF and can aid in the determination of the necessity and timing of listing for cardiac transplantation. A simple alternative that provides an estimate of exercise function is the six minute walk test. However, peak VO2 and exercise capacity can be affected by factors other than cardiac status, including deconditioning, pulmonary disease, and anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DETECTION OF CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HF due to ischemic cardiomyopathy have known coronary heart disease. As noted above, however, occult disease is a not uncommon cause of dilated cardiomyopathy, accounting for as many as 7 percent of initially unexplained cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/5\">",
"     5",
"    </a>",
"    ]. On the other hand, chest pain alone is not sufficient to make the diagnosis since up to one-third of patients with nonischemic cardiomyopathy have chest pain that may resemble angina or be atypical.",
"   </p>",
"   <p>",
"    Heart failure resulting from coronary disease is usually irreversible due to myocardial infarction and subsequent ventricular remodeling. However, revascularization may be of benefit in the appreciable number of patients in whom hibernating myocardium is in part responsible for the decline in myocardial function.",
"   </p>",
"   <p>",
"    This was illustrated in a meta-analysis of 24 studies involving 3088 patients (mean ejection fraction 32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/23\">",
"     23",
"    </a>",
"    ]. The 42 percent of patients with documented viability by thallium perfusion imaging, PET scanning, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography had a significant 80 percent reduction in annual mortality with revascularization (3.2 versus 16 percent for medical therapy). There was a direct relationship between the severity of left ventricular dysfunction and the magnitude of benefit. In contrast, there was no difference in outcome with revascularization or medical therapy in patients without viability (annual mortality 7.7 versus 6.2 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, exercise testing should be part of the initial evaluation of any patient with HF. Stress testing is particularly helpful in detection of ischemic heart disease and need for coronary arteriography. However, coronary angiography should be considered even in patients with a normal exercise test if HF is otherwise unexplained and there is a reasonable likelihood that CAD is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Coronary arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2009 focused update made the following recommendations for coronary arteriography, unless the patient is not eligible for revascularization of any kind (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"mobipreview.htm?21/9/21661\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary arteriography should be performed in patients presenting with HF who have angina or significant ischemia.",
"     </li>",
"     <li>",
"      Coronary arteriography is reasonable in patients who have chest pain that may or may not be cardiac in origin in whom cardiac anatomy is not known and in patients with known or suspected coronary artery disease who do not have angina (class IIa).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of an ischemic cardiomyopathy is an independent predictor of mortality; the extent of coronary artery disease as determined by angiography contributes more prognostic information than the clinical diagnosis of ischemic cardiomyopathy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the angiographic findings must be considered in the context of the patient's history and other data. The presence of asymptomatic angiographic coronary artery disease in patients with dilated cardiomyopathy does not prove causality unless there is evidence of prior infarction or hibernating myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a study of 55 patients who underwent heart transplantation; the patients carried a diagnosis of idiopathic DCM and all had had a normal coronary arteriogram within the preceding ten years and no ischemic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/25\">",
"     25",
"    </a>",
"    ]. Examination of the explanted heart revealed critical lesions in at least one coronary artery segment in 15 patients (27 percent) with no evidence of scars.",
"   </p>",
"   <p>",
"    In addition to defining coronary artery anatomy, other useful information can be obtained from cardiac catheterization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurements of cardiac output, the degree of left ventricular dysfunction, and left ventricular end-diastolic pressure are helpful in assigning a severity score.",
"     </li>",
"     <li>",
"      Right (or left) ventricular endomyocardial biopsy can be performed if an unusual cause of myocarditis is suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Endomyocardial biopsy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Intracardiac",
"      <span class=\"nowrap\">",
"       shunts/anomalies",
"      </span>",
"      and anomalous coronary arteries can be detected and the magnitude of secondary pulmonary hypertension can be assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If significant coronary disease is documented, an improvement in outcome with revascularization compared to medical therapy appears to be limited to those with hibernating myocardium as noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/23\">",
"     23",
"    </a>",
"    ]. Myocardial viability can be assessed by thallium perfusion imaging, PET scanning, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Potential complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization with coronary angiography is an invasive procedure with potentially serious complications such as atheroemboli and rarely myocardial infarction, ventricular tachyarrhythmias, stroke, and death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these concerns, noninvasive methods have been evaluated for the diagnosis of ischemic cardiomyopathy, although none is as yet recommended as a replacement for cardiac catheterization in patients with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONINVASIVE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on HF concluded that noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known coronary artery disease and no angina unless the patient is not a candidate for revascularization of any kind (",
"    <a class=\"graphic graphic_table graphicRef51433 \" href=\"mobipreview.htm?21/9/21661\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the evidence of efficacy is less well established, noninvasive imaging may be considered to define the likelihood of coronary artery disease in all patients with HF and left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging can be used to identify late myocardial enhancement after the injection of gadolinium and to identify coronary artery disease. Myocardial infarction is generally associated with characteristic patterns different from those observed in cardiomyopathy. CMR can also identify particular types of cardiomyopathy such as HCM, ARVC, and cardiac amyloid. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Noninvasive coronary angiography'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Coronary artery calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of coronary artery calcification (CAC) on electron beam computed tomography (EBCT) was, in several reports, highly suggestive of ischemic cardiomyopathy. It seems safe to assume that the presence of CAC on multidetector CT (MDCT) has the same diagnostic implications. On the other hand, the absence of CAC strongly favors a nonischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Noninvasive coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coronary artery disease can be directly imaged by coronary CT or CMR angiography. Early studies using MDCT have shown this to be a promising approach to the noninvasive distinction between ischemic and nonischemic cardiomyopathy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link&amp;anchor=H27#H27\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\", section on 'Other uses'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ENDOMYOCARDIAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications, potential benefit and risks of endocardial biopsy in identifying the etiology of dilated cardiomyopathy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     GENETIC EVALUATION OF CARDIOMYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of genetic factors in patients with cardiomyopathy has been increasingly recognized. Recognition of the genetic basis for various cardiomyopathies has implications for diagnosis and timely management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, among patients with idiopathic DCM, it is estimated that at least 25 percent have familial disease. No clinical or histologic criteria, other than family history and careful examination of relatives (including those who are asymptomatic), have been derived to distinguish familial from nonfamilial disease. The mode of inheritance is usually autosomal dominant, although autosomal recessive, X-linked, and mitochondrial inheritance have also been described. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/59/5047?source=see_link\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 HFSA genetic evaluation of cardiomyopathy guideline recommends a careful family history for three or more generations for all patients with cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"     27",
"    </a>",
"    ]. This recommendation applies to patients with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular noncompaction (LVNC), restrictive cardiomyopathy (RCM), and cardiomyopathies associated with extracardiac manifestations (eg, muscular dystrophy, Fabry disease, amyloidosis, or sarcoidosis).",
"   </p>",
"   <p>",
"    The initial evaluation of the index patient should include family history and pedigree analysis for unexplained heart failure (HF) before age 60 or sudden cardiac death in the absence of ischemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Referral to a center with expertise in genetic cardiomyopathies may be helpful in obtaining and reviewing family history and pedigree information, as well as providing genetic counseling and testing. Specialized centers may also compile databases and perform research that promotes advances in this field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Family screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 HFSA guideline recommends screening first-degree relatives of patients with cardiomyopathy (including all types for which the guidelines recommend detailed family history). These guidelines are supported by evidence that cardiomyopathy is frequently familial and that affected family members are frequently asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"     27",
"    </a>",
"    ]. Progressive disease may occur within a relatively short period of time in initially asymptomatic family members with abnormal electrocardiographic or echocardiographic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20679?source=see_link\">",
"     \"Screening for asymptomatic left ventricular dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following screening is recommended for first-degree relatives of patients with cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical screening for cardiomyopathy in asymptomatic first-degree relatives is recommended whether or not genetic testing has been undertaken, and whether or not a genetic cause has been found if genetic testing was performed. Screening should include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History (with special focus on HF symptoms, arrhythmias, presyncope, and syncope)",
"     </li>",
"     <li>",
"      Physical examination (with special attention to the cardiac and skeletal muscle systems)",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Echocardiogram",
"     </li>",
"     <li>",
"      CK-MM (at initial evaluation only)",
"     </li>",
"     <li>",
"      Signal-averaged electrocardiogram (SAECG) in ARVC only",
"     </li>",
"     <li>",
"      Holter monitoring in HCM and ARVC",
"     </li>",
"     <li>",
"      Exercise treadmill testing in HCM",
"     </li>",
"     <li>",
"      Cardiovascular magnetic resonance imaging in ARVC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic first-degree relatives with negative clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic screening should be rescreened at intervals or any time that symptoms or signs appear. The frequency of recommended rescreening varies with cardiomyopathy type:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HCM &mdash; every three years until 30 years old, except yearly during puberty",
"     </li>",
"     <li>",
"      DCM &mdash; every three to five years beginning in childhood",
"     </li>",
"     <li>",
"      ARVC &mdash; every three to five years after age 10",
"     </li>",
"     <li>",
"      LVNC &mdash; every three years beginning in childhood",
"     </li>",
"     <li>",
"      RCM &mdash; every three to five years beginning in adulthood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More frequent screening is recommended if a mutation is present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat clinical screening at one year is suggested in first-degree relatives with any abnormal clinical screening tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less detailed recommendations are included in the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines with 2009 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Genetic counseling and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 HFSA guideline includes the following recommendations for genetic counseling and genetic testing in patients with DCM and at-risk family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic and family counseling is recommended for all patients and families with cardiomyopathy.",
"     </li>",
"     <li>",
"      Since evaluation, genetic counseling, and genetic testing of cardiomyopathy patients are complex processes, referral to centers expert in genetic evaluation and family-based management is suggested. A similar recommendation is included in the 2005",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      HF guidelines with 2009 focused update [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic testing should be considered for the one most clearly affected person in a family to facilitate family screening and management. Screening the most affected individual increases the likelihood of detecting a relevant mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is the first major society guideline recommending routine consideration of genetic testing in a patient with cardiomyopathy of unknown cause. The HFSA guideline limits the purpose of genetic testing to enabling the screening of family members at risk of carrying a disease-causing mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"     27",
"    </a>",
"    ]. The HFSA guideline does not include a recommendation for genetic testing in cardiomyopathy patients with apparently sporadic (non-familial) disease. However, genetic testing to facilitate diagnosis in the patient is also at times compelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39369/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/13/21714?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical assessment of the patient with heart failure or cardiomyopathy includes history, physical examination, initial blood tests, electrocardiogram, chest x-ray and echocardiography. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .) Additional tests may be warranted to establish the etiology of dilated cardiomyopathy if this is diagnosed on echocardiography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiography should be performed in all patients with new onset HF. Echocardiography has a high sensitivity and specificity for the diagnosis of myocardial dysfunction, and may also establish the etiology of HF.",
"     </li>",
"     <li>",
"      Virtually all patients with unexplained HF should be evaluated for the presence of coronary heart disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Detection of coronary artery disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Noninvasive exercise testing is a reasonable first step as it not only provides information about the presence of ischemic heart disease, but also can be used for risk stratification and prognostic purposes. The role of other types of noninvasive imaging is less well established.",
"     </li>",
"     <li>",
"      Coronary catheterization with angiography should be considered in patients with angina or a positive exercise test. Even in patients with a normal exercise test, however, cardiac catheterization should be considered if HF is otherwise unexplained and there is a reasonable likelihood that CAD is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular magnetic resonance imaging may be helpful in distinguishing ischemic heart disease from cardiomyopathy and in identifying the type of cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endomyocardial biopsy should be reserved for patients with established indications. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Endomyocardial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and left ventricular noncompaction) have a substantial genetic basis and this has implications for diagnosis and timely management. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Genetic evaluation of cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A careful family history for at least three generations is recommended for all patients with cardiomyopathy.",
"     </li>",
"     <li>",
"      Clinical screening for cardiomyopathy in asymptomatic first-degree relative is recommended.",
"     </li>",
"     <li>",
"      Genetic testing should be considered for the one most clearly affected person in a family to facilitate family screening and management.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/1\">",
"      Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/2\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/3\">",
"      He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/4\">",
"      Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/5\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/6\">",
"      Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from \"diastolic heart failure\" or from misdiagnosis? A prospective descriptive study. BMJ 2000; 321:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/7\">",
"      Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/8\">",
"      Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/9\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/10\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/11\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/12\">",
"      Drazner MH, Hamilton MA, Fonarow G, et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999; 18:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/13\">",
"      Erbel R, Schweizer P, Krebs W, et al. Sensitivity and specificity of two-dimensional echocardiography in detection of impaired left ventricular function. Eur Heart J 1984; 5:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/14\">",
"      Yamaguchi S, Tsuiki K, Hayasaka M, Yasui S. Segmental wall motion abnormalities in dilated cardiomyopathy: hemodynamic characteristics and comparison with thallium-201 myocardial scintigraphy. Am Heart J 1987; 113:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/15\">",
"      Vigna C, Russo A, De Rito V, et al. Regional wall motion analysis by dobutamine stess echocardiography to distinguish between ischemic and nonischemic dilated cardiomyopathy. Am Heart J 1996; 131:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/16\">",
"      Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/17\">",
"      Mullens W, Borowski AG, Curtin RJ, et al. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation 2009; 119:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/18\">",
"      Diwan A, Diwan A, McCulloch M, et al. Doppler estimation of left ventricular filling pressures in patients with mitral valve disease. Circulation 2005; 111:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/19\">",
"      Giannuzzi P, Temporelli PL, Bosimini E, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/20\">",
"      Gola A, Pozzoli M, Capomolla S, et al. Comparison of Doppler echocardiography with thermodilution for assessing cardiac output in advanced congestive heart failure. Am J Cardiol 1996; 78:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/21\">",
"      Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999; 34:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/22\">",
"      Naqvi TZ, Goel RK, Forrester JS, et al. Usefulness of left ventricular mass in predicting recovery of left ventricular systolic function in patients with symptomatic idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 85:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/23\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/24\">",
"      Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/25\">",
"      Repetto A, Dal Bello B, Pasotti M, et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J 2005; 26:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/26\">",
"      Frustaci A, Chimenti C, Maseri A. Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis. Circulation 1999; 99:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/27\">",
"      Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail 2009; 15:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/28\">",
"      Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005; 45:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/29\">",
"      Mahon NG, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005; 143:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/30\">",
"      Crispell KA, Hanson EL, Coates K, et al. Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy. J Am Coll Cardiol 2002; 39:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39369/abstract/31\">",
"      Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009; 2:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3485 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-002C802214-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39369=[""].join("\n");
var outline_f38_28_39369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification of HF severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stages in the development of HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EXERCISE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DETECTION OF CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Stress testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Coronary arteriography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Potential complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONINVASIVE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Coronary artery calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Noninvasive coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ENDOMYOCARDIAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      GENETIC EVALUATION OF CARDIOMYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Family screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3485|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/36/1605\" title=\"diagnostic image 1\">",
"      M mode dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/18/13601\" title=\"diagnostic image 2\">",
"      Pulsed wave Doppler LV outflow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3485|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/37/32339\" title=\"figure 1\">",
"      M mode MV dilated CM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3485|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?40/35/41521\" title=\"movie 1\">",
"      Dilated cardiomyopathy four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?43/0/44035\" title=\"movie 2\">",
"      Dilated cardiomyopathy long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?38/61/39902\" title=\"movie 3\">",
"      Dilated cardiomyopathy short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?36/40/37507\" title=\"movie 4\">",
"      Cardiac amyloidosis four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?43/47/44787\" title=\"movie 5\">",
"      Cardiac amyloidosis parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?41/31/42481\" title=\"movie 6\">",
"      Cardiac amyloidosis short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/9/21661\" title=\"table 1\">",
"      ACC AHA evaluation HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/63/18429\" title=\"table 3A\">",
"      ESC 2008 CM familial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/42/8876\" title=\"table 3B\">",
"      ESC 2008 CM nonfamilial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20679?source=related_link\">",
"      Screening for asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39370="Treatment of acne vulgaris";
var content_f38_28_39370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acne vulgaris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Emmy Graber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/28/39370/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/28/39370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acne is not physically disabling, its psychological impact can be striking, contributing to lower self-esteem, depression, and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As a result, there is a significant demand for effective acne therapies. In 2001, the global market for prescription acne products was estimated to be two billion dollars; the non-prescription market was estimated at two to four times that size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of medications are available for the treatment of acne. The lack of standardization for grading acne severity and measuring treatment outcomes has made systematic interpretation of the literature difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/5\">",
"     5",
"    </a>",
"    ]. However, quality evidence-based literature in the field of acne is growing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical findings and therapeutic principles that support the selection of specific treatment regimens will be discussed here. A table summarizing the treatment recommendations for patients with acne vulgaris is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef76250 \" href=\"mobipreview.htm?14/7/14457\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the anti-acne products will be reviewed, including topical retinoids, topical antimicrobials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , oral antibiotics, and hormonal therapies (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ). Adjunctive therapies and over-the-counter regimens, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , hormonal therapies, and the pathogenesis and diagnosis of acne vulgaris are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link\">",
"     \"Oral isotretinoin therapy for acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acne includes a number of topical and systemic therapies and is guided by several clinical features (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/6\">",
"     6",
"    </a>",
"    ]. Deciding on the appropriate course of treatment for an individual patient requires a comprehensive assessment that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical type of acne (eg, comedonal, inflammatory, nodular)",
"     </li>",
"     <li>",
"      Severity of acne",
"     </li>",
"     <li>",
"      Skin type (dry, oily)",
"     </li>",
"     <li>",
"      Presence of acne scarring or postinflammatory hyperpigmentation",
"     </li>",
"     <li>",
"      Menstrual history and history of signs of hyperandrogenism in women",
"     </li>",
"     <li>",
"      History of prior successful and failed treatments",
"     </li>",
"     <li>",
"      History of acne-promoting medications",
"     </li>",
"     <li>",
"      Psychological impact of acne on the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence or absence of acne scarring should be assessed. Patients with acne who are experiencing scarring may warrant more aggressive initial therapy. In addition, acne-related postinflammatory hyperpigmentation can be distressing for patients. Patients with postinflammatory hyperpigmentation can benefit from the use of medications or procedures that accelerate resolution. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Therapy for postinflammatory hyperpigmentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women with irregular menses or signs of hyperandrogenism may warrant laboratory work-up and anti-androgenic therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Hyperandrogenism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain medications can cause acne. If medication-induced acne is suspected, the risks and benefits of discontinuing the medication should be addressed (",
"    <a class=\"graphic graphic_table graphicRef76762 \" href=\"mobipreview.htm?11/32/11787\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link&amp;anchor=H28#H28\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Drug-induced acne'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four key factors promote the development of acne lesions (",
"    <a class=\"graphic graphic_figure graphicRef57892 \" href=\"mobipreview.htm?34/20/35146\">",
"     figure 1",
"    </a>",
"    ). These factors are targeted during therapy, and include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular hyperproliferation and abnormal desquamation",
"     </li>",
"     <li>",
"      Increased sebum production",
"     </li>",
"     <li>",
"      <em>",
"       Propionibacterium acnes",
"      </em>",
"      (",
"      <em>",
"       P. acnes",
"      </em>",
"      ) proliferation",
"     </li>",
"     <li>",
"      Inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follicular hyperkeratinization and abnormal corneocyte desquamation lead to follicular obstruction. This, in combination with the androgen-stimulated increase in sebum production, promotes the formation of the microcomedo, the earliest lesion of acne. The microcomedo enlarges to form a comedo as lipids, bacteria, and desquamated corneocytes accumulate (",
"    <a class=\"graphic graphic_picture graphicRef62816 graphicRef80536 \" href=\"mobipreview.htm?15/16/15624\">",
"     picture 1A-B",
"    </a>",
"    ).",
"    <em>",
"     P. acnes",
"    </em>",
"    can proliferate in this environment. Follicular rupture may occur, leading to a host inflammatory response, with the appearance of papules and pustules consistent with inflammatory acne (",
"    <a class=\"graphic graphic_picture graphicRef70809 \" href=\"mobipreview.htm?35/26/36258\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective management of acne involves the use of therapeutic agents that combat these factors (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ). A global panel of experts has recommended a comprehensive treatment plan for patients with acne vulgaris (",
"    <a class=\"graphic graphic_algorithm graphicRef76250 \" href=\"mobipreview.htm?14/7/14457\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients should be given realistic expectations regarding timelines for improvement. It takes approximately eight weeks for a microcomedo to mature. Thus, therapy must be continued beyond this duration in order to assess efficacy.",
"   </p>",
"   <p>",
"    Topical retinoids are effective in the treatment of comedonal acne due to their ability to normalize follicular hyperkeratosis and prevent formation of the microcomedo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. Topical retinoids also improve inflammatory acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. This may be due to a combination of intrinsic anti-inflammatory properties of topical retinoids and their ability to prevent the formation of microcomedones. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Topical retinoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Topical retinoids can be used as monotherapy in individuals with exclusively comedonal acne. However, patients with an inflammatory component often benefit from the addition of concomitant antimicrobial therapies (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    or topical antibiotics) that reduce the number of proinflammatory",
"    <em>",
"     P. acnes",
"    </em>",
"    colonizing the skin. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Topical antimicrobials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with moderate to severe inflammatory acne often warrant more aggressive treatment with oral antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/7\">",
"     7",
"    </a>",
"    ]. Antibiotics in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    class are most frequently used, and appear to have both antibacterial and anti-inflammatory properties. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    with topical or oral antibiotics decreases the emergence of antibiotic resistant bacteria. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Oral antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Acne typically recurs over years and maintenance therapy is an important component of acne management. The preventive effect of topical retinoids and the concern for antibiotic resistance make topical retinoids ideal candidates. If clinical improvement cannot be maintained with topical retinoid monotherapy, an antimicrobial agent containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    can be added [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Androgens stimulate increased sebum production, which contributes to the formation of acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. Hormonal therapy may benefit women with moderate to severe acne, even in the absence of a hyperandrogenic state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , a retinoid, decreases sebum production, reduces",
"    <em>",
"     P. acnes",
"    </em>",
"    colonization, and normalizes follicular keratinization. It is an option for patients with severe acne that essentially cures or significantly improves acne in the majority of patients who complete a full course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/12\">",
"     12",
"    </a>",
"    ]. Oral isotretinoin is used as monotherapy; a typical treatment course is approximately 20 weeks. This drug has multiple side effects and is US Food and Drug Administration (FDA) approved only for use in patients with severe, recalcitrant, nodular acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/13\">",
"     13",
"    </a>",
"    ]. Oral isotretinoin is teratogenic and female patients who are potentially childbearing should utilize two forms of contraception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link\">",
"     \"Oral isotretinoin therapy for acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjunctive therapies, such as light-based and laser therapies, chemical peels, comedo extraction, and intralesional glucocorticoids have also been used for acne management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of vehicles for topical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of delivery system for topical acne medications depends upon the patient's skin type (dry versus oily) and preference. Gels have a drying effect; they may be preferred by patients with oily skin. Creams and lotions tend to be moisturizing. Solutions are drying but they cover large areas more easily than other preparations, and foams are easy to apply to hair-bearing areas. Pledgets are single-use absorbent pads impregnated with medication. They are convenient to use, and facilitate the spreading of medication over large areas.",
"   </p>",
"   <p>",
"    Further modifications to the vehicle of a drug may also affect characteristics such as efficacy, tolerability, or stability. As an example, the microsphere formulation of tretinoin consists of tretinoin contained in microscopic biodegradeable spherical particles. As the microspheres are degraded, tretinoin is slowly and progressively delivered to the skin. This formulation is associated with improved drug stability and decreased irritation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Topical retinoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOPICAL RETINOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical retinoids are used for the treatment of both noninflammatory and inflammatory acne, and should be included in the initial management of most patients.",
"   </p>",
"   <p>",
"    Topical retinoids are vitamin A derivatives that act by binding to two nuclear receptor families within keratinocytes: the retinoic acid receptors (RAR) and the retinoid X receptors (RXR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/16\">",
"     16",
"    </a>",
"    ]. The retinoid-receptor complexes are transported into the nucleus where they activate specific regulatory DNA sequences called retinoid hormone response elements, thereby stimulating the transcription of target genes. These events contribute to the normalization of follicular keratinization and decreased cohesiveness of keratinocytes, resulting in reduced follicular occlusion and microcomedone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to this direct effect of retinoids on comedogenesis, retinoids may also improve inflammatory acne through other mechanisms. The retinoid-receptor complex competes for coactivator proteins of AP-1, a key transcription factor involved in inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Retinoids also down-regulate expression of toll-like receptor (TLR)-2, which has been implicated in the inflammatory response in acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first topical retinoid for the treatment of acne, all-trans retinoic acid (tretinoin), is still extensively used.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     Adapalene",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    are other effective topical retinoids. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is not available in the United States, but is utilized in other countries. Properties of the individual preparations and comparisons of the available drugs are discussed below (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Combination gels containing a retinoid and an antimicrobial are available (",
"    <a class=\"graphic graphic_table graphicRef56087 \" href=\"mobipreview.htm?4/51/4923\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evidence for efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies support the efficacy of topical retinoids in the treatment of acne vulgaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/10,21-30\">",
"     10,21-30",
"    </a>",
"    ]. Representative trials of topical retinoids versus placebo include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-week randomized trial of 60 patients with acne vulgaris treated with tretinoin 0.05% solution, tretinoin 0.025% solution, or placebo showed greater reductions in acne lesions with the tretinoin formulations than with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 12-week randomized controlled trial, 200 patients were given either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% gel or vehicle. Treatment with adapalene led to significantly greater reductions in total, inflammatory, and noninflammatory lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/29\">",
"       29",
"      </a>",
"      ]. The mean percent reduction in total lesion counts at the end of therapy was 63.2 percent for patients who received adapalene gel versus 36.9 percent for patients treated with vehicle.",
"     </li>",
"     <li>",
"      A 12-week trial involved 653 patients who were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.3% gel, adapalene 0.1% gel, or vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/25\">",
"       25",
"      </a>",
"      ]. Adapalene 0.3% gel, adapalene 0.1% gel, and vehicle gel yielded 55.6, 48.2, and 36.4 percent reductions in total lesion counts, respectively. Thus, adapalene products were more effective than vehicle alone.",
"     </li>",
"     <li>",
"      Pooled results of two randomized controlled trials of a total of 847 patients with acne vulgaris treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"       tazarotene",
"      </a>",
"      0.1% cream or vehicle for 12 weeks showed a significantly greater reduction in noninflammatory, inflammatory, and total lesion counts in patients treated with tazarotene compared with patients who received the vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/28\">",
"       28",
"      </a>",
"      ]. The median percent reduction in total lesion counts for patients treated with tazarotene was 43 percent compared with 23 percent for patients treated with vehicle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to treating active acne, retinoids accelerate the resolution of acne-induced post-inflammatory hyperpigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/16\">",
"     16",
"    </a>",
"    ]. This complication occurs more frequently in patients with darker skin pigmentation, and is often a significant concern. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Therapy for postinflammatory hyperpigmentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Topical retinoids are also useful as maintenance therapy for patients who have responded to initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The use of retinoids as maintenance therapy can diminish the prolonged use of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, topical retinoids may enhance the penetration of other topical acne medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9,35\">",
"     9,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salicylic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    are alternative comedolytic therapies for patients who are unable to tolerate topical retinoids, but may be less effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Azelaic acid'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Instructions for application",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical retinoids are applied once daily and traditionally at night due to photolability reported with tretinoin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     Adapalene",
"    </a>",
"    is more light-stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, a newer formulation of tretinoin, tretinoin gel microsphere (Retin-A Micro",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), is less affected by light exposure than its precursors. In a study in which tretinoin gel microsphere 0.1% and tretinoin 0.025% gel were exposed to simulated solar ultraviolet radiation, 94 percent of tretinoin in the microsphere formulation remained stable after two hours, compared to only 19 percent of tretinoin in the 0.025% gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tretinoin should",
"    <strong>",
"     not",
"    </strong>",
"    be applied at the same time as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    . Tretinoin is less stable when exposed to benzoyl peroxide due to oxidation, an effect magnified during light exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     Adapalene",
"    </a>",
"    and tretinoin gel microsphere remain more stable than tretinoin in the presence of benzoyl peroxide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. A combination product, containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9507?source=see_link\">",
"     adapalene-benzoyl peroxide",
"    </a>",
"    (Epiduo",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) is available.",
"   </p>",
"   <p>",
"    Patients should be directed to apply a thin layer of the topical retinoid to the affected areas; a pea-sized amount of medication is usually sufficient to cover the face. Due to the preventive effect of topical retinoids on acne, the medication should be applied to the entire affected area, not as spot treatment of individual lesions. Skin should be dry at the time of application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical retinoids cause irritation, dryness, and flaking of the skin, an effect most notable during the first month of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/16\">",
"     16",
"    </a>",
"    ]. To minimize irritation, patients should avoid the concomitant use of over-the-counter irritating products, such as harsh soaps, toners, astringents, and alpha hydroxy acid or salicylic acid products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/39\">",
"     39",
"    </a>",
"    ]. A gentle non-soap cleanser should be recommended. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Home skin care recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If irritation is a problem, a decrease in the frequency of application to every other or every third night can be considered, and the frequency of application can be increased as tolerance improves. The fine skin flaking that is often seen can be gently exfoliated with a washcloth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/40\">",
"     40",
"    </a>",
"    ]. A non-comedogenic facial moisturizer can be applied on top of the retinoid if needed.",
"   </p>",
"   <p>",
"    Some patients may notice a transient worsening of acne during the first few weeks of topical retinoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/41\">",
"     41",
"    </a>",
"    ]. These flares spontaneously resolve with continued treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical retinoids are not true photosensitizing drugs, but patients using topical retinoids have described symptoms of increased sun sensitivity. This is thought to be due to thinning of the stratum corneum leading to a decreased barrier against ultraviolet light exposure, as well as an enhanced sensitivity due to the presence of cutaneous irritation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of sun-protective clothing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sunscreen is recommended, particularly when prolonged sun exposure is anticipated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large randomized trial evaluating the use of long term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    0.1% cream for the prevention of basal cell and squamous cell carcinoma reported an increase in mortality in elderly men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/43\">",
"     43",
"    </a>",
"    ]. However, there is a possibility that these findings may have been due to chance in the population studied, and the applicability of these findings to the use of tretinoin in younger patients for the treatment of acne is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of actinic keratosis\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of topical retinoids is not recommended in pregnancy. In particular,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    is a pregnancy category X drug. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Pregnancy and acne therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tretinoin and isotretinoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     Topical tretinoin",
"    </a>",
"    (all-trans retinoic acid) is available in multiple strengths and formulations. Irritation may be minimized by starting with the lowest strength preparation (0.025 percent cream) and then increasing the potency as tolerated (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ). In one study in which different formulations of tretinoin were applied under occlusion to the backs of 28 healthy subjects, the irritation potential of tretinoin in ascending order was: 0.025% cream and 0.01% gel, followed by 0.025% gel, followed by 0.05% cream and 0.1% cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/44\">",
"     44",
"    </a>",
"    ]. A newer 0.05% gel product is also available. Gels are more drying than creams, and patients may prefer one formulation over another.",
"   </p>",
"   <p>",
"    A microencapsulated form of tretinoin gel (Retin-A Micro",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) is less irritating, and is available as a 0.04% and 0.1% gel. Similarly, reduced irritation has been noted with a polyolprepolymer-2 base (Avita",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , the 13-cis isomer of retinoic acid, is not available in the United States, but is also effective for the treatment of acne vulgaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The drug is manufactured as a 0.05% gel and a 0.1% cream.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adapalene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     Adapalene",
"    </a>",
"    is available as a 0.1% cream, 0.1% gel, 0.1% lotion, and a 0.3% gel. Adapalene 0.1% gel produces less irritation than tretinoin 0.025% gel and cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tazarotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    can be prescribed as a 0.05% or 0.1% cream or gel. Tazarotene is used for the treatment of psoriasis as well as acne. Only the 0.1% strength is approved by the US FDA for the treatment of acne. In general, tazarotene has been considered the most effective, but also most irritating topical retinoid, when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    and tretinoin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A short-contact regimen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    is another treatment option, and can decrease irritation. Patients apply tazarotene for up to five minutes daily, then wash off the medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    is contraindicated in pregnancy (pregnancy category X (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 4",
"    </a>",
"    )). (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Pregnancy and acne therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and their meta-analyses have compared the efficacy and tolerability of topical retinoids. Interpretation of results needs to take into account the drug concentrations and formulations. The trials do not definitively support the use of one topical retinoid over another.",
"   </p>",
"   <p>",
"    A meta-analysis of five randomized trials found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    0.1% gel and tretinoin 0.025% gel had similar efficacy, but adapalene was somewhat better tolerated and produced more rapid improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/49\">",
"     49",
"    </a>",
"    ]. Adapalene 0.1% gel also appeared to have equivalent efficacy and greater tolerability when compared to tretinoin microsphere 0.1% gel or tretinoin 0.05% cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter randomized trial found that the reduction in noninflammatory lesions was greater with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.1% gel than tretinoin 0.025% gel (55 versus 42 percent reduction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/54\">",
"     54",
"    </a>",
"    ]. The preparations were similarly effective in reducing inflammatory lesions; tazarotene caused more skin irritation.",
"   </p>",
"   <p>",
"    Randomized trials found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    cream and gel were more efficacious than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    cream and gel at the same concentrations (0.1%); the creams had similar tolerability, but adapalene gel was better tolerated than tazarotene gel during the first few weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In another trial, adapalene 0.3% gel was noninferior to tazarotene 0.1% gel and remained better tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From these studies, it appears that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    is the best tolerated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    may be more effective but is the most irritating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TOPICAL ANTIMICROBIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antimicrobials are used to decrease the number of",
"    <em>",
"     P. acnes",
"    </em>",
"    colonizing the skin, with the goal of reducing the inflammatory response that occurs in acne. The most commonly used topical antimicrobials include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are additional treatment options. A list of topical antimicrobial preparations for the treatment of acne is provided (",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Combination therapy with a topical antimicrobial plus a topical retinoid appears to be more effective than either agent alone, and is recommended for the treatment of patients with inflammatory acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9,58\">",
"     9,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Benzoyl peroxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its antibacterial properties,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    is also comedolytic. The drug is available in the United States in both prescription and non-prescription products as 2.5 to 10% gels, lotions, creams, pads, masks, and cleansers, and is usually applied twice daily. Concentrations of benzoyl peroxide that are higher than 2.5% may not contribute to increased benefit. In one study, 2.5% benzoyl peroxide was as effective as 10% benzoyl peroxide in reducing the number of inflammatory acne lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/59\">",
"     59",
"    </a>",
"    ]. However, increased concentrations can lead to increased skin irritation.",
"   </p>",
"   <p>",
"    Irritation caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    may appear as erythema, scaling, xerosis, or stinging, tightening, or burning sensations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/4\">",
"     4",
"    </a>",
"    ]. Although irritation is common, true allergic contact dermatitis to benzoyl peroxide is rare. Only 0.25 to 2.5 percent of patients develop a true allergic contact sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Patients should also be advised that benzoyl peroxide can cause bleaching of the hair and clothing.",
"   </p>",
"   <p>",
"    Antibiotics may promote the appearance of resistant strains of",
"    <em>",
"     P. acnes",
"    </em>",
"    when used alone. Resistance is diminished by combination use with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tretinoin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    should not be applied simultaneously to the skin due to the oxidizing effect of benzoyl peroxide on tretinoin. If both agents are prescribed, benzoyl peroxide should be applied in the morning, and tretinoin in the evening.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     Adapalene",
"    </a>",
"    and the microsphere formulation of tretinoin appear to be more stable in the presence of benzoyl peroxide. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Instructions for application'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Topical antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antibiotics reduce the numbers of",
"    <em>",
"     P. acnes",
"    </em>",
"    in the sebaceous follicles and thereby suppress inflammation in patients with inflammatory acne. In addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , topical preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are available. All topical antibiotics may occasionally cause skin irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Erythromycin and clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are the most common topical antibiotics used for the treatment of acne. Erythromycin is available in gel and solution formulations; clindamycin is available as a gel, solution, lotion, foam, or as pledgets (antibiotic impregnated wipes). Erythromycin and clindamycin are often used in 2 and 1% concentrations, respectively.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    should not be used as monotherapy for acne, as evidence shows better treatment efficacy when these drugs are combined with retinoids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, the use of benzoyl peroxide with antibiotics decreases the occurrence of bacterial resistance. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Combination gels containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    or tretinoin combined with an antibiotic are available (",
"    <a class=\"graphic graphic_table graphicRef56087 \" href=\"mobipreview.htm?4/51/4923\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Sulfacetamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    is an antibacterial agent that inhibits",
"    <em>",
"     P. acnes",
"    </em>",
"    . It is often combined with 5% sulfur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link&amp;anchor=H5#H5\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\", section on 'Sulfur'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    should not be used in patients with sulfa or sulfonamide allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/4\">",
"     4",
"    </a>",
"    ]. Data regarding the effectiveness of sulfacetamide in the treatment of acne are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], and other antimicrobials are preferred as first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    5% gel is a newer effective treatment for acne vulgaris. Oral dapsone is known to have anti-inflammatory and antimicrobial properties, although the mechanism through which dapsone gel improves acne has not been confirmed. Both inflammatory and noninflammatory acne lesions improve with treatment, with the greatest improvement occurring in inflammatory lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In two phase 3 randomized trials with a total of 3010 patients, the percent reduction of inflammatory lesions after 12 weeks of twice daily treatment was significantly greater in patients treated with topical dapsone than in those treated with vehicle (48 versus 42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/66\">",
"     66",
"    </a>",
"    ]. An open label long-term study of patients treated with the same regimen for up to 12 months (mean 253 days) found a reduction in inflammatory lesions of 58 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased risk of hemolytic anemia is seen in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency taking oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    . However, patients with G6PD deficiency and acne have tolerated topical dapsone gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/66,68\">",
"     66,68",
"    </a>",
"    ]. Testing for G6PD deficiency is not necessary for use of the topical preparation of dapsone. In addition, dapsone is a sulfone, not a sulfonamide, and topical dapsone is not contraindicated in sulfonamide (&ldquo;sulfa&rdquo;) allergic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Temporary yellow to orange discoloration of the skin and hair may occur when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    gel and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    are applied concomitantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one study, 7 out of 100 patients experienced this adverse effect when the two drugs were applied 10 minutes apart; discoloration resolved between 4 and 57 days after discontinuation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/70\">",
"     70",
"    </a>",
"    ]. If both drugs are prescribed for the treatment of acne, applying the drugs at separate times of the day and washing skin between applications may reduce the risk of this side effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with inflammatory acne, combining a topical retinoid with antimicrobial agent(s) is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. Combination therapy with a topical antibiotic plus a topical retinoid appears to be more effective than either agent alone. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    with topical or oral antibiotics is also recommended. Adding benzoyl peroxide reduces the development of antibiotic resistance.",
"   </p>",
"   <p>",
"    Several combination products are available in the United States (",
"    <a class=\"graphic graphic_table graphicRef56087 \" href=\"mobipreview.htm?4/51/4923\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Topical retinoid and topical antimicrobial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies comparing monotherapy versus combination therapy with topical retinoids and antimicrobials (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    ) have demonstrated improved treatment efficacy with combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31,58,72-83\">",
"     31,58,72-83",
"    </a>",
"    ]. Representative trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial of 249 patients with mild to moderate acne vulgaris evaluated treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% gel plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% lotion versus clindamycin plus vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/75\">",
"       75",
"      </a>",
"      ]. Significantly greater reductions in total lesions were seen in patients who received combination therapy (46.7 versus 25.5 percent). Improvement was seen in both inflammatory and noninflammatory lesions.",
"     </li>",
"     <li>",
"      Two 12-week randomized controlled trials involving a total of 2219 patients with acne vulgaris compared treatment with a combination hydrogel containing 1%",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      and 0.025% tretinoin to one of three treatments: each agent as monotherapy or vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/58\">",
"       58",
"      </a>",
"      ]. The efficacy of the combination hydrogel was superior to monotherapy and vehicle in the reduction of inflammatory, noninflammatory, and total lesions. The reductions in total lesion counts for the combination hydrogel, clindamycin gel, tretinoin gel, or vehicle were 48.7, 38.3, 40.3, and 23.2 percent, respectively.",
"     </li>",
"     <li>",
"      A 12-week randomized controlled trial with 517 subjects compared treatment of acne vulgaris with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      2.5% combination gel to monotherapy with each drug and to vehicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/74\">",
"       74",
"      </a>",
"      ]. Treatment with the combination gel was more effective, with a significantly greater reduction in total lesion counts noted as early as one week after starting therapy. At the end of treatment, the combination gel, adapalene, benzoyl peroxide, and vehicle groups exhibited 51, 35.4, 35.6, and 31 percent reductions in total lesion counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of multiple anti-acne active ingredients may cause skin irritation. In one small trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    0.1% gel was less irritating than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.05% cream or tretinoin microsphere 0.04% gel when used in combination regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The topical retinoid and topical antimicrobial combination products available in the United States include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      1.2% and tretinoin 0.025% gel (Ziana",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Veltin",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       Benzoyl peroxide",
"      </a>",
"      2.5% and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% (Epiduo",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotics and benzoyl peroxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the widespread use of topical antibiotics, resistance to these agents has increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/85\">",
"     85",
"    </a>",
"    ]. Unlike the topical antibiotics",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <em>",
"     P. acnes",
"    </em>",
"    resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    has not been identified. Combining antibiotic therapy with the use of benzoyl peroxide decreases the development of antibiotic resistance and improves treatment efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/62,85-89\">",
"     62,85-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial found that a combination 3%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    gel was superior to either agent alone in terms of antibacterial activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/90\">",
"     90",
"    </a>",
"    ]. The combination gel also led to clinical improvement in an open-label study of patients with pretreatment erythromycin-resistant",
"    <em>",
"     P. acne",
"    </em>",
"    strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    is also more potent than monotherapy with either agent. In an open-label study, the combination of benzoyl peroxide and clindamycin decreased the numbers of",
"    <em>",
"     P. acnes",
"    </em>",
"    found on healthy skin more effectively than clindamycin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/91\">",
"     91",
"    </a>",
"    ]. The clinical efficacy of combination benzoyl peroxide and clindamycin gel was assessed in a meta-analysis of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/92\">",
"     92",
"    </a>",
"    ]. The meta-analysis found that gels containing benzoyl peroxide and clindamycin were modestly superior to benzoyl peroxide alone for the treatment of inflammatory acne lesions (mean percent reduction in lesions 56 (95% CI 54-58) versus 44 percent (95% CI 41-46) after treatment for 10 to 12 weeks). In addition, treatment with gels containing benzoyl peroxide and clindamycin resulted in more rapid improvement of both inflammatory and noninflammatory lesions than clindamycin alone (mean percentage reductions in lesions were 41 (95% CI 37-44) versus 21 percent (95% CI 17-26) and of 26 percent (95% CI 22-30) versus 10 percent (95% CI 5-15), respectively, after two to four weeks of treatment).",
"   </p>",
"   <p>",
"    Three topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    and antibiotic combination products are available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       Benzoyl peroxide",
"      </a>",
"      5% and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% gel (Benzaclin",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Duac",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       Benzoyl peroxide",
"      </a>",
"      5% and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      3% gel (Benzamycin",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       Benzoyl peroxide",
"      </a>",
"      2.5% and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1.2% gel (Acanya",
"      <sup>",
"       &reg;",
"      </sup>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When oral antibiotic therapy is indicated, concomitant use of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    is also advised to decrease antibiotic resistance. For patients who may not tolerate continuous use of benzoyl peroxide, pulse therapy of benzoyl peroxide or use between antibiotic courses has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     AZELAIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    is a naturally occurring dicarboxylic acid with antimicrobial, comedolytic, and mild anti-inflammatory properties. Azelaic acid also has an inhibitory effect on tyrosinase, and can improve acne-induced postinflammatory hyperpigmentation. The product is available in a 15% gel and 20% cream.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    20% cream is effective for the treatment of both inflammatory and non-inflammatory acne, and has comparable efficacy to tretinoin 0.05% cream,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    5% gel, or topical 2%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for mild to moderate acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 15% gel is FDA approved only for the treatment of rosacea, although it is approved for the treatment of acne in many European countries. Two randomized controlled trials revealed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    gel is well-tolerated and as effective as 5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    gel or 1%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    gel in the treatment of mild to moderate acne vulgaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ORAL ANTIBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies, including randomized trials, have shown oral antibiotics effective for the management of inflammatory acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/63,95-102\">",
"     63,95-102",
"    </a>",
"    ]. Utilization of these drugs is primarily indicated for patients with moderate to severe inflammatory acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/103\">",
"     103",
"    </a>",
"    ]. Oral antibiotics may also be used for patients who have milder truncal acne, for whom the application of topical antibiotics is difficult.",
"   </p>",
"   <p>",
"    Oral antibiotics improve inflammatory acne by inhibiting the growth of",
"    <em>",
"     P. acnes",
"    </em>",
"    within the pilosebaceous unit. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics also have direct anti-inflammatory properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic antibiotics produce more rapid clinical improvement than topical preparations, but may induce side effects such as vaginal candidiasis or gastrointestinal distress.",
"   </p>",
"   <p>",
"    Oral antibiotics should be prescribed for a limited course to limit the emergence of antibiotic resistance. Optimally, they are prescribed for daily use for less than six months with subsequent discontinuation as acne improves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9,103\">",
"     9,103",
"    </a>",
"    ]. In 2003, a panel of experts recommended limiting therapy to 12 to 18 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. No consensus exists regarding whether oral antibiotics should be tapered or abruptly stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/103\">",
"     103",
"    </a>",
"    ]. Oral antibiotics used in the treatment of acne include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef55642 \" href=\"mobipreview.htm?15/59/16318\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic resistance is increasing in patients with acne. One report suggests that the incidence of",
"    <em>",
"     P. acnes",
"    </em>",
"    antibiotic resistance increased from 20 percent in 1978 to 62 percent in 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/105\">",
"     105",
"    </a>",
"    ]. Factors that contribute to this increasing incidence include the widespread use of oral antibiotics and the practice of rotating antibiotics. Resistance is most commonly reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ; resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    is rare, but may be emerging in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rise of",
"    <em>",
"     P. acnes",
"    </em>",
"    antibiotic resistance is a concern for acne management; there is some evidence that the presence of resistant organisms can reduce treatment efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/107\">",
"     107",
"    </a>",
"    ]. There is also concern that long-term antibiotic therapy affects other host bacterial flora, although the clinical impact of this is unclear. In one cross-sectional study (n = 107), patients taking oral tetracyclines or topical antibiotics for at least three months had a three-fold increase in the prevalence of Streptococcus pyogenes in the oropharynx compared with those who were not on antibiotic therapy (33 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/108\">",
"     108",
"    </a>",
"    ]. However, the number of patients reporting upper respiratory tract illness or symptoms was not different in the two groups.",
"   </p>",
"   <p>",
"    Other studies have found an increased rate of upper respiratory infections in acne patients treated with oral antibiotic therapy. A more than threefold increase in pharyngitis was reported in a prospective cohort study and a cross-sectional study, and a large retrospective study (n = 118,496) found a twofold greater risk for upper respiratory infection among acne patients treated with either topical or oral antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. In the prospective study, which consisted of 36 university students with acne who received oral antibiotic therapy and 543 students with or without acne who were not treated with oral antibiotics, more students in the antibiotic therapy group reported visits to a health care provider for pharyngitis (11 versus 3 percent; adjusted odds ratio [OR] 4.34; 95% CI 1.51-12.47). In contrast to the cross-sectional study described above, an effect of antibiotic use on group A streptococcus colonization was not detected. Further prospective studies are necessary to evaluate the effect of antibiotic therapy on upper respiratory tract infections.",
"   </p>",
"   <p>",
"    The following practices may reduce the incidence of resistance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only prescribe antibiotics when necessary. The duration of treatment should be limited; an oral antibiotic should be discontinued when there is no additional clinical improvement or clinical improvement is absent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11\">",
"       11",
"      </a>",
"      ]. One panel of experts suggested limiting treatment courses to a maximum of 12 to 18 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In order to avoid changing oral antibiotics prematurely, six to eight weeks of therapy should be allowed prior to evaluating treatment efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/103,111\">",
"       103,111",
"      </a>",
"      ]. After six to eight weeks, a change in the antibiotic can be considered if there is no response. In cases in which a partial response is seen, therapy should be continued and response reassessed after another six to eight weeks.",
"     </li>",
"     <li>",
"      If oral antibiotics are stopped and need to be restarted, prescribe the same antibiotic the second time as long as it remains effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11,103\">",
"       11,103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An expert international panel, convened to develop optimal strategies for acne treatment, advises that patients should not be simultaneously treated with a topical antibiotic and an oral antibiotic that have different mechanisms of action [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prescribe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      at the start of antibiotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/103\">",
"       103",
"      </a>",
"      ]. Concomitant use of benzoyl peroxide can decrease the incidence of antibiotic resistance. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Topical antimicrobials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prescribe a topical retinoid. A topical retinoid should be used at the start of treatment with an oral antibiotic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11,112\">",
"       11,112",
"      </a>",
"      ]. Combination therapy with a retinoid and oral antibiotic improved treatment efficacy in several studies, including two randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/113-117\">",
"       113-117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical retinoids are effective as long-term maintenance therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31-34\">",
"       31-34",
"      </a>",
"      ] and can decrease dependence on the extended use of antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Maintenance therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In select cases, antibiotics may be continued indefinitely at the lowest effective dose in patients with persistent acne, although this practice can lead to antibiotic resistance. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    can be another option for patients who are unable to discontinue oral antibiotics despite adherence to a regimen for maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    may be administered for acne in doses of 500 mg twice daily. However, it has less anti-inflammatory activity than the tetracyclines. In addition,",
"    <em>",
"     P. acnes",
"    </em>",
"    often develops resistance to this drug, resulting in treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/118\">",
"     118",
"    </a>",
"    ]. Many patients experience intolerable gastrointestinal side effects. The use of erythromycin is now recommended only for patients in whom",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives are contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/63,95\">",
"     63,95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Tetracyclines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    , another oral macrolide antibiotic, has shown efficacy for the treatment of acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. The optimum dosing remains to be determined. Concern regarding the use of azithromycin for the routine treatment of acne is related to the rising incidence of antibiotic resistance to this drug. Azithromycin is often used as a first line agent for the treatment of respiratory infections and is also prescribed as an alternative drug for the treatment of other gram positive cocci infections in patients allergic to beta-lactam antibiotics. The risk of increasing the prevalence of antibiotic resistance makes azithromycin a less favorable choice for routine acne therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=see_link&amp;anchor=H3#H3\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was the preferred oral antibiotic due to its low cost and studies showing high efficacy. However, newer generation tetracycline derivatives are now used more commonly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    are newer generation",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives. These two drugs have replaced",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and tetracycline as the most frequently used oral antibiotics for acne therapy by dermatologists in the United States, both due to better tolerability and the presence of higher rates of",
"    <em>",
"     P. acnes",
"    </em>",
"    resistance to erythromycin and tetracycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/85,122\">",
"     85,122",
"    </a>",
"    ]. A shortage of tetracycline in North America in 2011 and 2012 has also contributed to the increased use of these agents. Unlike tetracycline, doxycycline and minocycline can be taken with meals since absorption is not inhibited by food.",
"   </p>",
"   <p>",
"    In clinical practice,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    is widely considered the most effective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative for the treatment of acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/85\">",
"     85",
"    </a>",
"    ]. Biologic evidence suggests that minocycline may result in greater reductions in",
"    <em>",
"     P. acnes",
"    </em>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or other antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/123,124\">",
"     123,124",
"    </a>",
"    ], and that some tetracycline-resistant strains of",
"    <em>",
"     P. acnes",
"    </em>",
"    show cross-resistance to doxycycline, but not to minocycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the evidence that supports the greater efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    in clinical response has methodological flaws, including lack of blinding in clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/126\">",
"     126",
"    </a>",
"    ]. A systematic review of minocycline for the treatment of acne did not find sufficient evidence to support the conclusion that minocycline is superior to other tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    induces more rapid improvement in inflammatory acne than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/127-129\">",
"     127-129",
"    </a>",
"    ]. However, the magnitude of clinical improvement with tetracycline or minocycline at the end of the treatment period was equivalent for all studies.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    is not used as first-line therapy due to its high cost and lack of clear benefit compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , as well as concerns about more severe toxicities than other tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. Some patients who have failed therapy with doxycycline or tetracycline may respond to minocycline.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    should not be administered to children under the age of nine or to pregnant women due to the potential for discoloration of developing permanent teeth and reduced bone growth. Antibiotics in the tetracycline class can cause gastrointestinal distress, and rarely esophagitis, esophageal ulceration, or idiopathic intracranial hypertension (pseudotumor cerebri). Photosensitivity may also occur, with doxycycline as the most photosensitizing drug. Patients taking doxycycline or tetracycline must be cautioned regarding this potential side effect, and should be encouraged to engage in sun-protective behavior.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    is the least photosensitizing of the three drugs, but can cause vertigo, skin discoloration (",
"    <a class=\"graphic graphic_picture graphicRef79772 \" href=\"mobipreview.htm?34/1/34834\">",
"     picture 3",
"    </a>",
"    ), serum sickness, and a lupus-like syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/132-135\">",
"     132-135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Dosing for tetracyclines",
"    </span>",
"   </p>",
"   <p>",
"    Tetracyline is initiated at a dose of 500 mg twice daily, although 250 mg twice daily may also be effective. Absorption is inhibited by food, dairy products, antacids, and iron; it must be taken on an empty stomach. Patients should be instructed to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    at least one hour prior to a meal or two hours after eating. Because of these requirements, compliance to therapy may be difficult for some patients.",
"   </p>",
"   <p>",
"    Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    can be taken with food and drink; doing so may reduce the risk for gastrointestinal side effects. Typical doses of doxycyline are 50 to 100 mg twice daily or 150 mg once daily. Minocycline is usually prescribed as 50 to 100 mg twice daily. However, newer research has provided additional dosing options for these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Extended-release minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer research has provided an additional dosing option for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    . A once daily, extended-release formulation of minocycline (Solodyn",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) is prescribed as a weight-based dose. The lowest effective dose with the most favorable side effect profile was determined to be 1",
"    <span class=\"nowrap\">",
"     mg/kg/day;",
"    </span>",
"    higher doses did not offer additional benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/136-138\">",
"     136-138",
"    </a>",
"    ]. Extended-release minocycline is available as 45, 90, and 135 mg tablets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Subantimicrobial dose doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern over the induction of antibiotic resistance with long-term antibiotic use for acne has led to the investigation of subantimicrobial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for the treatment of acne vulgaris. Subantimicrobial doses of antibiotics are doses for which the antiinflammatory properties are maintained, but antibacterial action is absent. In this manner, the potential for inducing antibacterial resistance is diminished. The tetracyclines, particularly doxycycline, are often administered at subantimicrobial doses for treating acne. This lower dosage may block inflammation in acne through multiple mechanisms, including the inhibition of matrix metalloproteinases, regulation of inflammatory cytokines, inhibition of leukocyte chemotaxis and activation, and anti-oxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter, randomized trial revealed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    20 mg twice daily was more effective than placebo for the treatment of moderate acne vulgaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/95\">",
"     95",
"    </a>",
"    ]. However, there are minimal data comparing subantimicrobial doxycycline to higher doses of the drug. In one randomized trial (n = 100), patients with moderate acne treated with either 20 mg or 100 mg doxycycline twice daily exhibited numerically similar reductions in inflammatory lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/140\">",
"     140",
"    </a>",
"    ]. Additional studies are necessary prior to a recommendation that subantimicrobial dosing can replace traditional doses for the treatment of acne vulgaris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    is effective in the treatment of severe acne. However, its use is limited by the potential for bone marrow suppression and for the development of severe immune-mediated drug eruptions such as toxic epidermal necrolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is limited because of the potential to induce pseudomembranous colitis. Other antibiotics are generally preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=see_link&amp;anchor=H12#H12\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5871658\">",
"    <span class=\"h3\">",
"     Cephalexin",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some physicians use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    to treat acne, the data to support its use are sparse. A retrospective study of 93 patients treated with cephalexin (primarily 500 mg twice daily) for a mean duration of nine months found that acne clearing or much improvement in acne occurred in 4 and 45 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/141\">",
"     141",
"    </a>",
"    ]. Of note, most patients received concomitant therapy with other anti-acne agents.",
"   </p>",
"   <p>",
"    Potential disadvantages of cephalosporin antibiotics include their hydrophilic nature, which prevents penetration into the pilosebaceous unit, the site of",
"    <em>",
"     P. acnes",
"    </em>",
"    colonization, and the potential for the promotion of methicillin resistant staphylococcus aureus. In general, we favor tetracyclines over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    for the treatment of acne. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Antibiotic use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     HORMONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation and hormonal therapies should be considered for patients with evidence for hyperandrogenism. Women without hyperandrogenism can also benefit from therapies that reduce androgen production or block androgen receptors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Hyperandrogenism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169690\">",
"    <span class=\"h1\">",
"     ORAL ISOTRETINOIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy is effective for the treatment of severe, recalcitrant nodular acne. In clinical practice, it is also used for milder acne that is resistant to other treatments or associated with significant scarring. The risk for adverse effects, including teratogenicity, precludes the use of this drug as routine acne therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link\">",
"     \"Oral isotretinoin therapy for acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169710\">",
"    <span class=\"h1\">",
"     NON-PRESCRIPTION TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    , other non-prescription agents including salicylic acid, sulfur, alpha hydroxy acid, and tea tree oil have been used in the treatment of acne. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link&amp;anchor=H2#H2\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\", section on 'Other topical medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169730\">",
"    <span class=\"h1\">",
"     PROCEDURAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acne vulgaris with lasers, visible light, chemical peels, and other procedures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link&amp;anchor=H8#H8\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\", section on 'Light/laser therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=see_link&amp;anchor=H11#H11\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\", section on 'Adjunctive therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, acne is a disorder in which symptoms typically recur over years. Consequently, identifying a sustainable treatment regimen is an important component of acne management. Concern regarding antibiotic resistance provides an incentive to limit the use of antibiotics, though effective, as long term therapy.",
"   </p>",
"   <p>",
"    Topical retinoids are a compelling option for maintenance therapy for patients with acne vulgaris. In addition to their ability to combat active acne through comedolytic and anti-inflammatory properties, these drugs play a critical preventive role through the inhibition of the formation of the microcomedone, the precursor lesion in acne vulgaris.",
"   </p>",
"   <p>",
"    Several randomized controlled trials support the use of retinoids as maintenance therapy following the cessation of antimicrobial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31-34,142\">",
"     31-34,142",
"    </a>",
"    ]. Representative trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-week randomized controlled trial involving 241 patients with moderate to moderately severe acne evaluated the effect of maintenance therapy for patients who had at least moderate improvement after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% gel and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% solution or clindamycin solution alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients who continued therapy with adapalene 0.1% gel had a 41.6 percent reduction in total lesion counts. Patients who stopped treatment exhibited a 92 percent increase in total lesion counts.",
"     </li>",
"     <li>",
"      A 16-week randomized controlled trial evaluated 253 subjects with severe acne who achieved at least moderate improvement after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% gel and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg or doxycycline 100 mg and a vehicle gel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/33\">",
"       33",
"      </a>",
"      ]. The percentage of patients sustaining 50 percent improvement in lesion counts was 75 percent in the adapalene group versus 54 percent in the vehicle group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For some patients, monotherapy with a topical retinoid may not be sufficient to sustain clinical improvement. In these cases, an antimicrobial agent containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    can be added to the treatment regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11,143\">",
"     11,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies will be useful for determining the best maintenance regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     THERAPY FOR POSTINFLAMMATORY HYPERPIGMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinflammatory hyperpigmentation can be a significant problem for patients with darker skin complexions and acne. In many cases, patients are more distressed by the \"dark spots\" that take several months or more to resolve, than by active acne lesions which resolve more quickly (",
"    <a class=\"graphic graphic_picture graphicRef78119 \" href=\"mobipreview.htm?20/25/20885\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both topical retinoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    accelerate the resolution of postinflammatory hyperpigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. In one randomized trial, black patients who applied tretinoin 0.1% cream exhibited significantly greater lightening of facial postinflammatory hyperpigmentation than those treated with vehicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/145\">",
"     145",
"    </a>",
"    ]. A regimen containing either of these agents will treat active acne and improve postinflammatory hyperpigmentation.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    is a depigmenting agent that inhibits melanin production, and is considered the \"gold standard\" for treatment of hyperpigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/144,146,147\">",
"     144,146,147",
"    </a>",
"    ]. Hydroquinone is available as 2% over-the-counter formulations and in prescription products in a 3 or 4% concentration. Exogenous ochronosis, a condition in which grayish discoloration of the skin occurs in sites of application, is an uncommon consequence of topical hydroquinone usage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/148\">",
"     148",
"    </a>",
"    ]. Additional safety concerns were raised when oral hydroquinone was reported to be tumorigenic in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/149\">",
"     149",
"    </a>",
"    ]. Carcinogenic effects have not been reported in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the use of a topical retinoid as a component of acne treatment regimens for patients with acne-induced postinflammatory hyperpigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/150\">",
"     150",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    is an alternative to a topical retinoid in patients who cannot tolerate the latter. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    can be applied twice daily to individual hyperpigmented lesions for greater improvement.",
"   </p>",
"   <p>",
"    Additionally, patients may benefit from superficial chemical peels with glycolic acid or salicylic acid, although care must be taken to avoid chemical peel-induced postinflammatory hyperpigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     HOME SKIN CARE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients frequently ask questions about general skin care. The following are some suggestions that patients will find useful, based upon clinical experience and clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should apply a gentle synthetic detergent cleanser (ie, syndet) with their fingers, and rinse with warm (not hot) water twice daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"       9",
"      </a>",
"      ]. Synthetic detergent cleansers possess a pH of 5.5 to 7, which is close to normal skin pH, while soap has a pH of 9 to 10. The lower pH of synthetic detergents, such as Cetaphil",
"      <sup>",
"       &reg;",
"      </sup>",
"      , minimizes skin irritation and dryness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/151,152\">",
"       151,152",
"      </a>",
"      ]. In a small randomized trial, patients with moderate acne (treated with a",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"        benzoyl peroxide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"        erythromycin",
"       </a>",
"      </span>",
"      combination gel alone or combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      ) were instructed to wash their faces with either a synthetic detergent bar (Dove",
"      <sup>",
"       &reg;",
"      </sup>",
"      Sensitive Skin Bar) or soap [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/153\">",
"       153",
"      </a>",
"      ]. After four weeks, the patients washing with the synthetic detergent bar exhibited less skin peeling, dryness, and irritation than those using soap.",
"     </li>",
"     <li>",
"      Patients should not aggressively scrub the skin; gentle massage with the fingertips is sufficient for cleansing. Repetitive mechanical trauma can aggravate inflammatory acne and promote the development of new acne lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several reports have suggested that antibacterial soaps such as triclosan, povidone-iodine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      can improve acne vulgaris [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/154-156\">",
"       154-156",
"      </a>",
"      ]. However, data supporting their use are limited, and these agents have not been proven superior to conventional therapy. We do not recommend these soaps for the management of acne vulgaris.",
"     </li>",
"     <li>",
"      Water-based lotions, cosmetics, and hair products are less comedogenic than oil-based products. Patients should be encouraged to seek out noncomedogenic skin care and cosmetic products.",
"     </li>",
"     <li>",
"      Patients should be advised not to pick their acne lesions, as this may exacerbate scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PREGNANCY AND ACNE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatments for acne are contraindicated in pregnancy. In particular, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    are classified as pregnancy category X drugs, and must never be given to pregnant women or women who are attempting pregnancy.",
"   </p>",
"   <p>",
"    In deciding whether to treat acne during pregnancy, as well as choosing a specific therapy, careful consideration should be given to the grade of acne, the patient's risk tolerance, and the preferences of the patient's obstetrical provider. If acne therapy is desired, reasonable options include oral or topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , which are pregnancy class B drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/28/39370/abstract/157,158\">",
"     157,158",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     Benzoyl peroxide",
"    </a>",
"    is categorized as pregnancy class C.",
"   </p>",
"   <p>",
"    A description of the pregnancy category labels (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 4",
"    </a>",
"    ) and a list of pregnancy categories of acne medications are provided (",
"    <a class=\"graphic graphic_table graphicRef69221 \" href=\"mobipreview.htm?12/27/12732\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=see_link\">",
"       \"Patient information: Acne (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=see_link\">",
"       \"Patient information: Acne (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determining the most effective course of treatment for acne involves a comprehensive assessment of the patient. Treatment of acne is aimed at counteracting follicular hyperproliferation, increased sebum production,",
"      <em>",
"       Propionibacterium acnes",
"      </em>",
"      (",
"      <em>",
"       P. acnes",
"      </em>",
"      ) proliferation, and inflammation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of acne therapy should be individualized, depending on acne severity and type of lesions, as well as tolerance and other factors (",
"      <a class=\"graphic graphic_algorithm graphicRef76250 \" href=\"mobipreview.htm?14/7/14457\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medications that are effective for comedonal acne include topical retinoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      , and salicylic acid. For patients with comedonal acne who desire treatment, we suggest topical retinoids as first line therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Topical retinoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate inflammatory acne with or without prominent comedonal lesions, we suggest the use of a topical retinoid, topical antibiotic, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). When benzoyl peroxide is used with a topical antibiotic, treatment is more effective than either agent alone. To reduce the development of antibiotic resistance, we prescribe topical antibiotics with benzoyl peroxide. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Topical antimicrobials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe inflammatory acne with or without prominent comedonal lesions, we suggest the use of a topical retinoid, topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      , and an oral antibiotic, rather than topical agents alone (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Oral antibiotics should be used for a limited course, ideally up to 12 to 18 weeks. Concomitant topical benzoyl peroxide should be prescribed to decrease the risk of antibiotic resistance. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Oral antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe, recalcitrant, nodular acne are generally treated with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      . Oral isotretinoin therapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link\">",
"       \"Oral isotretinoin therapy for acne vulgaris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with signs of hyperandrogenism should be evaluated for underlying endocrine disorders. Hormonal therapy can be a useful addition to a therapeutic regimen for moderate to severe acne vulgaris in women with or without hyperandrogenism. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Hormonal therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=see_link\">",
"       \"Hormonal therapy for women with acne vulgaris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acne may persist for years. In addition to their use in treatment, topical retinoids are also effective for the prevention of acne lesions, and can reduce the use of long term antibiotic therapy. In patients with acne that has improved with therapy, we suggest long-term treatment with a topical retinoid for maintenance, rather than discontinuing treatment (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For patients in whom improvement cannot be sustained with topical retinoids alone, an antimicrobial agent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      can be added. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acne-induced postinflammatory hyperpigmentation is a particular concern for patients with dark skin pigmentation. For patients with acne-induced postinflammatory hyperpigmentation, we suggest the use of a topical retinoid as a component of acne therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      , or chemical peels can also be beneficial. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Therapy for postinflammatory hyperpigmentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acne should use gentle cleansers and should avoid irritating skin care products. Patients should select \"non-comedogenic\" skin care products and cosmetics. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Home skin care recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women should not be treated with topical retinoids. If treatment during pregnancy is necessary,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      may be considered after a review of the risks and benefits of therapy. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Pregnancy and acne therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/1\">",
"      Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000; 43:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/2\">",
"      Dalgard F, Gieler U, Holm J&Oslash;, et al. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol 2008; 59:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/3\">",
"      Yazici K, Baz K, Yazici AE, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol 2004; 18:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/4\">",
"      Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg 2008; 27:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/5\">",
"      Lehmann HP, Robinson KA, Andrews JS, et al. Acne therapy: a methodologic review. J Am Acad Dermatol 2002; 47:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/6\">",
"      Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/7\">",
"      Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/8\">",
"      Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol 2008; 9:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/9\">",
"      Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/10\">",
"      Leyden JJ, Shalita A, Thiboutot D, et al. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther 2005; 27:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/11\">",
"      Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/12\">",
"      Liu A, Yang DJ, Gerhardstein PC, Hsu S. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients. J Drugs Dermatol 2008; 7:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/13\">",
"      Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/14\">",
"      Taglietti M, Hawkins CN, Rao J. Novel topical drug delivery systems and their potential use in acne vulgaris. Skin Therapy Lett 2008; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/15\">",
"      Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006; 19:2.",
"     </a>",
"    </li>",
"    <li>",
"     Kang S, Voorhees JJ. Topical retinoids. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, New York 2008. p.2106.",
"    </li>",
"    <li>",
"     Fernandez [Graber] EM, Zaenglein A, Thiboutot D. Acne Treatment Methodologies. In: Cosmetic Formulation of Skin Care Products, Taylor and Francis Group, New York 2006. p.273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/18\">",
"      Benkoussa M, Brand C, Delmotte MH, et al. Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Mol Cell Biol 2002; 22:4522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/19\">",
"      Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/20\">",
"      Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/21\">",
"      Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/22\">",
"      Webster GF. Safety and efficacy of Tretin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed 2006; 5:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/23\">",
"      Webster G, Cargill DI, Quiring J, et al. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis 2009; 83:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/24\">",
"      Berger R, Barba A, Fleischer A, et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007; 80:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/25\">",
"      Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006; 54:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/26\">",
"      Lucky A, Jorizzo JL, Rodriguez D, et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001; 68:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/27\">",
"      Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005; 76:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/28\">",
"      Shalita AR, Berson DS, Thiboutot DM, et al. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004; 26:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/29\">",
"      Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci 2008; 49:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/30\">",
"      Eichenfield LF, Jarratt M, Schlessinger J, et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010; 9:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/31\">",
"      Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/32\">",
"      Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006; 142:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/33\">",
"      Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/34\">",
"      Alirezai M, George SA, Coutts I, et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/35\">",
"      Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne--an evidence-based overview. J Dtsch Dermatol Ges 2008; 6:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/36\">",
"      Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin gel microsphere 0.1%. Cutis 2002; 70:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/37\">",
"      Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139 Suppl 52:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/38\">",
"      Nighland M, Yusuf M, Wisniewski S, et al. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis 2006; 77:313.",
"     </a>",
"    </li>",
"    <li>",
"     Sami N, Harper JC. Topical retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc, 2007. p.625.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/40\">",
"      Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg 2008; 27:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/41\">",
"      Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99:469.",
"     </a>",
"    </li>",
"    <li>",
"     Zaenglein AK, Thiboutot DM. Acne Vulgaris. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier, 2008. p.495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/43\">",
"      Weinstock MA, Bingham SF, Lew RA, et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol 2009; 145:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/44\">",
"      Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998; 139 Suppl 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/45\">",
"      Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/46\">",
"      Chalker DK, Lesher JL Jr, Smith JG Jr, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/47\">",
"      Dom&iacute;nguez J, Hojyo MT, Celayo JL, et al. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998; 37:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/48\">",
"      Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002; 147:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/49\">",
"      Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139 Suppl 52:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/50\">",
"      Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003; 49:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/51\">",
"      Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/52\">",
"      Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/53\">",
"      Cunliffe WJ, Danby FW, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/54\">",
"      Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/55\">",
"      Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol 2005; 4:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/56\">",
"      Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002; 69:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/57\">",
"      Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol 2008; 7:s3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/58\">",
"      Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/59\">",
"      Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986; 25:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/60\">",
"      Morelli R, Lanzarini M, Vincenzi C, Reggiani M. Contact dermatitis due to benzoyl peroxide. Contact Dermatitis 1989; 20:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/61\">",
"      Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/62\">",
"      Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin 2009; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/63\">",
"      Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/64\">",
"      Tarimci N, Sener S, Kilin&ccedil; T. Topical sodium sulfacetamide/sulfur lotion. J Clin Pharm Ther 1997; 22:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/65\">",
"      Breneman DL, Ariano MC. Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. Int J Dermatol 1993; 32:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/66\">",
"      Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56:439.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/67\">",
"      Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007; 6:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/68\">",
"      Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol 2008; 144:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/69\">",
"      Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol 2010; 9:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/70\">",
"      Fleischer, AB, Draelos, ZD, Abramovits, W, Pariser, DM. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double-blind study. J Am Acad Dermatol 2007; 56:AB16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/71\">",
"      Dubina MI, Fleischer AB Jr. Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. Arch Dermatol 2009; 145:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/72\">",
"      Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/73\">",
"      Hurwitz S. Acne vulgaris: pathogenesis and management. Pediatr Rev 1994; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/74\">",
"      Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/75\">",
"      Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003; 49:S211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/76\">",
"      Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/77\">",
"      Richter JR, F&ouml;rstr&ouml;m LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/78\">",
"      Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/79\">",
"      Shalita AR, Rafal ES, Anderson DN, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis 2003; 72:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/80\">",
"      Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007; 6:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/81\">",
"      Draelos ZD, Tanghetti EA, Tazarotene Combination Leads to Efficacious Acne Results (CLEAR) Trial Study Group. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002; 69:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/82\">",
"      Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J Drugs Dermatol 2006; 5:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/83\">",
"      Amblard P, Bazex A, Beylot C, et al. [The association tretinoin-erythromycin base: a new topical treatment for acne. Results of a multicentric trial on 347 cases (authors transl)]. Sem Hop 1980; 56:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/84\">",
"      Dosik JS, Gilbert RD, Arsonnaud S. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skinmed 2006; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/85\">",
"      Webster GF, Graber EM. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg 2008; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/86\">",
"      Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/87\">",
"      Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994; 131:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/88\">",
"      Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/89\">",
"      Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/90\">",
"      Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/91\">",
"      Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol 2001; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/92\">",
"      Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. J Am Acad Dermatol 2010; 63:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/93\">",
"      Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/94\">",
"      Gollnick HP, Graupe K, Zaumseil RP. [Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. J Dtsch Dermatol Ges 2004; 2:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/95\">",
"      Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/96\">",
"      Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003; :CD002086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/97\">",
"      Smith JG Jr, Chalker DK, Wehr RF. The effectiveness of topical and oral tetracycline for acne. South Med J 1976; 69:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/98\">",
"      Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol 1982; 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/99\">",
"      Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol 1976; 112:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/100\">",
"      Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol 1975; 111:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/101\">",
"      Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology 1993; 187:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/102\">",
"      Gammon WR, Meyer C, Lantis S, et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol 1986; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/103\">",
"      Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin 2009; 27:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/104\">",
"      Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/105\">",
"      Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/106\">",
"      Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/107\">",
"      Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/108\">",
"      Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/109\">",
"      Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. Arch Dermatol 2012; 148:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/110\">",
"      Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005; 141:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/111\">",
"      Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am J Clin Dermatol 2003; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/112\">",
"      Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49:S200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/113\">",
"      Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005; 4:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/114\">",
"      Mills OH Jr, Marples RR, Kligman AM. Acne vulgaris. Oral therapy with tetracycline and topical therapy with vitamin A. Arch Dermatol 1972; 106:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/115\">",
"      Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh) 1975; 74:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/116\">",
"      Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49:S218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/117\">",
"      Campbell JL Jr, Weiss JS. The results of the MORE trial: overview. Cutis 2006; 78:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/118\">",
"      Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/119\">",
"      Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat 2006; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/120\">",
"      Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005; 30:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/121\">",
"      Antonio JR, Pegas JR, Cestari TF, Do Nascimento LV. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat 2008; 19:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/122\">",
"      Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/123\">",
"      Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg 2001; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/124\">",
"      Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990; 122:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/125\">",
"      Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol 1993; 128:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/126\">",
"      Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012; 8:CD002086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/127\">",
"      Khanna, N. Treatment of acne vulgaris with oral tetracyclines. Indian J Dermatol Venereol Leprol 1993; 59:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/128\">",
"      Samuelson JS. An accurate photographic method for grading acne: initial use in a double-blind clinical comparison of minocycline and tetracycline. J Am Acad Dermatol 1985; 12:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/129\">",
"      Hubbell CG, Hobbs ER, Rist T, White JW Jr. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982; 118:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/130\">",
"      McManus P, Iheanacho I. Don't use minocycline as first line oral antibiotic in acne. BMJ 2007; 334:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/131\">",
"      Purdy S, de Berker D. Acne. BMJ 2006; 333:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/132\">",
"      Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/133\">",
"      Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/134\">",
"      Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/135\">",
"      Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999; 28:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/136\">",
"      Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006; 48:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/137\">",
"      Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis 2006; 78:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/138\">",
"      Fleischer AB Jr, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/139\">",
"      Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011; 63:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/140\">",
"      Toossi P, Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008; 7:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/141\">",
"      Fenner JA, Wiss K, Levin NA. Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol 2008; 25:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/142\">",
"      Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/143\">",
"      Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011; 164:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/144\">",
"      Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol 2002; 46:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/145\">",
"      Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/146\">",
"      Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/147\">",
"      Palumbo A, d'Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta 1991; 1073:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/148\">",
"      Levitt J. The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol 2007; 57:854.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services. Food and Drug Administration. Skin Bleaching Drug Products For Over-the-Counter Human Use; Proposed Rule. 71 Federal Register 51146-5115521 (2006) (codified at 21 CFR Part 310).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/150\">",
"      Callender VD. Considerations for treating acne in ethnic skin. Cutis 2005; 76:19.",
"     </a>",
"    </li>",
"    <li>",
"     Draelos ZD. Cosmetics and cosmeceuticals. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier, 2008. p.2301.",
"    </li>",
"    <li>",
"     Draelos ZD. Cosmetic therapy. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc, 2007. p.761.",
"    </li>",
"    <li>",
"     Subramanyan K, Johnson AW. Role of mild cleansing in the management of sensitive skin. Poster presented at the American Academy of Dermatology 61st Annual Meeting, San Francisco, CA, March 21 to 26, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/154\">",
"      Bettley FR, Dale TL. The local treatment of acne. Br J Clin Pract 1976; 30:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/155\">",
"      Milikan LE. A double-blind study of Betadine skin cleanser in acne vulgaris. Cutis 1976; 17:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/156\">",
"      Stoughton RB, Leyden JJ. Efficacy of 4 percent chlorhexidine gluconate skin cleanser in the treatment of acne vulgaris. Cutis 1987; 39:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/157\">",
"      Worret WI, Fluhr JW. [Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid]. J Dtsch Dermatol Ges 2006; 4:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/28/39370/abstract/158\">",
"      Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin 2006; 24:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 42 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39370=[""].join("\n");
var outline_f38_28_39370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of vehicles for topical treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOPICAL RETINOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evidence for efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Instructions for application",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tretinoin and isotretinoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adapalene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tazarotene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TOPICAL ANTIMICROBIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Benzoyl peroxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Topical antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Erythromycin and clindamycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Sulfacetamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Topical retinoid and topical antimicrobial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotics and benzoyl peroxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      AZELAIC ACID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ORAL ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Macrolides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Dosing for tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Extended-release minocycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Subantimicrobial dose doxycycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Clindamycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5871658\">",
"      - Cephalexin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      HORMONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169690\">",
"      ORAL ISOTRETINOIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169710\">",
"      NON-PRESCRIPTION TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169730\">",
"      PROCEDURAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      THERAPY FOR POSTINFLAMMATORY HYPERPIGMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      HOME SKIN CARE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PREGNANCY AND ACNE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/42\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/42|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?14/7/14457\" title=\"algorithm 1\">",
"      Treatment of acne",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/42|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/20/35146\" title=\"figure 1\">",
"      Pathogenesis acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/42|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/41/39570\" title=\"picture 1A\">",
"      Acne closed comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/4/28739\" title=\"picture 1B\">",
"      Acne open comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/26/36258\" title=\"picture 2\">",
"      Inflammatory acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/1/34834\" title=\"picture 3\">",
"      Minocycline pigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/25/20885\" title=\"picture 4\">",
"      Acne hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/42|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/59/16318\" title=\"table 1\">",
"      Acne medications 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/32/11787\" title=\"table 2\">",
"      Causes drug induced acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/51/4923\" title=\"table 3\">",
"      Topical combination acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 4\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/27/12732\" title=\"table 5\">",
"      Pregnancy class acne meds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44599?source=related_link\">",
"      Hormonal therapy for women with acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/54/33639?source=related_link\">",
"      Light-based, adjunctive, and other therapies for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_28_39371="Adolescent development";
var content_f38_28_39371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adolescent development",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tasks",
"      </td>",
"      <td class=\"subtitle1\">",
"       Early, 10-14 years",
"      </td>",
"      <td class=\"subtitle1\">",
"       Middle, 15-17 years",
"      </td>",
"      <td class=\"subtitle1\">",
"       Late, 18 and older",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical",
"      </td>",
"      <td>",
"       Initiation of puberty; preoccupation with appearance; potential to reproduce",
"      </td>",
"      <td>",
"       Completing puberty",
"      </td>",
"      <td>",
"       Physical reproductive maturity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cognitive",
"      </td>",
"      <td>",
"       Concrete thinking",
"      </td>",
"      <td>",
"       Increasing ability for abstract reasoning; risk-consequence deficits",
"      </td>",
"      <td>",
"       Abstract reasoning; understands risk-consequence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Emotional",
"      </td>",
"      <td>",
"       Egocentric",
"      </td>",
"      <td>",
"       Developing sense of identity; risk-taking and experimentation",
"      </td>",
"      <td>",
"       Intimacy as basis for sexual relationships; empathy and connectedness with others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Social",
"      </td>",
"      <td>",
"       Reliance on family/parents; same-sex peer relationships and few romantic relationships",
"      </td>",
"      <td>",
"       Peer influence, sexual exploration; differentiating from family",
"      </td>",
"      <td>",
"       Exploring new mature role in family, romantic relationships, social networks, and workplace",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexual",
"      </td>",
"      <td>",
"       \"Crushes\"; beginning sexual experimentation",
"      </td>",
"      <td>",
"       Exploration and experimentation; intense romantic relationships; serial monogamy",
"      </td>",
"      <td>",
"       Mature acceptance and enjoyment of sexual self; good communication and decision-making skills regarding sex",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Garofalo, MD, MPH, and Michelle Forcier, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39371=[""].join("\n");
var outline_f38_28_39371=null;
var title_f38_28_39372="Agents causing methemoglobinemia";
var content_f38_28_39372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents known to cause methemoglobinemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Acetanilid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            p-Amino salicylic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aniline, aniline dyes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzene derivatives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clofazimine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Local anesthetic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lidocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Prilocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menadione",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metoclopramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylene blue*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Naphthoquinone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Naphthalene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Nitrites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amyl nitrite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Farryl nitrite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sodium nitrite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nitroglycerin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nitric oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrobenzene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenacetin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenazopyridine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primaquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rasburicase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Resorcinol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonamides",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * While methylene blue is a recognized treatment for methemoglobinemia, it is an agent with oxidant potential, and may worsen the clinical situation, since in individuals with glucose-6-phosphate dehydrogenase deficiency it induces acute hemolysis that can further decrease oxygen delivery to the tissues. Paradoxically, in high doses methylene blue can also increase methemoglobinemia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39372=[""].join("\n");
var outline_f38_28_39372=null;
var title_f38_28_39373="Lung volume and capacities";
var content_f38_28_39373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary function tests: lung volumes and capacities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 208px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are boundaries of lung volume within which tidal volume can vary. A lung capacity is a combination of more than one lung volume. TLC for example, is the combination of FRC plus IC (or the combination of RV, ERV, VT, and IRV). TLC, RV, and their ratio provide the most information about restrictive lung disease and help differentiate between restrictive and obstructive disorders. However, TLC and RV are effort-dependent, so an evaluation of strength and/or effort is needed. In contrast, the FRC is effort-independent.",
"    <div class=\"footnotes\">",
"     IRV: inspiratory reserve volume; VT: tidal volume; ERV: expiratory reserve volume; RV: residual volume; IC: inspiratory capacity; FRC: functional residual capacity; TLC: total lung capacity; VC: vital capacity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39373=[""].join("\n");
var outline_f38_28_39373=null;
var title_f38_28_39374="Normal LV hemodynamics";
var content_f38_28_39374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal left ventricular hemodynamics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel shows left ventricular (LV) volume versus time while the bottom panel shows the rate of change of LV volume (dV/dt). The cardiac cycle begins at end diastole (*). With the onset of systole, the LV volume decreases and reaches its minimum at end systole. Diastole, which begins at this point, has three distinct phases: rapid filling phase (RFP) during which the LV fills rapidly, dV/dt reaches its maximum, and the peak filling rate occurs; diastasis (D) during which there is little change in LV volume; and atrial systole (AS) in which active atrial contraction fills the LV which attains its end diastolic volume. Important diastolic parameters include the peak filling rate, the time to peak filling rate (TPFR), the percent contribution of atrial systole, and the first third filling fraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39374=[""].join("\n");
var outline_f38_28_39374=null;
var title_f38_28_39375="Transthecal block";
var content_f38_28_39375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transthecal block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transthecal block (or flexor tendon sheath digital block) is performed by infusing the flexor tendon sheath with an anesthetic solution through a single injection. The needle is inserted at a 45 degree angle just distal to the distal palmar crease. The black ink lines on the skin outline the flexor tendon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baldor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_28_39375=[""].join("\n");
var outline_f38_28_39375=null;
